

**CHEMICAL AND BIOLOGICAL STUDIES OF LEAVES AND TWIGS OF
ANOGEISSUS RIVULARIS AND SOME HYPOGLYCEMIC HERBAL
FORMULATIONS**



**A Dissertation for the Degree
of
Masters of Philosophy**

Submitted by

Md. Anowar Hosen

**Department of Chemistry
University of Dhaka
Dhaka-1000
Bangladesh**

June 2017

DECLARATION

Experimental work described in this thesis has been carried out by himself at the Laboratory of Organic Section, Department of Chemistry, University of Dhaka, Dhaka-1000, Bangladesh and Department of Chemistry, Mahidol University, Bangkok-10400, Thailand under our supervision. The work has not been and will not be presented for any other degree.

Professor Dr. Nilufar Nahar
(Supervisor)
Chairperson
Department of Chemistry
University of Dhaka
Dhaka-1000

Signature/ Date.....

Dr. Rausan Zamir
(Co-Supervisor)
Associate Professor
Department of Natural Science
Daffodil International University
Dhaka-1207

Signature/ Date.....

Md. Anowar Hosen
(Author)
M. Phil. Student
Department of Chemistry
University of Dhaka
Dhaka-1000

Signature/Date.....

**DEDICATED
TO
My Beloved Parents**

ACKNOWLEDGEMENT

I would like to express my sincere gratitude and deep appreciation to my Supervisor, Professor Dr. NilufarNahar, M.Sc. (Dhaka), PhD (Uppsala, Sweden), Department of Chemistry, University of Dhaka, for her kind supervision, valuable instructions, suggestions and encouragement throughout the course of my M.Phil study and research work. Her guidance helped mein all the time of research and writing of this thesis. I could not have imagined having a better advisor for my for my M.Phil study.

I wish to thank my co-supervisor, Associate Professor Dr. RausanZamir, PhD (Dhaka), Department of Natural Science, Daffodil International University, for his kindness and valuable advice and comments on this thesis.

Moreover, I am also grateful to Professor Dr. VichaiReutrakul, Professor Dr. ManatPohmakotr and Associate professor Dr. Chutimakuhakarn, Department of Chemistry, Mahidol University, Bangkok-10400, Thailand, for their valuable suggestion and comments on this research work.

My special thank to Professor Dr. Mohammad Sheob, Professor Dr. Md. IqbalRoufMamun, Assistant Professor Dr. Abida Sultana, Lecturer Md. Kamrul Hassan, Department of Chemistry, University of Dhaka, for their scholarly contributions in this research work.

I am grateful to Ministry of Science and Technology, Bangladesh for offering honorable NST fellowship.

I am thankful to International Science Program (ISP), Uppsala University, Sweden for research fund.

I am grateful to International Foundation for Science (IFS), Uppsala University, Sweden for research fund.

I am also grateful to National Research Council of Thailand (NRCT), Mahidol University, Thailand, for research fund.

I thankful to SakchaiHongthong, SupesakChaturonrutsamee, Nolan Betterley, PhD student, Department of Chemistry, Mahidol University, Bangkok, Thailand for their help and stimulating discussions .

I wish to thank Dr. NasirUddin Al Mahnud, Farzana Khalil, TonimaMostofa, JarinSultana, and other BAN-04 research students, Department of Chemistry, University of Dhaka for their encouragement.

I am thankful to Md. AkramHossain (Tecnician), Md. AbulFazol, Md. MizanurRahman, KaziIshtiak, Md. Abdul Malek, Md. AtikurRahman, Md. Abdullah and ShiplopBalmiky, Department of Chemistry, University of Dhaka, are acknowledge for their assistance during research work.

Author

CONTENTS

INTRODUCTION

PART-A

Biological and Chemical Studies of *Anogeissus rivularis* Gannep O. Lecompte

1.1	General Introduction.....	1
1.2	Medicinal Importance of Plant Materials.....	2
1.3	<i>Anogeissus</i> genus.....	7
1.4	Coumarins from plants in <i>Anogeissus</i> genus.....	9
1.5	Lignans from plant of <i>Anogeissus</i> genus.....	10
1.6	Benzenoides from plants in <i>Anogeissus</i> genus.....	12
1.7	Triterpenoids from plants in <i>Anogeissus</i> genus.....	12
1.8	Tannins from plants in <i>Anogeissus</i> genus.....	14
1.9	Flavonoid from plants in <i>Anogeissus</i> genus.....	16
1.10	Objective of the present research work	18

PART-B: Herbal Formulation

1.11	General Introduction.....	20
1.12	Use of Herbal formulation for Diabetic Mellitus.....	20
1.13	Safety and Efficacy of Herbal Preparation.....	21
1.14	Objective of the present research work.....	21

EXPERIMENTAL

PART-A

Biological and Chemical Studies of *Anogeissus rivularis* Gannep O. Lecompte

2.1	General Methods.....	23
2.2	Plant Materials.....	24
2.3	Extraction and Isolation of the extract of leaves and twigs of <i>A. rivularis</i>	24
2.4	Purification of Hexane extract.....	24
2.5	Purification of Ethyl acetate extract	37

PART-B: Herbal Formulation

2.6	Study area and sample collection.....	78
2.7	Determination of pH of sample.....	78
2.8	Preparation of media.....	78
2.9	Total aerobic bacterial count and total coliform count.....	78
2.10	<i>Escherichia coli</i> 0157	79
2.11	<i>Escherichia coli</i> , (total)	79
2.12	<i>Salmonella</i> spp.	79
2.13	Qualitative Fungi Counts.....	80
2.14	Sample Preparation and Heavy Metal Analysis.....	80

RESULT AND DISCUSSION

PART-A: Biological and Chemical Studies of *Anogeissus rivularis* Gannep O. Lecompte

3.1	Biological Studies.....	84
3.2	Chemical Studies.....	87

PART-B**Herbal Formulations**

3.3	Microbial Contamination.....	128
3.4	Heavy Metal Content.....	133
	Conclusion	136
	References.....	139

List of Tables

Table-1.1:	Biological activities of selected Anogeissus species.....	8
Table 2.1:	Composition of different antidiabetic herbal preparations (ADHPs).....	81
Table-3.1:	Cytotoxic assays of hexane extract and fractions.....	84
Table-3.2:	Cytotoxic assays of ethyl acetate extract and fractions	85
Table-3.3:	Result of Anti-HIV 1RT of Hexane extract and fractions.....	86
Table-3.4:	Results of Anti-HIV–1RT of ethyl acetate extract and fractions.....	86
Table-3.5:	The ¹ H and ¹³ C NMR data of compound3	89
Table-3.6:	The ¹ H and ¹³ C NMR data of compound6	91
Table-3.7:	The ¹ H and ¹³ C NMR data of compound7.....	93
Table- 3.8:	The ¹ H and ¹³ C NMR data of compound8	95
Table-3.9:	The ¹ H and ¹³ C NMR data of compound9.....	97
Table-3.10:	The ¹ H and ¹³ C NMR data of compound12.....	99
Table-3.11:	The ¹ H and ¹³ C NMR data of compound13.....	101
Table-3.12:	The ¹ H and ¹³ C NMR data of compound14.....	102
Table-3.13:	The ¹ H and ¹³ C NMR data of compound15	103
Table-3.14:	The ¹ H and ¹³ C NMR data of compound16	104
Table-3.15:	The ¹ H and ¹³ C NMR data of compound17.....	105
Table-3.16:	The ¹ H and ¹³ C NMR data of compound18.....	107
Table-3.17:	The ¹ H and ¹³ C NMR data of compound19	108
Table-3.18:	The ¹ H, ¹³ C, DEPT 90 and DEPT 135 NMR data of compound20.....	110
Table-3.19:	The HSQC and HMBC correlation data of compound20.....	112

Table 3.20: The COSY correlation data for selected protons of compound20	113
Table 3.21: The ¹ H, ¹³ C, DEPT 90 and DEPT 135 NMR data of compound21.....	115
Table 3.22: The HMQC and HMBC NMR data of compound21.....	116
Table 3.23: The COSY correlation data for selected protons of compound21.....	117
Table-3.24: The ¹ H, ¹³ C, DEPT 90 and DEPT 135 NMR data of compound22.....	119
Table-3.25: The ¹ H, HMQC and HMBC NMR data of compound22	120
Table 3.26: The COSY correlation data for selected protons of compound22.....	121
Table-3.27: The ¹ H, ¹³ C DEPT 90 and DEPT 135 NMR data of compound23	123
Table-3.28: The ¹ H, HMQC and HMBC correlation of compound23	125
Table 3.29: The COSY correlation data for selected protons of compound23	126
Table 3.30: The NOESY correlation data for selected protons of compound23.....	127
Table 3.31: Microbial assessment of different ADHPs.....	128
Table 3.32: Microbial limits for finished herbal/botanical preparations	132
Table 3.33: Heavy metal content of investigated ADHP samples	133
Table 3.34: Permissible limit of heavy metal in herbal drugs.....	134
Table 3.35: Heavy metal content of investigated ADHP samples	135
Table 3.36: JECFA heavy metal limits for herbal dietary supplements.....	135

List of Figures

Figure-1.1: Anogeissusrivularis Tree and Leave & Flower.....	7
Figure-1.2: Some herbal formulation of Bangladesh.....	22
Figure-2.1: Some working pictures during column chromatography.....	82
Figure-2.2: Some pictures equipments.....	83
Figure 3.1: Compound 3.....	88
Figure 3.2: Compound 6.....	90
Figure 3.3: Compound 7.....	92
Figure 3.4: Compound 8.....	94
Figure 3.5: Compound 9.....	96
Figure 3.6: Compound 12.....	98
Figure 3.7: Compound 13.....	100
Figure 3.8: Compound 14.....	102

Figure 3.9: Compound 15.....	103
Figure 3.10: Compound 16.....	104
Figure 3.11: Compound 17.....	105
Figure 3.12: Compound 18.....	107
Figure 3.13: Compound 19.....	108
Figure 3.14: Compound 20.....	109
Figure 3.15: HMBC of Compound 20.....	111
Figure 3.16: COSY of Compound 20.....	113
Figure 3.17: Compound 21.....	114
Figure 3.18: HMBC of Compound 21.....	116
Figure 3.19: COSY of Compound 21.....	117
Figure 3.20: Compound 22.....	118
Figure 3.21: HMBC of Compound 22.....	120
Figure 3.22: COSY of Compound 22.....	121
Figure 3.23: Compound 23.....	122
Figure 3.24: HMBC of Compound 23.....	124
Figure 3.25: COSY of Compound 23.....	125
Figure 3.26: NOESY of Compound 23.....	126
Figure 3.27: Incubation of ADHPs in different agar media for microbial count.....	129
Figure 3.28: Incubation of ADHPs in Potato Dextrose agar (PDA)	130

List scheme


Scheme-2.1 Extraction procedure of leaves and twigs of <i>A. rivularis</i>	24
Scheme 2.2 Fractionation of hexane extract of leaves and twigs of <i>A. rivularis</i> .	25
Scheme 2.3 Fractionation of 1F ₃ (2F) of hexane extract obtained from 1 st column	26
Scheme 2.4 Fractionation of the 3F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	27
Scheme 2.5 Fractionation of the 5F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	28
Scheme 2.6 Fractionation of the 3F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	29
Scheme 2.7 Fractionation of the 10F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	30
Scheme 2.8 Fractionation of 11F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	31
Scheme 2.9 Fractionation of 8F of leaves and twigs of <i>A. rivularis</i> .	32
Scheme 2.10 Fractionation of 14F and 15F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	33
Scheme 2.11 Fractionation of 16F & 17F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	34
Scheme 2.12 Fractionation of 4F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	35
Scheme 2.13 Fractionation of 19F & 20F of hexane extract of leaves and twigs of <i>A. rivularis</i> .	36
Scheme-2.14 Fractionation Ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	37
Scheme-2.15 Fractionation Et1F ₄ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	39
Scheme-2.16 Fractionation of Et2F ₄ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	41
Scheme-2.17 Fractionation of Et 4F _{4,5} Et 4F _{1,2,3} of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	43
Scheme-2.18 Fractionation of Et12F ₄ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	45
Scheme-2.19 Fractionation of Et12F ₄ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	48
Scheme-2.20 Fractionation of Et25F ₄ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	50

rivularis.

Scheme-2.21 Fractionation of Et2F3 of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	51
Scheme-2.22 Fractionation of Et5F4 & Et5F5 of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	53
Scheme-2.23 Fractionation of Et1F5 of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	54
Scheme-2.24 Fractionation of Et8F ₂ to Et8F ₆ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	57
Scheme-2.25 Fractionation of Et3F ₃ &Et3F ₄ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	59
Scheme-2.26 Fractionation of Et3F ₆ & Et3F ₇ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	60
Scheme-2.27 Fractionation of Et10F ₂ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	63
Scheme-2.28 Fractionation of Et10F _{3,5} of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	65
Scheme-2.29 Fractionation of Et10F _{3,5} of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	67
Scheme-2.30 Fractionation of Et1F ₆ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	69
Scheme-2.31 Fractionation of Et19F _{2,4,5,6} of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	72
Scheme-2.32 fractionation of Et1F ₃ of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	74
Scheme-2.33 Fractionation of Et22F _{4,5} of ethyl acetate extracts of leaves and twigs of <i>A. rivularis</i> .	76

ABSTRACT

Hexane and Ethyl acetate extracts of leaves and twigs of *Anogeissusrivularis* and their sub-fractions were tested for anticancer activities on the six common human cancer cell lines; P-388, KB, HT-29, MCF-7, A549 and two normal human kidney cell lines ASK and Hek293. Sub-fractions, 1F-3, 1F-5, Et-1F-2, Et-1F-3, and Et-1F-4 were found to possess significant anticancer activities (ED₅₀ <4, 3.40, 4.50, 4.60 and 6.37 µg/mL respectively) on P-388 cell lines. The same extracts and their sub-fractions were also tested for anti-HIV-1 RT. The two extracts showed moderate activity but the two sub-fractions, 1F-5 & Et-1F-7 were found to be very active (growth inhibition 97% & 92%, respectively). From the active extracts four new compounds namely, 2-(3',4'-Dimethoxy-phenyl)-3-methyl-5-propenyl-2,3-dihydro-benzofuran (**20**), Dimer of 4,6-Dihydroxy-2-(4'-hydroxy-benzyl)-benzofuran-3-one (**21**), 2-[(3',4'-Dihydroxy-phenyl)-hydroxymethyl]-4,6-dihydroxy-benzofuran-3-one (**22**), 2,5-Bis-[(4'-hydroxy-phenyl)(4''-hydroxy-phenyl)]-3,4-dimethyl-tetrahydro-furan-3-ol (**23**), together with thirteen known compounds namely, betulinic acid (3β-Hydroxy-19β-hydrogen-lup-20-(29)-en-28-oic acid)(**3**), 3β-Hydroxy-20(29)-en-lupan-30-al (**6**), 29-Nor-20-oxolupeol (**7**), 3β,6β-Dihydroxylup-20(29)-ene(**8**), 3,3',4'-Tri-*o*-methylellagic acid (**9**), 3,3'-Di-*o*-methylellagic acid(**12**), (*S*)-naringenin(4',5,7-Trihydroxyflavanone) (**13**), *p*-Cumaric acid ((*E*)-3-(4'-Hydroxyphenyl)-2-propenoic acid)(**14**), 2,3-dihydro-*p*-cumaric acid(3-(4'-Hydroxyphenyl)-propanoic acid)(**15**), protocatechuic acid (3,4-Dihydroxybenzoic acid)(**16**), Stigmast-5-en-3-*o*-β-glucoside(**17**), loliolide (6-Hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydro-4H-benzofuran-2-one) (**18**), vanillic acid (3-Methoxy 4-hydroxybenzoic acid) (**19**) were isolated by chromatographic techniques. The structure of these compounds were elucidated by spectroscopic methods using UV, FTIR, high resolution ¹H & ¹³C NMR and Mass spectrometry (HRMS-ESI-TOP) and Single Crystal X-ray Diffraction.



A few local herbal formulations (13) were evaluated for antimicrobial and heavy metal contaminants (Cu, Cd, Cr, Mn, Pb and Zn). All of the herbal formulations showed the presence of different bacteria & fungi and their level were also slightly higher the safe level for consumption. Lead content in almost all of the samples (except two) exceeded the permissible limit according to WHO and US FDA.

DECLARATION

Md. Anowar Hosen made necessary correction and modifications of his thesis according to the report of one of the external examiners of examination committee. The correction and modifications were done under my supervision.

Professor Dr. Nilufar Nahar
(Supervisor)
Chairperson
Department of Chemistry
University of Dhaka
Dhaka-1000

Signature/ Date.....

Md. Anowar Hosen
(Author)
M. Phil. Student
Department of Chemistry
University of Dhaka
Dhaka-1000

Signature/Date.....

CHAPTER I

INTRODUCTION

PART-A

Biological and Chemical Studies of *Anogeissus rivularis* Gannep O. Lecompte

1.1 General Introduction

Plant plays a vital role throughout our life. A major part of the four basic needs, that is food, clothing, medicine and shelter are obtain from the plant kingdom. We depend on plants directly or indirectly for all our needs. The primary compound glucose and by product oxygen, which are very essential for our life are produced in plant by the process of photosynthesis. Plants are important to human in many other ways. It is also important for oxygen balance in the atmosphere. The role of forest in controlling climate regulation is well known to us. A major of global energy is also supplied from the plants as fuel.

Plants have been used extensively as a source of medicine for the majority of the world population from the primeval age. Still now 80% of world population use plant as their primary medicine. Plants produce a lot of compounds such as glycosides, steroids, terpenoids, alkaloids, tannins, essential oils, flavonoids, pigments etc. in their cell through different metabolic pathway. These are usually called secondary metabolites and are mainly responsible for their various therapeutic properties and pharmacological actions. Isolation of the useful compounds from the plant sources started in the last century and a number of important drugs have been developed from the plants.


Mankind has known the important of herbs, shrubs trees for medicinal purpose from primeval age. Primitive people learned from experience that some of the plants made them sick and could cure them. Using that experience and knowledge, the natural product researchers have been trying to find out active constituents from plant source for developing new drug against various diseases including diseases like cancer, AIDS, diabetics etc. The people of different part of the world are working under collaborative research program between Chemists, Biochemists, Pharmacists, Pharmacologists, and Taxonomists to find out new active compound of plant, which have therapeutic value or making a plant products into a commercial drug.

1.2 Medicinal Importance of Plant Materials


Phyto-medicines are as old as human civilization. Phyto-medicine comes to traditional medicine with or without clinical trial and phyto-medicine laid the foundation of stone of all forms of medicinal treatment that are practiced today. Illness, physical discomfort, injuries, wounds and fear of death had forced the early man to use any natural substance that he could be lay his hands on. Thus, the human started using plant as means of treatment of diseases and injuries from the early days of men's life on the earth and it is long journey from ancient time to modern age the human race successfully use plant product as a effect therapeutic tools for fighting against diseases and various health hazards.

People of the developing country countries are mostly users of traditional medicine. The World Health Organization (WHO) estimates that 80% of the people in developing countries rely on traditional medicine for their primary health care, and above 85% of the traditional medicine involve the use of plant extract. This means that the above 4 billion people in the world rely on plant as sources of drugs. In all type of diseases natural products played and continue to play a unique role in the therapeutic system. Some natural product that are used as a therapeutic agents are describe below-


The natural analgesic drug morphine (1) and Codeine (2) were isolated first in 1804 from latex of *papeversomniferium* capsules (opium). These are probably the first drug by which plant has directly contributed to the modern medicine. They are used for the depressant action on the nervous system.



In this way quinine (**3**) was isolated cinchona bark, which still used for the treatment of malaria. Malaria is still the most important diseases and the number of clinical case is estimated to ca. 200 million annually.




The most promising antibacterial drug artemisinin (**4**) was isolated from the herb *Artemisia annua*. The herb was used previously as remedy for malaria, which was written in ancient Chinese medical text. From this indication, in the late 1960s, Chinese researcher initiated evaluation of the various extract of this plant. Bioassay guided isolation yielded the new anti-malaria compound artemisinin(**4**) and was found to be effect in treating chloroquine resistance case and other severe case without major toxicity.




A synthetic analogy artemisinin named artemether (**5**) was developed in the People's Republic of China [1]. Two recent clinical studies suggested that artemether (**5**) was effective as quinine (**3**) in the treatment of severe malaria [2].


Likhitwitawuid et al. (1993) isolated some alkaloids (-) ambiline (6), (-) Lycorine (7), Buphanisine (8), (-) Augustine (9), (+) crinamine (10) from the blubs of *Crinum amabile*, which have effective antimalarial activity.




(-)- Amabiline (6)




(-)- Lycorine (7)



(-)- Buphanisine (8)




(-)-Augustine (9)




(-)- Crinamine (10)


In the early 1980s, a Chinese scientist isolated huperzineA (11) from the plant club moss as a potent, reversible and selective inhibitor of acetylcholinesterase [1]. A total synthesis was developed due to very small amount present in nature and to be promising candidate for the treatment of cholinergic related neurodegenerative disorders such as Alzheimer's diseases (AD).



A natural product, galanthamine (**12**), isolated from *Galanthus nivalis* in the 1950s is a long-acting, certainly active competitive cholinesterase inhibitor. Galanthamine under the name of nivalein is marketed in Austria for AD and in Germany for other indications such as facial neuralgia [1].




A novel coumarin derivative Calanolide A (**13**) is a reverse-transcript inhibitor isolated from Malaysian rainforest tree, *Callophylamlangerum* by NIC USA. It exhibited synergistic anti-HIV activity in combination with nucleoside reversed-transcript inhibitor, including AZT, DDI and DCC [3]. In June 1997, Medichem Pharmaceuticals, Inc. and the state of Sarawak, Malaysia began clinical development of Calanolide A as a potential drug for the treatment of AIDS and HIV infections.



Calanolide (13)

The immune stimulating peptide FK 565(14), a secondary metabolites from *Streptomyces sp.* Was discovered by Fujisawa. It possesses antitumor activities against marine (p-388) leukemia. The activity appeared to be a host media effect. FK565 was brought into phase II clinical trials in the USA for the treatment of cancer and AIDS [1].



FK 565 (14)

1.3 *Anogeissus* genus

The Combretaceae family comprises 20 genera and more than 600 species. Combretum and Terminalia are the largest genera, with over 200 species each. The investigation by Smttinand tem indicated the presence of 6 genera, mainly *Anogeissus*, *Combretum*, *Getonia*, *Lumnitzera*, *Quisqualis* and *Terminalia* in Thailand.[4]

Anogeissus is a genus of trees, native to South Asia, Africa and Arabian Peninsula. It belongs to the family Combretaceae.[5-6] This genus was elevated from the section of *Conocarpus* and distinguish from *Conocarpus* by the fruits.[7] *Anogeissus* fruits are aggregated into cone-like heads with wings or ribs and a beak at the apex, representing the persistence calyx-stalks. *Conocarpus* fruits have a deciduous Calyx-stalk. The genus *Anogeissus* comprises 19 species, namely *A. rivularis*, *A. acuminata*, *A. pierrei*, *A. tokenensis*, *A. lotifolia*, *A. leiocarpus*, *A. bentile*, *A. dhofarica*, *A. rotundifolia*, *A. schimperia*, *A. pendula*, *A. coronata*, *A. fischeri*, *A. sericea*, *A. harmandii*, *A. hirta*, *A. myrtofolia*, *A. nummulria* and *A. phillyreaefoli*. In Thailand onely two species are found, namely *A. acuminata* (Roxb. Ex DC) Guill&Perr. Var. *lanceolata* and *A. rivularis* (Gagnep) O. Lecopte[ST][4].

Anogeissus rivularis is a shrub or small tree, growing up to 15m with limb weakness, leaf stlak bract, stem and other tubes sepals short with soft hairs. It was found in Laos and Thailand. In Thailand it grows in KhongChaim district of UbonRatchathani province and Phichit province. *Anogeissus rivularis* is called by local name ‘TakhianNarm’ in UbonRatchathani province and ‘Cro-thein’ in phichit province [8]. The picture of *Anogeissus rivularis* showing bellow-



Figure-1.1 *Anogeissus rivularis* Tree and Leave & Flower

Plants of *Anogeussis* are used in folkloric medicine as indicated in NAPRALERT DATA BASE. *Anogeussislatifolia* is used for the treatment of cancer on the face [9], stomach ache [10], diarrhea and urinary disease [11], treatment of snake and scorpion bite [10], colic and cough [10]. *Anogeussisleiocarpus* is used to treat syphilitic ulcers [12], malaria, diarrhea [13] typhoid fever, gonorrhoea and toothache [14]. *Anogeussisshimperi* is used as chewing stick [15], as a blood purifier [16], as well as for fever and whooping cough [17]. *Anogeussissericeais* used for typhoid fever [18]. Biological activities of extracts of *Anogeissus* species found in NAPRALERT DATABASE are listed in Table-1.1. Preliminary result indicate that methanol extract of stem of *Anogeissusacuminata* var. *lanceolata* exhibited HIV-1 reverse transcriptase inhibitory activity in the cell line by Raimond et al. in 1994 [19].

Table-1.1: Biological activities of selected *Anogeissus* species-


Species	Type of Biological Activities	Ref.
<i>A. Latifolia</i>	Antioxident	10,20
	Antiulcer	21
	Antimicrobial	21
	Antibacterial	22
	Antihyperglycemim	23
	Antihelmintic.	24
<i>A. leiocarpus</i>	Antimicrobial	14
	Antibacterial	25
	Antifungal	26
	Anti-plasmodial	27
<i>A. accuminata</i>	Antidermatophytic	28
	Cytotoxicity	29
	HIV-1reverse transcriptase.	19
<i>A. pendula</i> Edgew	Anti-inflammatory	30
	Antioxident.	31
<i>A. dhofarica</i>	Antioxident	32





On the basis of SciFinder Scholar 2007(developed by CAS Chemical Abstracts Service) and NAPRALERT DATABASE indicated that the compounds isolated from *Anogeissus* genus were classified as follows-

- 1) Coumarins
- 2) Lignans
- 3) Benzenoides
- 4) Triterpenoides
- 5) Tannins
- 6) Flavonoides

1.4 Coumarins from plants in *Anogeissus* genus

3,3',4-tri-O-methylflavagelic acid (**15**) was reported from the chloroform extract of the bark of *A. latifolia* by Row and Raju [33] in 1974. The extract of this plant was studied by Deshpande coworkers [34]. The investigation leading to the isolation of new glycosides of ellagic acid and flavagelic acid, i.e. 3,3'-di-O-methylellagic acid-4'- β -D-xyloside (**16**) and 3,4,3'-tri-O-methylflavagelic acid-4'- β -D- glucoside (**17**) was reported in 1976. In 1988, Ndjui and Okwute [35] reported the identification of ellagic acid derivatives, 3,3',4-tri-O-methylflavagelic acid (**18**) and 3,3'-di-O-methylellagic acid (**19**) from the bark of *A. schimperii* collected from Nigeria.







1.5 Lignans from plant of *Anogeissus* genus


A. acuminata (Roxb. Ex DC) Guill & Perr. Var. *lanceolata* Wall ex C.B. Clarke stem, collected in Thailand was found to contain lignans. In 1994, Rimando *et al* [19] reported the isolation of four lignans, anolignan A (**20**), anolignan B (**21**), anolignan C (**22**) and (-)-secoisolariccinresinol (**23**) from methanol extract. Compound **20** and **21** were identified as the active HIV-1 reverse transcriptase (RT) inhibitory constituents of this plant. Compound **21**, which was weakly active when tested alone, showed high activity when combined with **20**. In other words, the activity of **20** was enhanced in the presence of **21**. Compounds **22** and

23 did not have high activity against HIV-1RT. Compound **20** and **21** were weakly cytotoxic while compound **22** moderate cytotoxicity against ZR-75-1 cell line.




Another report on the isolation of compounds from the same plant in 1994 by Rimando *et al.* [29] was on the isolation of two neolignans, dihydrodehydro-diconiferyl alcohol (**24**) and conocarpan (**25**). Compound (**24**) showed moderate cytotoxic activity human melanoma cancer cell line with ED_{50} value of 11.8 $\mu\text{g/mL}$ and compound (**25**) exhibited cytotoxic against several cancer cell lines, Lu-1, col-1, P-388, and ZR-75-1 with ED_{50} values of 17.6, 15.7, 3.0 and 8.7 $\mu\text{g/mL}$ respectively.






1.6 Benzenoides from plants in *Anogeissus* genus


Pterostilbene (**26**) from the methanol extract of stems of *A. acuminata* (collected in Thailand) was reported by Rimando *et al* [29] in 1994. This compound was found to exhibit *in vitro* cytotoxicity against BC-1, HT-1080, Lu-1, Col-1, KB, KB-V1, P-388, A-341, LNCaP, ZR-75-1, and U-373, cells with ED₅₀ values of 3.5, 6.6, 9.2, 8.0, 6.5, 16.7, 2.3, 15.0, 10.1, 6.6 and 8.1 μg/mL respectively.




1.7 Triterpenoids from plants in *Anogeissus* genus

The investigation of the stem bark of *Anogeissus latifolia* collected from Dhaka, Bangladesh, was reported by Mohammads group in 2007 [37]. Two triterpenes namely 3-β-hydroxy-28-acetyltaraxaren (**27**) and β-sitosterol (**28**) were isolated from the ethyl acetate extract.





Furthermore the bark extract of *Anogeissus leiocarpus* collected from Nikola Koba National Park in southeastern Senegal, was investigated by Chaabi and Co-workers [36]. The isolation and identification of two triterpenoid glycosides, Stericosides (**29**) and tracheloperoxide E1 (**31**) as well as triterpenoides namely, Sericic acid (**30**), Trachelosperogenin E (**32**) and Arjungenin (**33**) were reported in 2008.



29 R= H, R² = OH, R=glucose

30 R= R¹= H, R² = OH,


31 R=glucose

32 R= H, R¹=R² = OH,





33 R¹= OH, R² = R=H

1.8 Tannins from plants in *Anogeissus* genus

C-Glycosidichydrolyzable tannins, castalin (**34**), castalagin (**35**), vescalagin carboxylic acid(**36**), grandinin(**37**), acutissinim C(**38**), acutissinim A (**39**), eugenigrandin A (**40**) and castamollinin, together with three complex tannins (flavano- ellagitannins), anogeissinin, anoguissusins A and anogeissusin B, were isolated by Lin *et al* [38] in 1991 from the bark of *A. acuminata* (Roxb. Ex DC) Guill.&Perr. Var. lanceolata wall ex C.B. Clake collected from Yunnan in China.




	R ¹	R ²	R ³	R ⁴
34	OH	H	H	H
35	OH	H	HHDP	
36	H	CO ₂ H	HHDP	




1.9 Flavonoid from plants in *Anogeissus* genus


Flavonoid C- glycoside (**41**) was isolated from a methanol extract of stem of *Anogeissus latifolia* collected in India. S.K. Chaturvedi and B.S. Chhabra [39] reported their work on this extract in 2005.




The investigation on an alcoholic extract from leaves of *Anogeissus pendula* by S. Lata and BM Bhadoria [40] in 2010 revealed the presence of a new chromone- substituted dihydrotriflavanol.

In 2011, another report by Attioua and co-worker [41] demonstrated the isolation of eight known flavonoids, catechin (**42**), 4H-1- benzopyran-4-one-[(6-deoxy- α -L-mannopyranosyl)oxy]-5-hydroxy-2-(4-hydroxy-3-methoxyphenyl) (**43**), quercetin (**44**), isoquercetin(**45**), rutin (**46**), vitexin (**47**), kaempferol (**48**) and procyanidin (**49**) from an ethyl acetate extract of leaves of *Anogeissus leiocarpus* collected near Segula (North Ivory Coast). Compound **44** and **49** showed antiplasmodial activity with IC_{50} values of 6.6 and 5.3 μ M respectively whereas compound (**46**) exhibited in vitro anti leishmanial activity with best IC_{50} value of 1.6 μ M.






	R ¹	R ²	R ³	R ⁴	R ⁵	R ⁶
43:	H	O-Rha	H	H	OMe	OH
44:	OH	OH	H	OH	OH	H
45:	O-Gluc	OH	H	OH	OH	H
46:	O-Gluc-Rha	OH	H	OH	OH	H
47:	H	OH	Rha	H	OH	H
48:	OH	OH	H	H	OH	H



The isolation of 5,7,3',4',5'-pentahydroxydihydroflavanol-O-(2''-O galloy)- β -D-glucopyroside (API) (41) was reported by Arunadeviet *al* [42] from *Anogeissuspendula* Edgew in the same year.



This type of compounds has biological activities especially Anti HIV, Antimicrobial, Cytotoxicity etc. Ongoing works to search for bioactive compound from plants, numerous biologically testing including cytotoxic, anti-inflammatory, anti-microbial and anti-oxidant activities are the development of folk-medicine. In this thesis *Anogeissusrivularis* was chosen to be investigated for its chemical constituent, as well as biological activities of the isolated compounds.

1.10 Objective of the present research work

Infectious diseases are the world's leading cause of premature death and killing a large number of people in every year. Since diseases, decay, and death have always coexisted with our life, so the study of diseases and their treatment must have been contemporaneous with the dawn of intellect. Among all other diseases the most dangerous and deadly diseases are cancer and AIDS. Still no unique therapeutic agent has been discovered which could completely cure these diseases. Plants have been the almost exclusive source of drugs for the majority of the world population since the primeval age. It is apparent that science made a lot of progress in the field of medicine, but still plant

materials continue to play a major role in primary health care and as therapeutic remedies in many developing countries. The approach to discover and developed new drugs from plant origin is therefore an alternative area along with complementary synthetic and biosynthetic approaches.

The phytochemical studies on medicinal plants serve dual purpose of bringing up the new therapeutic agent and provide useful lead for further studies directed towards the synthesis of new drugs, modeled on the basis of chemical structure of the natural product. Moreover, they promote studies in the correlation of chemical structures of the plant materials (cordell 2000). Bangladesh is a developing country where different types of in curable diseases are prevalent. But the country is blessed with large number of medicinal plants and marine organisms.

During the course work of this study, a number of plant materials were investigating on the basis of ethnomedical and folkloric reputations. On the basis of above studies **Leaves and Twigs of *Anogeissus rivularis*** were selected for isolation and characterization of bioactive compounds. Cytotoxicity of the plant extract was studied on different cell lines (P-388, KB, HT29, MCF-7, A549, ASK AND Hek293) and Anti-HIV-1RT was also studied. Isolation and characterization of compounds from plant part were also done by chromatographic and spectroscopic methods. The whole works were carried out in the Department of Chemistry, **Mahidol University (MU), Thailand**, under a collaborative research program between MU and University of Dhaka.

PART-B

Herbal Formulations

1.11 General Introduction

Over the recent times, the popularity of herbal medicine is increasing to such an extent that around 20% of world population is now using herbal medicine in different forms for different purposes[43]. In developing countries, it is estimated that 70-80% of the populations somehow rely on nonconventional medicines mainly herbal origins for the primary health care [44], as they are cheap and easily accessible[45]. Herbal preparations are produced from any raw or processed part of a plant, which includes leaves, stems, flowers, roots, seeds and in most of the cases it is a complex mixture of organic chemicals from natural sources[43,46,47]. As different plant parts are used in a herbal preparation, it may carry a large number of various kinds of microbes originating from soil usually adhering to different parts of herbs [47]. Moreover, in some of the herbal preparations, particularly Ayurvedic formulation, the use of heavy metals is intentional, as some of these heavy metals are believed to have beneficial effects on our body. In general, most of the common contaminants are heavy metals, pesticides, microbes and mycotoxins [48,49].

1.12 Use of Herbal formulation for Diabetic Mellitus

The range of the usage [50] of herbal preparations is vast as they are frequently used in the treatment of several chronic diseases including type 2 diabetes (diabetic mellitus). Diabetes is a noncommunicable heterogeneous group of disorders and affects approximately 200 million individuals globally. Moreover, it is predicted that over 300 million people will be diabetic by 2015[50,51]. In general, this poses challenges to the health care and social welfare but in particular, it is a huge challenge to developing countries like Bangladesh because of its limited resources and weak economy. The trend of use of antidiabetic herbal preparations (mostly based on Ayurvedic and Unani formulations) is increasing day by day among the population of Bangladesh. In parallel, there is a rising concern regarding the safety and efficacy of these herbal preparations as most of them contain different contaminants including microbial contaminants and heavy metals (particularly in Ayurvedic preparations). In most of the developed countries, herbal preparations are defined as dietary supplements. As a result, unlike pharmaceutical preparations, manufacturers are producing, selling and marketing herbal preparations without any

evidence based scientific study regarding their safety and efficacy [43]. Although in several countries herbal medicine (a part of complementary and alternative medicine) is the officially approved system, there are no guidelines and regulations for assuring the safety of these preparations.

1.13 Safety and Efficacy of Herbal Preparation

The safety of these herbal preparations is very important because Ayurvedic formulation contains several heavy metals as therapeutic ingredients. But the use of these heavy metal beyond the limit could be toxic. Moreover the level of microbial contamination of herbal preparation is dependent on the quality of raw materials used and manufacturing environment. Most raw materials for herbal preparations support some form of microbial growth, as medicinal plants used in herbal preparations provide nutrition to microorganisms and facilitate the multiplication of microorganism. In addition, inappropriate cleaning, unsuitable transportation, prolonged drying and storage, inadequate hygiene of producers, and congenial climatic conditions render the medicinal plants vulnerable to infestations and exposed them to many microbial contaminations. Inadvertent contamination, like fungal contamination during the production stage can also lead to deterioration in safety and quality as the risk of mycotoxin production, specially aflatoxin, may arise which has proven mutagenic, carcinogenic, teratogenic, neurotoxic, nephrotoxic, and immunosuppressive activities [52-58]. Therefore, it is important to evaluate the safety of these anti diabetic herbal preparations based on relevant scientific investigation. This research project focuses on the safety of antidiabetic herbal preparation available in Bangladesh particularly related to heavy metal and microbial contamination.

1.14 Objective of the present research work

In Bangladesh several herbal antidiabetic herbal preparations are readily available and are being used, but studies regarding microbial contaminants and heavy metal content in locally produced herbal preparations are limited. Therefore, it is necessary to evaluate microbial contamination as well as heavy metal content in some locally produced and widely used herbal preparations. In this study, we investigated the level of microbial contamination and heavy metal content present in antidiabetic herbal preparations widely used and formulated in Bangladesh.



Figure-1.2 Some herbal formulation of Bangladesh

CHAPTER II

EXPERIMENTAL

PART-A

Biological and Chemical Studies of *Anogeissus rivularis* Gannep O. Lecompte

2.1 General Methods


Melting points (uncorrected) were recorded in °C and were determined on a digital Electrothermal Melting apparatus. Infrared spectra were recorded by using Perkin Elmer System 2000 FT-IR. Major bands (ν_{\max}) were recorded in wave number (cm^{-1}). Optical rotations were measured on a JASCO DIP 370 digital polarimeter by using a 50 mm microcell (1 ml). Ultraviolet absorption spectra were measured in ethanol, methanol and dichloromethane solutions on a JASCO 530 spectrophotometer. Principle bands (λ_{\max}) were reported as wavelengths (nm) and $\log \epsilon$. Low resolution EI mass spectra were recorded on a Thermo Finnigan Polaris Q mass spectrometer at 70 eV (probe). The high resolution mass spectra (HRMS) were recorded on a Micromass model VQ-TOF2. The high resolution nuclear magnetic resonance spectra were mainly recorded on Bruker AV-500 spectrometer. Solvents for extraction, chromatography and recrystallization were distilled at their boiling point ranges prior to use. Pre-coated TLC aluminum sheets of silica gel 60 PF₂₅₄ (20 x 20 cm, layer thickness 0.2 mm) were used for analytical purposes and the bands were visualized by ultraviolet light (at λ_{\max} 254 and λ_{\max} 366 nm) and/or spraying solution of anisaldehyde [abs. EtOH (90 mL), H₂O (3 mL), anisaldehyde (2 mL), conc. H₂SO₄ (2 mL)]. Plates of silica gel PF₂₅₄ (Art. no. 7747), 20 x 50 cm, thickness 1.25 mm, activated at 120 °C for 2h were utilized in case of separation by preparative TLC technique. Bands were visualized by ultraviolet light either at λ_{\max} 254 or λ_{\max} 366 nm. Column chromatography was performed by using silica gel 60H (70-230 mesh ASTM, cat. No. 7734, E. Merck) and vacuum column chromatography was performed by using silica gel 60H (230-400 mesh ASTM, Art. no. 7731, E. Merck).

2.2 Plant Materials

The leaves and twigs of *Anogeissus rivularis* were collected from Ubon Ratchathani province of Thailand in July, 2011. A voucher specimen (BKF no. 173843) has been deposited at the Forest Herbarium, Royal Forest Department, Ministry of Agriculture and Cooperative, Bangkok, Thailand.

2.3 Extraction procedure for Chemical & Biological Studies

Air-dried and finely powdered leaves and twigs of *Anogeissus rivularis* (21.1kg) were divided to two parts; one part (16.4kg) was subjected to sequential extraction with hexane, ethyl acetate and methanol at room temperature and other part (4.7kg) was subjected to direct methanol extraction. All extracts were submitted to test the biological activities as well as the results were summarized in Scheme 2.1.




Scheme-2.1 Extraction procedure of leaves and twigs of *A. rivularis*.

2.4 Purification of Hexane extract:

Air-dried and finely powdered leaves and twigs of *Anogeissus rivularis* (16.4kg) was successively macerated with hexane (5 x 10.9 L) at room temperature, followed by filtration. The filtrates were combined and evaporated to dryness under reduced pressure to give a crude hexane extract (199.52g).

The hexane extract (199.52g) was subjected to flash column chromatography on silica gel [1000 g, Merck Art. No.7736: Ø 15 x16 cm], eluting with 100% hexanes(4mL), followed by 5%(4L), 10%(6L), 15%(6L), 20%(6L), 25%(6L), 40%(4L), 60%(2L), 80%(2L) ethyl acetate/hexane and 100% ethyl acetate followed by 100% methanol (300 mL). Fractions (500 mL each) were collected and combined on the basis of their TLC pattern and NMR characteristics to give five fractions (1F₁–1F₅) Scheme 2.2.



Scheme 2.2 Fractionation of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 1F₁ (12.65 g), eluted with 100% hexane and 5% hexane/EtOAc, was obtained as a yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.


Fraction 1F₂ (125.32 g), eluted with 10-15% hexane/EtOAc, was obtained as a greenish yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.

Fraction 1F₃ (13.53 g), eluted with 20-25% hexane/EtOAc, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (300 g, Merck Art.No.7734, 7.32 x 20 cm), eluting with hexane/CH₂Cl₂, followed by increasing amount of MeOH in hexane/CH₂Cl₂ and finally with MeOH. Fractions (200 mL each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub-fractions 2F₁–2F₇ (Scheme 2.3).

Fraction 1F₄ (9.71 g), eluted with 25-40% hexane/EtOAc, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (400 g, Merck Art.No.7734, 7.32 x 24 cm), eluting with hexane, followed by increasing amount of acetone and finally with MeOH. Fractions (200 mL each) were collected, monitored by TLC

and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 4F₁–4F₆ (Scheme-2.12).

Fraction 1F₅ (90.94 g), eluted with 60-100% Hexane/EtOAc and 100% MeOH, was obtained as a greenish yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.




Scheme 2.3 Fractionation of 1F₃(2F) of hexane extract obtained from 1st column

Fraction 2F₁ (0.1797 g), eluted with 30% hexane/CH₃Cl₂, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out. Pure fatty aldehyde and fatty alcohol (Compound-1&2) also found from this fraction.

Fraction 2F₂ (8.90 g), eluted with 70:30:2-70:30:2.5; hexane:CH₂Cl₂:MeOH was obtained as a greenish yellow semi-solid. It was separated by column chromatography on silica gel (450 g, Merck Art.No.7734, 7.32 x 26 cm), eluting with hexane, followed by increasing amount of EtOAc in hexane and finally with MeOH. Fractions (100 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 3F₁–3F₇ (Scheme-2.4).

Fraction 2F₃&2F₄ (0.8856 g), eluted with 3:30:70-4:30:70; MeOH: CH₃Cl₂: hexanes, was obtained as a green semi-solid with crystals. Pure **Betulinic acid (compound 3)** also found from this fraction by recrystallization.

Fraction 2F₅, 2F₆ and 2F₇ eluted with 6:30:70; HexaneCH₂Cl₂: MeOH to 100% MeOH, was obtained as a greenish yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.



Scheme 2.4 Fractionation of the 3F of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 3F₁ (0.0253 g), eluted with 5% hexane/EtOAc was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction 3F₂ (0.44 g), eluted with 7-10% hexane/EtOAc was obtained another fatty alcohol as white powder (**compound 4**). Pure **β-sitosterol** and **stigmasterol (compound 5)** 0.05g also found from this fraction as a mixture.


Fraction 3F₃ (1.33 g), eluted with 10-14% hexane/EtOAc was obtained as a green semi-solid with white needle crystal of **3β-hydroxy-20(29)-en-lupan-30-al (compound 6)**. To get compound -6 more it was separated by column chromatography on silica gel (66 g, Merck Art.No.7734, 3 x 22 cm), eluting with hexane, followed by increasing amount of EtOAc in hexane and finally with MeOH. Fractions (50 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 6F₁–6F₆ (Scheme-2.6).

Fraction 3F₄ (0.4403 g), eluted with 16% hexane/EtOAc, was obtained as a green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting

with 50/50; CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 5F₁–5F₃ (Scheme-2.5).

Fraction 3F₅(2.98 g), eluted with 16% hexane/ EtOAc, was obtained as a greenish brown semi-solid. It was separated by column chromatography on silica gel (165 g, Merck Art.No.7734, 4.4 x 26 cm), eluting with hexane, followed by increasing amount of EtOAc in hexane and finally with MeOH. Fractions (50 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 8F₁–8F₇ (Scheme-2.9).

Fraction 3F₆and 3F₇, eluted with 16-100 hexane/EtOAc and 100% MeOH, was obtained as a brown semi-solid and was found to contain mainly fat, so further purification was not carried out.



Scheme 2.5 Fractionation of the 5F of hexane extract of leaves and twigs of *A. rivularis*.


Fraction 5F₁, eluted with 50% CH₂Cl₂/MeOH, was obtained as a green semi-solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction 5F₂ (0.1411 g), eluted with 50% CH₂Cl₂/MeOH, was obtained as a green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and

combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 9F₁–9F₃ (Scheme-2.5).

Subfraction 9F₁, 9F₂ and 9F₃ was obtained dark brown semi-solid and this fraction didn't have interesting NMR peak, so further purification was not carried out.

Fraction 5F₃, eluted with 50% MeOH/CH₂Cl₂, was obtained 0.0310g pure white needle crystal of **29-Nor-20-oxolupeol (Compound7)**.




Scheme 2.6 Fractionation of the 3F of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 6F₁ (0.382 g), eluted with 100% hexane to 10% hexane/EtOAc, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction 6F₂ (0.4403 g), eluted with 12-15% hexane/ EtOAc, was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 11F₁–11F₆ (Scheme 2.8).

Fraction 6F₃ (0.4346 g), eluted with 15-18% hexane/EtOAc, was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 10F₁–10F₆ (Scheme 2.7).

Fraction 6F₄, 6F₅ and 6F₆ was obtained dark brown semi-solid and this fraction didn't have interesting NMR signal, so further purification was not carried out.



Scheme 2.7 Fractionation of the 10F of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 10F₁ (0.0151g), eluted with 50% CH₂Cl₂/MeOH, was obtained as a green semi-solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction 10F₂ (0.383 g), eluted with 50% CH₂Cl₂/MeOH was obtained as a green semi-solid. It was separated by preparative thin layer chromatography (PTLC), eluting with 70:20:5; Hexane:CH₂Cl₂:MeOH. The bands were collected to afford subfractions 12F₁–12F₃ (Scheme-2.7).


Subfraction 12F₁, 12F₂ and 12F₃ was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction 10F₃ (0.0046g), eluted with 50% CH₂Cl₂/MeOH was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction 10F₄ (0.0203g), eluted with 50% CH₂Cl₂/MeOH was obtained 0.0095g pure white needle crystal of **29-Nor-20-oxolupeol (Compound 7)**.

Fraction 10F₅ (0.0198g) eluted with 50% CH₂Cl₂/MeOH, was obtained 0.0175g pure white needle shaped crystal of **3β,6β-Dihydroxylup-20(29)-ene(Compound8)**.

Fraction 10F₆ (0.0011g), eluted with 50% CH₂Cl₂/MeOH was obtained as a reddish brown solid and was found to contain mainly pigments, so further purification was not carried out.



Scheme 2.8 Fractionation of 11F of hexane extract of leaves and twigs of *A. rivularis*.


Fraction 11F₁(0.0293g)&**11F₂**(0.3188g), eluted with 50% CH₂Cl₂/MeOH, was obtained as a green semi-solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction 11F₃ (0.0861g), eluted with 50% CH₂Cl₂/MeOH was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction 11F₄ (0.0198g) eluted with 50% CH₂Cl₂/MeOH, was obtained 0.0140g white needle crystal of **3β-hydroxy-20(29)-en-lupan-30-al(compound6)**.

Fraction 10F₅ (0.1022g) eluted with 50% CH₂Cl₂/MeOH was obtained 0.0985g pure white needle crystal of **3β,6β-Dihydroxylup-20(29)-ene(Compound8)**.

Fraction 10F₆ (0.0056g), eluted with 50% CH₂Cl₂/MeOH, was obtained as a reddish brown solid and was found to contain mainly pigments, so further purification was not carried out.



Scheme 2.9 Fractionation of 8F of leaves and twigs of *A. rivularis*.

Fraction 8F₁ (0.0550 g), eluted with 100% hexane to 10% hexanes/EtOAc, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction 8F₂ (0.1547 g), eluted with 10-15% hexane/EtOAc, was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 13F₁–13F₅ (Scheme 2.9).

Subfraction 13F₁, 13F₂, 13F₃ and 13F₄ eluted with 50% CH₂Cl₂/MeOH was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Subfraction 13F₅ (0.0519g), eluted with 50% CH₂Cl₂/MeOH, was obtained pure white needle crystal of **Betulinic acid (Compound 3)**.

Fraction 8F₃ (0.7864g), eluted with 15% hexane/EtOAc, was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 18F₁–18F₄ (see Scheme 2.9).


Subfraction 18F₁, 18F₂ and 18F₃ eluted with 50% CH₂Cl₂/MeOH, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Subfraction 18F₄ (0.1647g), eluted with 50% CH₂Cl₂/MeOH, was obtained pure white needle crystal of **Betulinic acid (Compound 3)**.

Fraction 8F₄ (0.5980g), eluted with 15-20% hexane/EtOAc, was obtained dark brown semi-solid. It was divided by two parts and separated by column chromatography on sephadex-LH20, eluting with 50% /CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 14F₁–14F₄ and 15F₁–15F₄ (Scheme-2.10).

Fraction 8F₅ (0.4858g), eluted with 20-30% hexane/EtOAc, was obtained dark brown semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% /CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 16F₁–16F₄ (Scheme-2.11).

Fraction 8F₆ (0.3175g), eluted with 50-100 hexane/EtOAc and 100% MeOH, was obtained as a brown semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 17F₁–17F₄ (Scheme-2.11).




Scheme 2.10 Fractionation of 14F and 15F of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 14F₁(0.0239g), **14F₂**(0.4131g) and **14F₃**(0.1198g)eluted with 50% CH₂Cl₂/MeOH was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat,so further purification was not carried out.

Fraction 14F₄ (0.0312g), eluted with 50% CH₂Cl₂/MeOH was obtained pure white needle crystal of **Betulinic acid(Compound-3)**.

Fraction 15F₁(0.0092g), **15F₂**(0.0438g) and **15F₃**(0.0038g)eluted with 50% CH₂Cl₂/MeOH, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat,so further purification was not carried out.

Fraction 15F₄ (0.0362g), eluted with 50% CH₂Cl₂/MeOH, was obtained pure white needle crystal of **Betulinic acid(Compound3)**.




Scheme 2.11 Fractionation of 16F & 17F of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 16F₁(0.0469g), **16F₂**(0.2445g), **16F₃**(0.0096g) and **16F₄**(0.0151g) eluted with 50% CH₂Cl₂/MeOH, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction 16F₅ (0.0876g), eluted with 50% /CH₂Cl₂/MeOH, was obtained pure white needle crystal of **Betulinic acid(Compound3)**.

Fraction 17F₁(0.0561g),**17F₂**(0.1582g), and **17F₃**(0.0173g)eluted with 50% CH₂Cl₂/MeOH, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat,so further purification was not carried out.

Fraction 17F₄ (0.2730g), eluted with 50% MeOH/CH₂Cl₂, was obtained pure white needle crystal of **Betulinic acid(Compound-3)**.



Scheme 2.12 Fractionation of 4F of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 4F₁ (0.3978 g), eluted with 100% hexane to 10% hexane/Acetone, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction 4F₂(0.2977g)&**4F₃**(2.1508g), eluted with 10-15% hexane/acetone, was obtained as a green semi-solid and was found to contain mainly porphyrine derivatives , so further purification was not carried out.

Fraction 4F₄ (2.7979g), eluted with 15% hexanes/acetone, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (130 g, Merck Art.No.7734, 4.46 x 22.5 cm), eluting with CH₂Cl₂, followed by increasing amount of Acetone in CH₂Cl₂ and finally with MeOH. Fractions (50 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 7F₁–7F₇ (Scheme-2.12).


Subfraction 7F₁ (0.1420g), eluted with 100% CH₂Cl₂, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Subfraction 7F₂ (0.129g), eluted with 100% CH₂Cl₂, was obtained dark brown semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 19F₁–19F₄ (Scheme-2.13).

Subfraction 7F₃ (0.5611g), eluted with 1% CH₂Cl₂/acetone, was obtained dark brown semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% CH₂Cl₂/MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions 20F₁–20F₄ (Scheme-2.13).

Subfraction 7F_{4,5,6,7} eluted with 1% acetone/CH₂Cl₂ to 100% acetone, was obtained dark brown semi-solid. This subfraction didn't have interesting NMR signal, so further purification was not carried out.

Fraction 4F₅ (2.6911g) & **4F₆** (0.4940g), eluted with 18-100% hexane/acetone was obtained as a green semi-solid and was found to contain mainly porphyrine derivatives and fatty acid, so further purification was not carried out.



Scheme 2.13 Fractionation of 19F & 20F of hexane extract of leaves and twigs of *A. rivularis*.

Fraction 19F₁(0.0079g) &**19F₂**(0.0588g), eluted with 50% CH₂Cl₂/MeOH was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction 19F₃(0.0016g) &**19F₄** (0.0127g), eluted with 50% CH₂Cl₂/MeOH, was obtained pink semi-solid and was found to contain mainly pigments, so further purification was not carried out.


Fraction 20F₁(0.029g) &**20F₂** (0.3865g), eluted with 50% CH₂Cl₂/MeOH, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction 20F₃(0.0232g) &**20F₄**(0.0027g), eluted with 50% CH₂Cl₂/MeOH, was obtained pink semi-solid and was found to contain mainly pigments, so further purification was not carried out.

2.5 Purification of Ethyl acetate extracts:

Residue of hexane extract of leaves and twigs of *A. rivularis* (16.4kg) were successively macerated with ethyl acetate (5 x 10.9 L) at room temperature, followed by filtration. The filtrates were combined and evaporated to dryness under reduced pressure to give a crude ethyl acetate extract (194.36g).

The ethyl acetate extract (194.36g) was first subjected to vacuum column chromatography on silica gel [202 g, Merck Art. No.7736: Ø 15x16 cm], eluting with hexane (5000mL), followed by 5% (8L), 10% (4L), 20% (4L), 40% (4L), 60% (4L), 100% acetone/hexane, 50% MeOH/acetone and followed by 100% methanol (300 ml). Fractions (500 ml each) were collected and combined on the basis of their TLC and NMR characteristics to give five fractions (Et1F₁–Et1F₆) after removal of solvents (Scheme-2.14).



Scheme-2.14 Fractionation Ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et1F₁ (8.1972g), eluted with 100% hexane, was obtained as a yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.

Fraction Et1F₂ (22.473g), eluted with 5% acetone/hexane, was obtained as a green semi-solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.


Fraction Et1F₃(9.7953g), eluted with 10% acetone/hexane, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (305 g, Merck Art. No.7734, 6.5 x 17 cm), eluting with hexane and followed by increasing amount of EtOAc in hexane and finally with MeOH. Fractions (100 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et22F₁–Et22F₇ (Scheme-2.32).

Fraction Et1F₄(22.7431g), eluted with 20% acetone/hexane, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (400 g, Merck Art.No.7734, 6 x 25 cm), eluting with CH₂Cl₂, followed by increasing amount of MeOH. Fractions (200 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et2F₁–Et2F₅ (Scheme-2.15).

Fraction Et1F₅(46.1379g), eluted with 40% acetone/hexane, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (1200g, Merck Art.No.7734, 9.5 x 27 cm), eluting with CH₂Cl₂, followed by increasing amount of MeOH. Fractions (200 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et3F₁–Et3F₈ (Scheme-2.23).

Fraction Et1F₆(52.8904g), eluted with 60-100% acetone/hexane, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (800g, Merck Art.No.7734, 9.5 x 20 cm), eluting with CH₂Cl₂, followed by increasing amount of MeOH. Fractions (200 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et19F₁–Et19F₉ (Scheme-2.30).

Fraction Et1F₇ (12.4159 g), eluted with 50% MeOH/acetone and 100% MeOH, was obtained as a greenish yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.



Scheme-2.15 Fractionation Et1F₄ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et2F₁(0.9756g) & **Et2F₂**(0.0667g), eluted with 100% CH₂Cl₂ to 1% MeOH/CH₂Cl₂, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction Et2F₃ (2.3559g), eluted with 2% MeOH/CH₂Cl₂, was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et5F₁–Et5F₇ (Scheme-2.21).

Fraction Et2F₄(15.3000g), eluted with 4-6% MeOH/CH₂Cl₂, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (400 g, Merck Art.No.7734, 6 x 22.5 cm), eluting with hexane, followed by increasing amount of Acetone in hexane and finally 100% MeOH. Fractions (200 mL each) were collected, monitored by TLC and combined on the basis of their TLC and ¹H NMR characteristics. The solvents were evaporated to afford subfractions Et4F₁–Et4F₆ (Scheme-2.16).

Fraction Et2F₅ (2.3859g), eluted with 10% MeOH/CH₂Cl₂ to 100% MeOH, was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH₂₀, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected,

monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et13F₁–Et13F₄ (Scheme-2.15).

Subfraction Et13F₁(0.5189g), eluted with 70% MeOH/CH₂Cl₂ was obtained as a greenish brown. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et13F₂(1.0257g), eluted with 70% MeOH/CH₂Cl₂ was obtained as a greenish brown. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.


Subfraction Et13F₃(0.1702g), eluted with 70% MeOH/CH₂Cl₂ was obtained as a greenish brown. The ¹H NMR spectrum of this fraction is interesting. It was separated by column chromatography on silica gel (30 g, Merck Art.No.7736, 2 x 15 cm), eluting with Hexane, followed by increasing amount of EtOAc in hexane to 100% EtOAc, after that increase amount of MeOH in EtOAc and finally 100% MeOH. Fractions (10 mL each) were collected, monitored by TLC and combined on the basis of their TLC and ¹H NMR characteristics. The solvents were evaporated to afford subfractions Et60F₁–Et60F₆ (Scheme-2.15).

The ¹H NMR spectrum of **Et60F₁-Et60F₃** was not interesting, so further purification was not carried out.

The ¹H NMR spectrum of **Et60F₄ & Et60F₅** indicates that it contain simple common compound, so further purification was not carried out.

The ¹H NMR spectrum of **Et60F₆** indicates that it contains pigments, so further purification was not carried out.

Subfraction Et13F₄(0.0765g), eluted with 70% MeOH/CH₂Cl₂ was obtained as a greenish brown. The ¹H NMR spectrum of this fraction was not interesting, so it was not further investigated.



Scheme-2.16 Fractionation of Et₂F₄ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et4F₁ (0.9288g), eluted with 100% hexane to 10% acetone/hexane, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction Et4F₂ (2.2091g), eluted with 20% acetone/hexane, was obtained as a green semi-solid and was found to contain mainly porphyrine derivatives and the ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et4F₃ (4.4033g), eluted with 20% acetone/hexane, was obtained as a green semi-solid. It was separated by column chromatography on silica gel (220 g, Merck Art.No.7734, 5 x 27 cm), eluting with 10% EtOAc/hexane, followed by increasing amount of EtOAc in hexane and finally 100% MeOH. Fractions (50ml each) were collected, monitored by TLC and combined on the basis of their TLC and ¹H NMR characteristics. The solvents were evaporated to afford subfractions Et14F₁–Et14F₄ (Scheme-2.16).

Subfraction Et14F₁ (0.291g), eluted with 10-30% EtOAc/hexane was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et35F₁–Et35F₄ (Scheme-2.17).

Subfraction Et14F₂ (1.1917g), eluted with 40% EtOAc/hexane was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et38F₁–Et38F₄ (Scheme-2.17).


Subfraction Et14F₃ (1.7538g), eluted with 50-85% EtOAc/hexane was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et39F₁–Et39F₆ (see Scheme-2.17).

Subfraction Et14F₄ (0.8492g), eluted with 100% EtOAc and 100% MeOH was obtained as a dark green semi-solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et4F₄ (3.038g), eluted with 25-30% acetone/hexane was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et15F₁–Et15F₃ (Scheme-2.17).

Fraction Et4F₅ (2.7269g), eluted with 35-100% acetone/hexane was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et12F₁–Et12F₄ (Scheme-2.17).

Fraction Et4F₆ (1.6845g), eluted with 50% MeOH/acetone and 100% MeOH was obtained as a greenish brown semi-solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.



Scheme-2.17 Fractionation of Et4F_{4,5} Et4F_{1,2,3} of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et12F₁(1.0873g) & **Et12F₂**(0.5552g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction Et12F₃(0.3567g), eluted with 50% MeOH/CH₂Cl₂, was obtained pink semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et12F₄ (0.6733g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et20F₁–Et20F₄ (Scheme-2.18).

Fraction Et15F₁(0.3987g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction Et15F₂(0.4281g), eluted with 50% MeOH/CH₂Cl₂, was obtained pink semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et15F₃ (0.2058g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red semi-solid. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et25F₁–Et25F₆ (Scheme-2.19).

Fraction Et35F₁(0.1129g), eluted with 70% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction Et35F₂(0.0935g), eluted with 70% MeOH/CH₂Cl₂, was obtained dark brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et35F₃(0.0624g), eluted with 70% MeOH/CH₂Cl₂, was obtained brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et35F₄(0.0022g), eluted with 70% MeOH/CH₂Cl₂, was obtained brown semi-solid and was found contain mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et38F₁(0.2828g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction Et38F₂(0.7250g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et38F₃(0.1036g), eluted with 50% MeOH/CH₂Cl₂, was obtained brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.


Fraction Et35F₄(0.0174g), eluted with 50% MeOH/CH₂Cl₂, was obtained red semi-solid and was found contain mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et39F₁(0.2130g) & **Et39F₂**(0.5639g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction Et39F₃(0.1630g) & **Et39F₄** (0.6356g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et39F₅(0.0775g), eluted with 50% MeOH/CH₂Cl₂, was obtained brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et39F₆(0.0089g), eluted with 50% MeOH/CH₂Cl₂, was obtained yellow powder and was found contain mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.



Scheme-2.18 Fractionation of Et12F₄ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et20F₁(0.0312g), eluted with 70% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction Et20F₂ (0.4516g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a red semi-solid. It was separated by column chromatography on sephadex-LH₂₀, eluting with 100% MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on

the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et41F₁–Et41F₅ (Scheme-2.18).

Subfraction Et41F₁(0.0162g), eluted with 100% MeOH, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Subfraction Et41F₂(0.1123g), eluted with 100% MeOH, was obtained dark brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et41F₃(0.2634g), eluted with 100% MeOH, was obtained brown semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et41F₄(0.0389g), eluted with 100% MeOH, was obtained red semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et41F₅(0.0070g), eluted with 100% MeOH, was obtained pink semi-solid and was found contain mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et20F₃ (0.2337g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a brown semi-solid. It was separated by preparative thin layer chromatography (PTLC), running with 1.5% MeOH/CH₂Cl₂. Seven bands were collected. The solvents were evaporated to afford sub fractions Et40F₁–Et40F₇ (Scheme-2.18).

Subfraction Et40F₁(0.0614g), run with 1.5% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found interesting ¹H NMR spectrum. It was separated by preparative thin layer chromatography (PTLC), running with 10% EtOAc/Hexane. Five bands were collected. The solvents were evaporated to afford sub fractions Et46F₁–Et46F₅ (Scheme-2.18).

Subfraction Et46F₁(0.0054g), obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et46F₂(0.0020g), obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et46F₃(0.0034g), obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et46F₄(0.0052g), obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et46F₅(0.0050g), obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et40F₂(0.0029g), run with 1.5% MeOH/CH₂Cl₂, was obtained brown solid was found. The ¹H NMR spectrum of this fraction is interesting and almost pure. It can run 2D NMR but small.

Subfraction Et40F₃(0.0039g), run with 1.5% MeOH/CH₂Cl₂, was obtained brown solid was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.


Subfraction Et40F₄(0.0634g), run with 1.5% MeOH/CH₂Cl₂, was obtained pure yellowish **Vanilic acid (3-methoxy 4-hydroxybenzoic acid)(compound 19)** was found.

Subfraction Et40F₅(0.0523g), run with 1.5% MeOH/CH₂Cl₂, was obtained pink semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et40F₆(0.0887g), run with 1.5% MeOH/CH₂Cl₂, was obtained pink semi-solid and was found. The ¹H NMR spectrum of this fraction is interesting. This fraction was separated by HPLC with solvent system 30% W/M. Twelve peaks were collected. The solvents were evaporated to afford sub fractions Et58F₁–Et58F₇ (Scheme-2.19).

Subfraction Et40F₇(0.0115g), run with 1.5% MeOH/CH₂Cl₂, was obtained yellow semi-solid and was found. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et20F₄(0.0256g), eluted with 70%; MeOH/CH₂Cl₂, was obtained yellow powder and was found contain mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.



Scheme-2.19 Fractionation of Et12F₄ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et58F₁(0.0072g), run with 30% H₂O/MeOH, obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et58F₂(0.0025g), run with 30% H₂O/MeOH, obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et58F₃(0.0039g), run with 30% H₂O/MeOH, obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et58F₄(0.0094g), run with 30% H₂O/MeOH, obtained pure **2,3-dihydro-*p*-Cumaric acid (Compound 15)** as a white solid.

Fraction Et58F₅(0.0020g), run with 30% H₂O/MeOH, obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et58F₆(0.0172g), run with 30% H₂O/MeOH, obtained pure ***p*-Cumaric acid (Compound 14)** as a white solid.

Fraction Et58F₇(0.0023g), run with 30% H₂O/MeOH, obtained as a white solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et25F₁ (0.1210g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat, so further purification was not carried out.

Fraction Et25F₂ (0.8040g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives. The ¹H NMR is not interesting, so further purification was not carried out.

Fraction Et25F₃ (0.8666g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark green semi-solid. It was separated by column chromatography on sephadex-LH₂₀, eluting with 100% MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et44F₁–Et44F₅ (Scheme-2.19).

Subfraction Et44F₁(0.0037g), obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et44F₂(0.4289g), obtained as a green solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et44F₃(0.2478g), obtained as a yellowish white solid. The ¹H NMR spectrum of this fraction is interesting and almost pure so need to further purification.

Subfraction Et44F₄(0.0249g), obtained as a yellowish white solid. The ¹H NMR spectrum of this fraction is interesting and almost pure so need to further purification.


Subfraction Et44F₅(0.0012g), obtained as a pink solid, contained mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et25F₄ (0.2780g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected,

monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et56F₁–Et56F₃ (Scheme-2.20).

Fraction Et25F₆ (0.0321g), eluted with 50% MeOH/CH₂Cl₂, was obtained pink solid. The ¹H NMR is not interesting, so further purification was not carried out.

Fraction Et25F₇ (0.0013g), obtained as a pink solid, contained mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.



Scheme-2.20 Fractionation of Et25F₄ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et56F₁ (0.0073g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark brown solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et56F₂ (0.2492g), eluted with 50% MeOH/CH₂Cl₂. It was separated by reverse phase column chromatography, eluting with 70% H₂O/MeOH to 100% MeOH. Fractions (5 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et64F₁–Et64F₈ (Scheme-2.20).

Due to the limitation of time **Subfraction Et64F₁, Et64F₂**, was not investigated, so further investigation is needed.


Subfraction Et64F₃, eluted with 50% H₂O/MeOH, **Vanilic acid (compound-19)** was crystal out as a white crystal.

Due to the limitation of time **Subfraction Et64F₄,Et64F₅**, was not investigated, so further investigation is needed.

Subfraction Et64F₆, eluted with 50% H₂O/MeOH, 0.0056g of **compound 23,(New)** was crystal out as a white crystal.

Due to the limitation of time **Subfraction Et64F₇,Et64F₈**, was not investigated, so further investigation is needed.

Fraction Et56F₃ (0.0042g), eluted with 50% MeOH/CH₂Cl₂, was obtained redsolid, contain mainly pigments,so further purification was not carried out.



Scheme-2.21 Fractionation of Et₂F₃ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et5F₁ (1.1987g)&**Et5F₂**(0.3105g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark green semi-solid and was found to contain mainly porphyrine derivatives and fat,so further purification was not carried out.

Fraction Et5F₃ (0.0567g), eluted with 50% MeOH/CH₂Cl₂, was obtained dark brown semi-solid with white crystal of (**Compound10**),so further purification was not carried out.

Fraction Et5F₄ (0.1127g), eluted with 50% MeOH/CH₂Cl₂,**3,3',4'-tri-o-methylelagic acid(compound 9)** was powder out. The ¹H NMR spectrum of mother liquor is interesting and similar to **Et5F₅**, so it's combined with **Et5F₅** to run column again.

Fraction Et5F₅ (0.3354g), eluted with 50% MeOH/CH₂Cl₂ and mother liquor of **Et5F₄**, was combined on the basis of ¹H NMR spectrum. It was separated by column chromatography on sephadex-LH20, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et16F₁–Et16F₃ (Scheme-2.22).

Fraction Et5F₆ (0.0292g), eluted with 50% MeOH/CH₂Cl₂, was obtained red solid with white crystal. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 100% MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et7F₁–Et7F₆ (Scheme-2.21).

Subfraction Et7F₁ (0.0028g), obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.


Subfraction Et7F₂ (0.0102g), obtained as a white crystal of two compounds (**Comp^d-11**). Both of these are known compounds, so further purification was not carried out.

Subfraction Et7F₃ (0.0060g), obtained as a red solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et7F₄ (0.0022g), eluted with 100% MeOH, was obtained reddish brown solid and was found interesting ¹H NMR spectrum. It was separated by preparative thin layer chromatography (PTLC), running with 2% MeOH/CH₂Cl₂. Six bands were collected. The solvents were evaporated to afford sub fractions Et43F₁–Et43F₆ (see Scheme-2.21). The ¹H NMR spectrum of Et43F₁–Et43F₆ fraction is not interesting, so further purification was not carried out.

Subfraction Et7F₅ (0.0021g), obtained as a pink solid, contained mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Subfraction Et7F₆(0.0103g), obtained as a off-white powder, contained mainly pigments and fatty acid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.



Scheme-2.22 Fractionation of Et5F₄ & Et5F₅ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et16F₁(0.0046g), eluted with 70% MeOH/CH₂Cl₂ obtained as a dark brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et16F₂(1.1996g), eluted with 70% MeOH/CH₂Cl₂ obtained as a dark brown solid. It was separated by column chromatography on silica gel (30 g, Merck Art.No.7736, 3 x 15 cm), eluting with acetone/hexane gradient, followed by increasing amount of acetone in hexane and finally 100% MeOH. Fractions (5ml each) were collected, monitored by TLC and combined on the basis of their TLC and ¹H NMR characteristics. The solvents were evaporated to afford subfractions Et26F₁–Et26F₉ (Scheme-2.22).

The ¹H NMR spectrum of **Subfraction Et26F₁–Et26F₅** fraction is not interesting, so further purification was not carried out.

Subfraction Et26F₆ eluted with 20% acetone/hexane, obtained 0.0035g pure loliolide (Comp^d-18) as a white crystal.


The ^1H NMR spectrum of **Subfraction Et26F₇-Et26F₉** fraction is not interesting, so further purification was not carried out.

Fraction Et16F₃(0.0910g), eluted with 70% MeOH/CH₂Cl₂, pure 0.0006g **3,3',4'-tri-*o*-methylellagic acid (Compound9)** was powder out. The ^1H NMR spectrum of mother liquor is interesting. It was separated by column chromatography on silica gel (20 g, Merck Art.No.7736, 3 x 15 cm), eluting with EtOAc/hexane gradient, followed by increasing amount of EtOAc in hexane and finally 100% MeOH. Fractions (5ml each) were collected, monitored by TLC and combined on the basis of their TLC and ^1H NMR characteristics. The solvents were evaporated to afford subfractions Et23F₁-Et23F₅ (Scheme-2.22).

The ^1H NMR spectrum of **Subfraction Et23F₁** fraction is not interesting, so further purification was not carried out.

Subfraction Et23F₂(0.0101g), eluted with 20% EtOAc/hexane, obtained as a red solid. The ^1H NMR spectrum of this fraction is interesting and almost pure. It was separated by preparative thin layer chromatography (PTLC), running with 0.1% MeOH/CH₂Cl₂. The bands red with anisaldehyde reagent was collected 0.0032g as a pure **new compound (Compound20)**.

The ^1H NMR spectrum of **Subfraction Et23F₃-Et26F₅** fraction is not interesting, so further purification was not carried out.



Scheme-2.23 Fractionation of Et1F₅ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et3F₁ (0.1853g), eluted with 100% CH₂Cl₂ to 0.5% MeOH/CH₂Cl₂, was obtained as a yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.

Fraction Et3F₂ (0.0333g), eluted with 1% MeOH/CH₂Cl₂, was obtained as a green semi-solid. **3,3',4'-tri-*o*-methyllellagic acid (compound9)** also powder out as a yellow powder. The mother liquor was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et3F₃(1.1744g), eluted with 2% MeOH/CH₂Cl₂, was obtained as a green semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et6F₁–Et6F₅ (Scheme-2.25).

Fraction Et3F₄(1.5948g), eluted with 3% MeOH/CH₂Cl₂, was obtained as a dark green semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et9F₁–Et9F₆ (Scheme-2.25).

Fraction Et3F₅(5.6589g), eluted with 5% MeOH/CH₂Cl₂, was obtained as a dark green semi-solid. It was separated by column chromatography on silica gel (140 g, Merck Art. No.7734, 4 x 25 cm), eluting with hexanes and followed by increasing amount of Acetone in hexane and finally with methanol. Fractions (100 mL each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et8F₁–Et8F₇ (Scheme-2.23).

Subfraction Et8F₁ (0.1235g), eluted with 10-20% acetone/hexane, was obtained as a white solid and was found to contain mainly fat, so further purification was not carried out.

Subfraction Et8F₂(2.7082g), eluted with 30% acetone/hexane, was obtained as a green semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml

each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et21F₁–Et21F₃ (Scheme-2.24).

Subfraction Et8F₃(1.0454g), eluted with 35-50% acetone/hexane, was obtained as a dark green semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et17F₁–Et17F₄ (see Scheme-2.24).

Subfraction Et8F₄(0.6419g), eluted with 60% acetone/hexane, was obtained as a dark green semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et18F₁–Et18F₃ (Scheme-2.24).


Subfraction Et8F₅(0.1700g)&**Et8F₆**(0.0885g), eluted with 70-80% acetone/hexane, was obtained as a dark green semi-solid. The ¹H NMR spectrum is interesting. It was combined and separated by column chromatography on sephadex-LH20, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et24F₁–Et24F₄ (Scheme-2.24).

Subfraction Et8F₆ (0.4849g), eluted with 100% acetone and 100% MeOH, was obtained as a brown solid and was found to contain mainly fatty acid, so further purification was not carried out.

Fraction Et3F₆(13.7141g), eluted with 5% MeOH/CH₂Cl₂, was obtained as a dark brown semi-solid. It was separated by column chromatography on silica gel (350 g, Merck Art. No.7734, 6 x 20 cm), eluting with hexane and followed by increasing amount of EtOAc in hexane and finally with methanol. Fractions (100 mL each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et10F₁–Et10F₇ (Scheme-2.26).

Fraction Et3F₇(14.62g), eluted with 7-15% MeOH/CH₂Cl₂, was obtained as a dark brown semi-solid. It was separated by column chromatography on silica gel (300 g, Merck Art. No.7734, 6 x 16 cm), eluting with hexane and followed by increasing amount of EtOAc in hexane and finally with methanol. Fractions (100 mL each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et11F₁–Et11F₆ (Scheme-2.26).

Fraction Et3F₈ (5.7860g), eluted with 20-100% MeOH/CH₂Cl₂, was obtained as a brown solid and was found to contain mainly fatty acid, so further purification was not carried out.



Scheme-2.24 Fractionation of Et8F₂ to Et8F₆ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et17F₁ (0.8665g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et17F₂ (0.1647g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et17F₃ (0.0327g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et17F₄ (0.0117g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et18F₁ (0.5710g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a green solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et18F₂ (0.0273g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et18F₃ (0.0096g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et21F₁ (0.4136g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et21F₂ (1.3690g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.


Fraction Et21F₄ (0.9609g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et24F₁ (0.2156g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a green solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et24F₂ (0.0187g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et24F₃ (0.0073g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.

Fraction Et24F₄ (0.0027g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments. The ¹H NMR spectrum of this fraction is not interesting, so further purification was not carried out.



Scheme-2.25 Fractionation of Et3F₃ & Et3F₄ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et6F₁ (0.3545g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a dark green solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et6F₂ (0.4599g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et6F₃ (0.2182g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a dark brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et6F₄ (0.0849g), eluted with 70% MeOH/CH₂Cl₂, 0.0226g **3,3',4'-tri-*o*-methyllellagic acid (compound-09)** was powder out. The ¹H NMR spectrum of mother liquor is interesting and similar to **Et6F₅**, so it's combined with **Et6F₅** to run column again.

Fraction Et6F₅ (0.0078g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a red solid and mother liquor of **Et6F₄**, was combined on the basis of ¹H NMR spectrum. It was separated by column chromatography on silica gel (18 g, Merck Art. No.7736, 2 x 24 cm), eluting with hexane and followed by increasing amount of EtOAc in hexane and finally with MeOH. Fractions (5 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et30F₁–Et30F₉ (Scheme-2.25).

The ¹H NMR spectrum of **subfraction Et30F₁–Et30F₉**, is not interesting and the amount was very small, so further purification was not carried out.

Fraction Et9F₁ (0.6750g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a dark green solid and was found to contain mainly porphyrine derivatives, so further purification was not carried out.


Fraction Et9F₂ (0.4379g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et9F₃ (0.1120g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a dark brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et9F₄ (0.0849g), eluted with 70% MeOH/CH₂Cl₂, 0.0015g **4,4'-di-*o*-methylellagic acid (compound12)** was powder out as a yellow powder.

Fraction Et9F₅ (0.0099g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a red solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et9F₆ (0.0029g), eluted with 70% MeOH/CH₂Cl₂. Pure 0.0029g **4',5,7-trihydroxyflavanone (compound13)** was powder out as a yellow powder.



Scheme-2.26 Fractionation of Et₃F₆ & Et₃F₇ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et10F₁ (0.6392g), eluted with 20-50% EtOAc/hexane, was obtained as a white powder and was found to contain mainly fat, so further purification was not carried out.

Fraction Et10F₂ (1.8805g), eluted with 60% EtOAc/hexane, was obtained as a dark green semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et28F₁–Et28F₇ (Scheme-2.27).

Fraction Et10F₃ (2.7248g), eluted with 60-70% EtOAc/hexane, was obtained as a dark green semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et31F₁–Et31F₆ (Scheme-2.28).

Fraction Et10F₄ (2.0352g), eluted with 80% EtOAc/hexane, was obtained as a dark brown semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et32F₁–Et32F₆ (Scheme-2.28).

Fraction Et10F₅(1.9841g), eluted with 100% EtOAc, was obtained as a brown semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et33F₁–Et33F₆ (Scheme-2.28).

Fraction Et10F₆(2.0352g), eluted with 10% MeOH/EtOAc, was obtained as a dark brown semi-solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et10F₆(0.8301g), eluted with 30-100% MeOH/EtOAc, was obtained as a brown semi-solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et11F₁ (0.2486g), eluted with 20-50% EtOAc/hexane, was obtained as a dark brown semi-solid. Pure 0.0079g, *p*-Cumaryl acid(**compound 14**) and 0.0254g, **3,4-dihydroxy benzoic acid(compound16)** was crystal out in vial no. 3 and vial no. 4-5 respectively. The ¹H NMR spectrum of mother liquor is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et29F₁–Et29F₆ (Scheme-2.29).


Fraction Et11F₂(1.6402g), eluted with 60-70% EtOAc/hexane, was obtained as a brown semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et34F₁–Et34F₄ (Scheme-2.29).

Fraction Et11F₃(2.6812g), eluted with 80% EtOAc/hexane, was obtained as a brown semi-solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et36F₁–Et36F₄ (Scheme-2.29).

Fraction Et11F₄(2.9925g), eluted with 100% EtOAc to 10% MeOH/EtOAc, was obtained as a brown solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et37F₁–Et37F₃ (Scheme-2.29).

Fraction Et11F₅ (4.2363g), eluted with 10-30% MeOH/EtOAc. Pure 0.0067g, **Stigmast-5-en-3-O-β-glucoside (compound 17)** was powder out as a white powder.

Fraction Et11F₆(1.4398g), eluted with 30-100% MeOH/EtOAc, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.



Scheme-2.27 Fractionation of Et10F₂ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et28F₁ (0.9982g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et28F₂ (0.7296g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark green. The ¹H NMR spectrum is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et42F₁–Et42F₃ (Scheme-2.27).

Subfraction Et42F₁ (0.0053g) & **Et42F₂** (0.0662g), eluted with 100% MeOH, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Subfraction Et42F₃ (0.0053g), eluted with 100% MeOH, was obtained as a brown solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on silica gel (30 g, Merck Art. No.7736, 2 x 15 cm), eluting with CH₂Cl₂ and followed by increasing amount of MeOH in CH₂Cl₂ and finally with MeOH. Fractions (5 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et61F₁–Et61F₆ (Scheme-2.27). The ¹H NMR spectrum of **subfractions Et61F₁–Et61F₆** are not interesting, so further purification were not carried out.

Subfraction Et42F₄ (0.0197g) & **Et42F₅** (0.0046g), eluted with 100% MeOH, was obtained as a red solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.

Fraction Et28F₃ (0.0935g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et28F₄ (0.0153g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et28F₅ (0.0070g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et28F₆ (0.0767g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink solid. The ¹H NMR spectrum of this fraction is interesting. It was separated by HPLC

(C-18, reverse phase column), eluting with 30% H₂O/MeOH. Eight pick were collected, monitored by TLC. The solvents were evaporated to afford sub fractions Et52F₁–Et52F₈ (Scheme-2.27).

The ¹H NMR spectrum of **subfraction 52F₁** is not interesting, so further purification was not carried out.

Subfraction Et52F₂ (0.0057g), obtained as a yellow powder, It is pure compound (**compound 22, new**).


The ¹H NMR spectrum of **subfraction 52F₃ & 52F₄** is interesting but very small amount, so further purification was not carried out.

Subfraction Et52F₅ (0.0012g), obtained as a white powder is interesting but very small amount, so further purification was not carried out.

The ¹H NMR spectrum of **subfraction 52F₆ & 52F₇** is interesting but very small amount, so further purification was not carried out.

Subfraction Et52F₈ (0.0338g), obtained as a yellow solid, It is pure compound (**Compound 21, new**).

Fraction Et28F₇ (0.0070g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.



Scheme-2.28 Fractionation of Et10F₃₋₅ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et31F₁ (1.2115g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et31F₂ (0.3437g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et31F₃ (0.9682g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et31F₄ (0.0952g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et31F₅ (0.0076g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et31F₆ (0.0045g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.

Fraction Et32F₁ (0.5910g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et32F₂ (0.5682g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et32F₃ (0.5709g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et32F₄ (0.2662g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et32F₅ (0.0173g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et32F₆ (0.0650g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.

Fraction Et33F₁ (0.1775g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.


Fraction Et33F₂ (0.5040g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et33F₃ (0.1372g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et33F₄ (0.1355g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et33F₅ (0.0397g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et33F₆ (0.0091g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.



Scheme-2.29 Fractionation of Et10F_{3.5} of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et29F₁ (0.1115g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid, it's contained mainly porphyrine derivatives. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et29F₂ (0.0305g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et29F₃ (0.0321g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et29F₄ (0.0221g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et29F₅ (0.0154g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et29F₆ (0.0290g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.

Fraction Et34F₁ (1.1544g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. It's contained mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et34F₂ (0.2395g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et34F₃ (0.1803g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et34F₄ (0.0260g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink semi-solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.

Fraction Et36F₁ (0.6622g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. It's contained mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et36F₂ (1.6456g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.


Fraction Et36F₃ (0.3682g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a yellow solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et36F₄ (0.0053g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red semi-solid, contained mainly pigments. The ¹H NMR spectrum is not interesting also, so further purification was not carried out.

Fraction Et37F₁ (1.1744g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. It's contained mainly porphyrine derivatives, so further purification was not carried out.

Fraction Et37F₂ (0.7451g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et34F₃ (1.0620g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.



Scheme-2.30 Fractionation of Et1F₆ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et19F₁ (1.6320g), eluted with 100% CH₂Cl₂ to 3% MeOH/CH₂Cl₂, was obtained as yellow semi-solid and was found to contain mainly fat, so further purification was not carried out.

Fraction Et19F₂ (1.9130g), eluted with 3-6% MeOH/CH₂Cl₂, was obtained dark brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et55F₁–Et55F₅ (Scheme-2.31).

Fraction Et19F₃ (1.9130g), eluted with 3-6% MeOH/CH₂Cl₂, was obtained dark brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et54F₁–Et54F₃ (Scheme-2.30).

Subfraction Et34F₁ (1.0927g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. It's contained mainly porphyrine derivatives, so further purification was not carried out.

Subfraction Et54F₂ (0.7278g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Subfraction Et54F₃ (0.4480g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et19F₄ (5.380g), eluted with 9% MeOH/CH₂Cl₂, was obtained dark brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 80% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et53F₁–Et53F₃ (Scheme-2.31).

Fraction Et19F₅ (4.5657g), eluted with 12-15% MeOH/CH₂Cl₂, was obtained dark brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 80% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et51F₁–Et51F₃ (Scheme-2.31).

Fraction Et19F₆ (12.1494g), eluted with 20% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is interesting. It was separated by column chromatography on silica gel (300 g, Merck Art. No.7734, 6 x 16 cm), eluting with CH₂Cl₂ and followed by increasing amount of MeOH in CH₂Cl₂ and finally with MeOH. Fractions (5 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford subfractions Et57F₁–Et57F₇ (Scheme-2.31).

Fraction Et19F₇ (4.5657g), eluted with 30% MeOH/CH₂Cl₂, was obtained dark brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH₂₀, eluting with 70% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et48F₁–Et48F₃ (Scheme-2.30).

Subfraction Et48F₁ (2.7386g), eluted with 70% MeOH/CH₂Cl₂, was obtained as a green solid. It's contained mainly porphyrine derivatives, so further purification was not carried out.

Subfraction Et48F₂(2.2787g), eluted with 70% MeOH/CH₂Cl₂, was obtained brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 100% MeOH. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et62F₁–Et62F₄ (Scheme-2.30).


The ¹H NMR of sub fractions **Et62F₁–Et62F₄** was not interesting, so further purification was not carried out.

Subfraction Et48F₃(1.4921g), eluted with 70% MeOH/CH₂Cl₂, was obtained brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 100% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et63F₁–Et63F₆ (Scheme-2.30).

The ¹H NMR of sub fractions **Et63F₁–Et63F₆** was not interesting, so further purification was not carried out.

Fraction Et19F₈ (3.94g), eluted with 50% MeOH/CH₂Cl₂, was obtained as reddish brown solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et19F₉, (2.8391g), eluted with 100% MeOH, was obtained as reddish brown and was found to contain mainly fatty acid, so further purification was not carried out.



Scheme-2.31 Fractionation of Et19F_{2,4,5,6} of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et51F₁ (1.3981g), eluted with 80% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et51F₂ (2.12g), eluted with 80% MeOH/CH₂Cl₂, was obtained as a dark brown solid. It's need to further purification.

Fraction Et51F₃ (1.0382g), eluted with 80% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Fraction Et53F₁ (1.9024g), eluted with 80% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et53F₂ (2.5438g), eluted with 80% MeOH/CH₂Cl₂, was obtained as a dark brown solid. It's need to further purification.

Fraction Et53F₃ (1.0382g), eluted with 80% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Fraction Et55F₁ (1.3563g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et55F₂ (0.2841g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a dark brown solid. It's need to further purification.

Fraction Et55F₃ (0.0285g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Fraction Et55F₄ (0.0409g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Fraction Et55F₅ (0.0062g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a reddish brown solid, it contained mainly pigments, so further purification was not carried out.

Fraction Et57F₁, eluted with 50-80% EtOAc/hexane, was obtained as a green solid and was found to contain mainly fat, so further purification was not carried out.

Fraction Et57F₂, eluted with 100% EtOAc/hexane to 2% MeOH/CH₂Cl₂. Pure 0.0752g, **Stigmast-5-en-3-O-β-glucoside (compound17)** was powder out as a white powder.


Fraction Et57F₃, eluted with 5% MeOH/CH₂Cl₂, 0.0637g, was powder out as a white powder.

Fraction Et57F₄, eluted with 10% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Fraction Et57F₅, eluted with 15-20% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Fraction Et57F₆, eluted with 30% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Fraction Et57F₇, eluted with 50% MeOH/CH₂Cl₂ to 100% MeOH, was obtained as a brown semi-solid. It's contained mainly fatty acid, so no need to further purification.



Scheme-2.32 fractionation of Et1F₃ of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et22F₁ (1.6032g), eluted with 100% hexane 1% EtOAc/hexane, was obtained as a yellow semi-solid, contained mainly fat, so further purification was not carried out.

Fraction Et22F₂ (0.0420g), eluted with 10% EtOAc/hexane, was obtained as a green semi-solid. The ¹H NMR spectrum is not interesting, so further purification was not carried out.

Fraction Et22F₃(0.3136g), eluted with 15% EtOAc/hexane, was obtained brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et45F₁–Et45F₆ (Scheme-2.32).

Subfraction Et45F₁ (0.2198g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid, it contained mainly porphyrine derivatives, so further investigation was not carried out.

Subfraction Et45F₂ (0.0294g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid. The ¹H NMR spectrum is not interesting, so further investigation was not carried out.

Subfraction Et45F₃ (0.0170g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further investigation was not carried out.

Subfraction Et45F₄ (0.0296g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid, The ¹H NMR spectrum is interesting. It was separated by reverse phase column chromatography, eluting with MeOH/H₂O and followed by increasing amount of MeOH in H₂O and finally with MeOH. This column needs to subfractionate on the basis of their TLC characteristic.

Subfraction Et45F₅ (0.0031g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid. The ¹H NMR spectrum is not interesting, so further investigation was not carried out.

Subfraction Et45F₆ (0.0016g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a pink solid, it's contained mainly pigments, so further investigation was not carried out.

Fraction Et22F₄(0.6104g), eluted with 20% EtOAc/hexane, was obtained brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC

characteristics. The solvents were evaporated to afford sub fractions Et47F₁–Et47F₆ (Scheme-2.33).

Fraction Et22F₅(1.6636g), eluted with 20% EtOAc/hexane, was obtained brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et49F₁–Et49F₆ (Scheme-2.33).

Fraction Et22F₆(2.8728g), eluted with 25-30% EtOAc/hexane, was obtained brown semi-solid. The ¹H NMR is interesting. It was separated by column chromatography on sephadex-LH20, eluting with 50% MeOH/CH₂Cl₂. Fractions (2 ml each) were collected, monitored by TLC and combined on the basis of their TLC characteristics. The solvents were evaporated to afford sub fractions Et50F₁–Et50F₆ (Scheme-2.32).

Subfraction Et50F₁ (0.3468g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Subfraction Et50F₂ (0.3949g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.


Subfraction Et50F₃ (0.9786g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Subfraction Et50F₄ (0.1605g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. It's need to further purification.

Subfraction Et50F₅ (0.0220g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a reddish brown solid. It's need to further purification.

Subfraction Et50F₆ (0.0070g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments, so no need to further purification.

Fraction Et22F₇(3.0077g), eluted with 40-100% EtOAc/hexane to 100% MeOH, was obtained brown semi-solid. The ¹H NMR is interesting, so it needs to further purification.



Scheme-2.33 Fractionation of Et22F_{4,5} of ethyl acetate extracts of leaves and twigs of *A. rivularis*.

Fraction Et47F₁ (0.2572g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid, it contained mainly porphyrine derivatives, so further investigation was not carried out.

Fraction Et47F₂ (0.0399g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is not interesting, so further investigation was not carried out.

Fraction Et47F₃(0.1288g), eluted with 50% MeOH/CH₂Cl₂. Pure 0.0708g, **Betulinic acid (comp^d-03)** was powder out as a white needle crystal.

Fraction Et47F₄ (0.0220g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a reddish brown solid. It's need to further purification.

Subfraction Et47F₅ (0.0894g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid, The ¹H NMR spectrum is interesting. It was separated by reverse phase column chromatography, eluting with MeOH/H₂O gradient and followed by increasing amount of MeOH in H₂O and finally with MeOH. This column needs to subfractionate on the basis of their TLC characteristic. Vial no. 98-102 has white crystal its need to characterize also.

Fraction Et47F₆(0.0032g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments, so no need to further purification.

Fraction Et49F₁ (1.1732g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a green solid, it contained mainly porphyrine derivatives, so further investigation was not carried out.

Fraction Et49F₂ (0.3389g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a brown solid. The ¹H NMR spectrum is interesting, so it's need to further purification.

Fraction Et49F₃ (0.1357g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a reddish brown solid. It's need to further purification.

Fraction Et49F₄ (0.0139g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a reddish brown solid. It's need to further purification.

Fraction Et47F₆(0.0021g), eluted with 50% MeOH/CH₂Cl₂, was obtained as a red solid, contained mainly pigments, so no need to further purification.

PART-B: Herba Fomulations

2.6 Study area and sample collection

Samples of thirteen antidiabetic herbal preparations (ADPHs) as finish commercial pack were purchased randomly from different herbal medicine outlets of Dhaka city. Initially, all the samples were prepared for analysis in the research laboratory, Department of Chemistry, University of Dhaka, Microbiological contamination and heavy metal content were analyzed in the Centre for Advanced Research in Sciences (CARS), University of Dhaka, Bangladesh.

2.7 Determination of pH of sample

The pH of different herbal preparation was determined by using microprocessor pH meter (HI 2210; Hanna Instrument, USA) as described earlier [59]. For pH determination, sample solution was prepared by dissolving 12.5 g in 100 mL sterile distilled water with shaking to obtain a homogeneous solution. The pH of the solution of different herbal preparation was measured by microprocessor pH meter and the data are presented as the average of triplicate.

2.8 Preparation of media

All the media of microbiological analysis were perpetrated according to the manufactures guidelines and sterilized in an autoclave (CL-32S; ALPCo. Ltd., Japan) at 121°C for 40 minutes. The sterile media were dispensed or poured into sterilized Petri dishes or test tube as required. The sterility of the prepared media was confirmed by incubating blindly selected plates at 37°C for overnight.

2.9 Total aerobic bacterial count and total coliform count

Total aerobic bacterial count was performed to assess the quality and shelf life of the herbal formulation. Twenty five (25) g of each sample were homogenized in 225 ml of sterile saline water. After that, 0.1 ml from two fold diluted samples was spread on a Petridish containing Tryptic Soy agar (TSA)(Oxoid Ltd, Hampshire, England) and incubated at 35°C for 24 hours for total aerobic bacterial count [60]. To assess the hygiene of the formulations, total coliform count was performed by spreading 0.1 ml of the sample (as used for total aerobic count) on MacConkey agar (Oxoid Ltd, Hampshire, England) and was incubated at 35°C and 42°C for 24 hours [61].

2.10 *Escherichia coli* 0157

Twenty five (25) g of each sample were homogenized in 225 ml EC medium and incubated at 42°C for 20 hours. The enriched cultures were streaked onto Sorbitol MacConkey agar complemented with Cefixime and potassium tellurite supplement and characteristic colonies were subjected to biochemical tests (IMViC). Biochemically confirmed isolates were screened through Caprylate-thallos Agar (CTA) and CHROM Agar. The colonies, which gave characteristic color, were subsequently serotyped by 0157 antisera.

2.11 *Escherichia coli*, (total)

Twenty five (25) g of each sample were homogenized in 225 ml *Enterobacteria* enrichment broth-Mossel pre-enrichment medium and incubated at 35°C for 20 hours. One milliliter aliquots of pre-enriched cultures was mixed with nine milliliters of 2x EC medium and incubated at 35°C for 20 hours. One loop-full of the culture was inoculated into 10 milliliters 1x EC medium with Durham fermentation tubes and incubated at 42°C for 20 hours. To isolate *E. coli*, one loop-full of gas produced 1x EC culture broth was streaked on Chromocult agar (CTA) plates and developed typical colonies. The same pre-enrichment culture was used for isolation and characterization of coliform bacteria on Sorbitol MacConkey (SMAC) agar.

2.12 *Salmonella* spp.

Twenty five (25) g of each sample were homogenized in 225 ml of buffered peptone water and incubated at 35°C for 20 hours. One milliliter pre-enrichment cultures was mixed with nine milliliters of Hanja Tetrathionate Broth and incubated at 35°C for 20 hours and nine milliliters of Rappaport-Vassiliadis Broth and incubated at 42°C for 20 hours. The culture broths were subsequently streaked onto Bismuth sulfite ager (BSA). For isolating of each microorganism original solution and 10^{-2} (hundred times diluted solution) were used for microbial limit test and p^H of the samples were controlled within the range of 6.9 - 7.9 by adding NaOH or HCL.

2.13 Qualitative Fungi Counts

Fungi were identified on Potato dextrose agar (PDA) (Oxoid Ltd, Hampshire, England) after incubation at 30°C for 5 days. Procedure and dilution were followed as described for total bacterial aerobic count. At the end of 5 days incubation the fungal growth was observed under microscope [62].

2.14 Sample Preparation and Heavy Metal Analysis

Heavy metals were analyzed in flame atomizer based Atomic Absorption Spectrometer using hollow cathode lamp as a radiation source. Accurately 25g of herbal preparation were transferred into silica crucible and kept in a muffle furnace for ashing at 700°C for 1 hour. The sample was then cooled down to room temperature and the

heating process was repeated for three times. The ash was then dissolved by adding 5-10 ml of concentrated HCl and finally diluted the sample by 0.1 N HNO₃ up to 25 ml. Finally the sample was prepared for heavy metal analysis by filtering through Whiteman filter paper.

For heavy metal analysis, the samples were aspirated through nebulizer and the absorbance was measured against a blank as reference. Specific hollow cathode lamps were used to analyze Copper (wavelength 324.8 nm), Cadmium (wavelength 228.8 nm) and Chromium (wavelength 357.9 nm), Manganese (wavelength 297.5 nm), Lead (wavelength 283.3 nm) and Zinc (wavelength 213.9 nm). Before analysis, the samples were diluted to the appropriate factor according to the detection limit of the Atomic Absorption Spectrophotometer (AAAnalyst 200; Perkin Elmer, USA). Calibration curve was obtained using referent standard and all the measurements were run in triplicate for the samples and standards solutions.

Table 2.1: Composition of different antidiabetic herbal preparations (ADHPs) and daily adult dose as indicated on the label of the products.

Sample ID	Brand Name	Composition of the preparation as indicated on the label of finished product	Daily adult (70 kg bw) dose in g	pH
ADHP-1	Diacare	<i>Bambusabambos</i> (surface of inner skin) <i>Gymnema Sylvester</i> (leaf), <i>Acacia Arabica</i> (leaf) <i>Rumexvesicarius</i> (seeds)	1.5	5.86
ADHP-2	Ziabit	<i>Natrum sulfuricum</i> (a constitutional Homeopathy remedy),Glauber's Salts (Sodium sulphatedeca-hydrate)	1	5.36
ADHP-3	Insucontrol	<i>Syzygiumcumini</i> (seeds),Ferrous sulphate (Salt) <i>Rumexvesicarius</i> (seeds)	3	5.44
ADHP-4	Dolabi	<i>Gymnemasylvestre</i> (leaf), <i>Rumexvesicarius</i> (seeds) <i>Bambusabambos</i> (surface of inner skin),Asphalt	2.5	6.74
ADHP-5	Diazym	<i>Gymnema Sylvester</i> (leaf),Asphalt <i>Mytilusmargaritiferus</i>	2.5	6.25
ADHP-6	Alisa	<i>Allium sativum</i> , <i>Allium cepa</i> , <i>Mangiferaindica</i> (leaf) <i>Myristicafragrance</i> (dried kernel of the seed) <i>Syzygiumaromaticum</i> (flower)	3.75	8.18
ADHP-7	DaruchiniJa	<i>Cinnamomumzeylanicum</i> (bark)	4.25	5.81

	mseed	<i>Accacia acuminata</i> (seeds)		
ADHP-8	Garlic	<i>Allium sativum</i> (bulbs), <i>Allium cepa</i> (bulbs) <i>Syzygiumcumini</i> (seed), <i>Mangiferaindica</i> (leaf) <i>Myristicafragrance</i> (dried kernel of the seed) <i>Syzygiumaromaticum</i> (flower)	3.5	7.83
ADHP-9	Methicrash	<i>Trigonellafoenum-graecum</i> (seed)	30	6.70
ADHP-10	Diano	<i>Bambusaarundinacea</i> (surface of inner skin) <i>Rumexvesicarius</i> (seed), <i>Gymnemasylvestre</i> (leaf) Hen's egg shell, Ferrous sulphate, <i>Mytilusmargaritiferus</i> , Asphalt	2.5	7.10
ADHP-11	Azadiracha Indica	<i>Azadirachtaindica</i> (leaf extract)	2.5	6.35
ADHP-12	Cuzium Jam	<i>Cinnamomumzeylanicum</i> (bark) <i>Accacia acuminata</i> (seeds)	4	5.72
ADHP-13	Silaraj	<i>Salvia haematodes</i> (bark and root),Asphalt Calcined iron oxide,Calcinedstannum	2.5	7.56


Figure-2.1Some working pictures during column chromatography



Flash column



Vacuum Column



Column

Figure-2.2 Some pictures equipments



NMR (400 MHz)



AAS

CHAPTER III

RESULTS AND DISCUSSION

PART-A

Biological and Chemical Studies of *Anogeissus rivularis* Gagnep O. Lecompte**3.1 Biological Studies:**

The air-dried leaves and twigs of *Anogeissus rivularis* (Gagnep O. Lecompte) were percolated successively with hexane, ethyl acetate and methanol at room temperature, the extracts were collected by filtration. The filtrates were evaporated to dryness under reduce pressure to afford a crude extracts. The crude extracts and the sub-fractions thereof were subjected to biological especially; cytotoxic and anti HIV-1 RT. The results are shown in Table-3.1 to 3.4

Table-3.1: Cytotoxic assays of hexane extract and fractions of leaves and twigs of *A. rivularis*

Extraction/ fractions	Cytotoxicity						
	Cell lines*						
	P-388	KB	HT-29	MCF-7	A549	ASK	Hek 293
Hexane extract	>20	>20	14.31	>20	>20	>20	>20
1F-1	>20	>20	>20	>20	>20	>20	>20
1F-2	10.00	>20	>20	>20	>20	>20	>20
1F-3	<4	15.29	13.94	12.31	13.93	>20	9.30
1F-4	>20	>20	>20	>20	>20	>20	>20
1F-5	3.40	>20	>20	16.83	>20	>20	>20

*Results are expressed as ED₅₀ (µg/mL): ED₅₀< 20 µg/mL is considered active. P-388 = murine lymphocytic leukemia, KB = human nasopharyngeal carcinoma, HT29 = human colorectal adenocarcinoma, MCF-7 = human breast cancer, A549 = human lung carcinoma, ASK = rat glioma, Hek 293= normal human kidney cell.

The results in Table-3.1 indicated that the crude hexane extract was not toxic in all the cell lines except HT-29 (ED₅₀ 14.µg/mL) whereas of its sub-fractions 1F-5 1F-3 and 1F-2 were found to be significantly active against P388 cell line [ED₅₀ were 3.40, <4 and 10.00 µg/mL respectively].

Fraction 1F-3 showed was moderately cytotoxic against KB HT-29 MCF-7A549 and Hek293 cell lines and ED₅₀were found to be 15.29, 13.94, 12.31, 13.93 and 9.30µg/mL, respectively. Fraction 1F-5 was also moderately cytotoxic against the cell line MCF-7 (ED₅₀16.83).

Table-3.2: Cytotoxic assays of ethyl acetate extract and fractions of *A. rivularis*

Extraction/ fractions	Cytotoxicity						
	Cell lines*						
	P-388	KB	HT-29	MCF-7	A549	ASK	Hek 293
EtOAc extract	16.66	>20	>20	>20	>20	>20	>20
Et-1F-1	>20	>20	>20	>20	>20	>20	>20
Et-1F-2	5.40	>20	>20	>20	>20	>20	11.17
Et-1F-3	4.60	18.91	14.71	18.44	>20	>20	12.78
Et-1F-4	6.37	16.70	12.41	16.22	14.76	16.04	12.94
Et-1F-5	9.53	>20	17.29	>20	>20	>20	>20
Et-1F-6	>20	>20	>20	>20	>20	>20	19.90
Et-1F-7	>20	>20	>20	>20	>20	>20	7.49

*Results are expressed as ED₅₀ (µg/mL): ED₅₀< 20 µg/mL is considered active. P-388 = murine lymphocytic leukemia, KB = human nasopharyngeal carcinoma, HT29 = human colorectal adenocarcinoma, MCF-7 = human breast cancer, A549 = human lung carcinoma, ASK = rat glioma, Hek 293 = normal human kidney cell.

The results in Table-3.2 indicated that the ethyl acetate extract of leaves and twigs of *A. rivularis* was moderately cytotoxic against P-388 cell line (ED₅₀ (µg/mL 16.66) but its sub-fraction Et-1F-2 Et-1F-3 and Et-1F-4 possessed high anticancer activity in P388 cell line and ED₅₀ were found to be 5.40, 4.60 and 6.37 µg/mL, respectively. Other fractions were moderately cytotoxic against other cell lines.

Cytotoxicity of the extracts and sub-fractions are dependent on the chemical component(s) present in the extracts and sub-fractions. Cytotoxicity assay showed that some of the sub-fractions are potent to isolate cytotoxic compounds which help in anticancer drug discovery program.

Table-3.3: Result of Anti-HIV 1RT of Hexane extract and fractions of *A. rivularis*

Extract/Fraction	Anti-HIV-1 RT**	
	%inhibition	Activity
Hexane extract	60.50	M
1F-1	1.08	I
1F-2	51.49	M
1F-3	22.56	I
1F-4	3.01	I
1F-5	97.29	VA

**RT assay: VA= very active (>70% inhibition), M = moderately active (>50% to 70% inhibition), W = weakly active (30% to 50% inhibition), I = inactive (<30% inhibition).

The results from the Table-3.3 showed that the hexane extract and fraction 1F-2 are moderately active against anti-HIV-1-RT assay with 60.50 and 51.49 % inhibition respectively. Fraction 1F-5 is very active against anti-HIV-1-RT with 97.29 % inhibition.

Table-3.4: Results of Anti-HIV-1RT of ethyl acetate extract and fractions of *A. rivularis*

Extract/Fraction	Anti-HIV-1 RT**	
	%inhibition	Activity
EtOAc extract	59.31	M
Et-1F-1	14.24	I
Et-1F-2	26.90	I
Et-1F-3	23.84	I
Et-1F-4	43.64	W
Et-1F-5	32.08	W
Et-1F-6	48.54	W
Et-1F-7	92.56	VA

**RT assay: VA= very active (>70% inhibition), M = moderately active (>50% to 70% inhibition), W = weakly active (30% to 50% inhibition), I = inactive (<30% inhibition).

The results from the Table-3.4 showed that the ethyl acetate extracts are moderately active against anti-HIV-1-RT assay with 59.31 % inhibition. Fraction Et-1F-4, Et-1F-5 and Et-1F-6 are weakly active against anti-HIV-1-RT assay with 43.64%, 32.08% and 48.54% inhibition. Fraction Et-1F-7 is very active against anti-HIV-1-RT assay with 92.56 % inhibition.

3.2 Chemical Studies

The search for bioactive constituents from the traditionally used medicinal plant sources has led us to initiate bioassay-guided isolation on *Anogeissus rivularis*. Eight compounds (**1-8**) were isolated from hexane extract among them **1** was found as a fatty aldehyde, **2** and **4** were fatty alcohol (as the compounds are very simple their structures are not given in the Thesis) and **5** was a mixture of two compounds (β -sitosterol and stigmasterol). From the ethyl acetate extract fifteen compounds (**9-23**) including four new compounds (**20-23**) were isolated. Compound **10** and **11** were found to be a mixture of two compounds and were not further studied. Isolated known compounds were characterized from their physical properties (melting point, optical rotation), UV, FTIR, high resolution ^1H & ^{13}C NMR and mass spectral data and comparison with NMR spectral data of known compounds. Isolated four new compounds were characterized from their physical properties (melting point, optical rotation) and extensive spectroscopic studies; UV, FTIR, high resolution ^1H & ^{13}C NMR (including H-H COSY, HSQC, HMBC and NOSEY) spectral data, high resolution mass and CD spectra.

Compound **3**: **Betulinic Acid** was obtained as white needle shaped crystal. Melting point was recorded as 295 °C and specific rotation was $[\alpha]_D^{25} = +4.64$ (c 0.41, pyridine). Reported melting point (290-295 °C) and specific rotation were fitted very well $\{[\alpha]_D^{25} = +7.5$ (c 0.37, Pyridine) $\}$ [63] with experimental value. The melting point and specific rotation value is low compare to the reported value might be due to the presence of insignificant amount of impurity and or experimental error. The molecular formula was determined as $C_{30}H_{50}O_2$ from high resolution mass spectrum (HRMS-ESI-TOP) at m/z 479.3485 $[M+Na]^+$ (Calculated value 479.3496 for $[C_{30}H_{48}NaO_3]^+$) which was also confirmed the molecular formula of compound **3**.




Figure-3.1 Compound 3: 3 β -Hydroxy-19 β -hydrogen-lup-20-(29)-en-28-oic acid (Betulinic Acid)

The 1H -NMR spectrum of Compound-**3** (pyridine- d_5) showed twenty four signals for protons and ^{13}C -NMR spectrum of Compound **3** (in pyridine- d_5) showed thirty signals for thirty carbons (Table 3.5). The spectral data of Compound **3** was compared with reported NMR spectral data of betulinic acid (Table-3.5)[64]. From the physical properties and spectroscopic data and comparison with reported values Compound **3** was identified as Betulinic acid. Betulinic acid is a common constituent of medicinal plants. In this plant it was found as a major compound.

Table-3.5: The ^1H and ^{13}C NMR data of Compound **3** in comparison with reported data

Position	Our data (Pyidine- d_5)			Reported data (pyridine- d_5) [64]		
	δ_{H} (mult., J (Hz)) ppm		δ_{C} ppm	δ_{H} (mult., J (Hz)) ppm		δ_{C} ppm
	H_{α}	H_{β}		H_{α}	H_{β}	
1	0.99 (m)	1.66 (m)	39.6	0.99 (m)	1.67 (m)	39.3
2	1.85 (m)		28.6	1.85 (m)		28.3
3	3.48 (t, 8)		78.4	3.45 (t, 7.2)		78.1
4			39.8			39.5
5	0.82 (m)		56.2	0.82 (m)		56.0
6	1.56 (m)	1.38 (m)	19.1	1.56 (m)	1.38 (m)	18.8
7	1.46 (m)	1.38 (m)	35.2	1.45 (m)	1.38 (m)	34.9
8			41.4			41.1
9	1.38 (m)		51.3	1.38 (m)		51.0
10			37.8			37.6
11	1.43 (m)	1.21(m)	21.5	1.43 (m)	1.21(m)	21.2
12	1.21(m)	1.95 (m)	26.4	1.21(m)	1.94 (m)	26.2
13	2.75 (m)		38.9	2.74 (m)		38.7
14			43.2			42.9
15	1.26 (m)	1.88 (m)	30.6	1.26 (m)	1.88 (m)	30.3
16	1.56(m)	2.65 (m)	33.2	1.55 (m)	2.63 (m)	32.9
17			56.9			56.6
18	1.78 (m)		51.1	1.77(t, 11.5)		49.8
19	3.55 (m)		48.1	3.52 (m)		47.8
20			151.6			151.3
21	1.54 (m)	2.25 (m)	31.5	1.53(m)	2.24(m)	31.2
22	1.57 (m)	2.28 (m)	37.9	1.57(m)	2.25(m)	37.6
23	1.22 (s)		29.0	1.22 (s)		28.7
24	1.03 (s)		16.6	1.00 (s)		16.3
25	0.84 (s)		16.7	0.83 (s)		16.4
26	1.07 (s)		16.7	1.06 (s)		16.4
27	1.09 (s)		15.2	1.07 (s)		14.9
28			179.2			178.8
29	4.97 (s)	4.79 (s)	110.2	4.95 (s)	4.77 (s)	109.9
30	1.81 (s)		19.8	1.79 (s)		19.5

Compound **6**: **3 β -hydroxy-20(29)-en-lupan-30-al** was obtained as white needle shaped crystal. Melting point was recorded as 229°C and specific rotation was $[\alpha]_D^{25} = +6.51$ (c 0.14, CHCl₃). Reported melting point (284°C) and specific rotation fitted very close $[\alpha]_D^{25} = +5.14$ (c 0.19, CHCl₃) [65] to the experimental value. The melting point value is low compare to the reported value might be due to the presence of insignificant amount of impurity. The difference between reported and recorded value of specific rotation is might be due presence of impurity and or experimental error. The molecular formula was determined as C₃₀H₄₈O₂ from high resolution mass spectrum (HRMS-ESI-TOP) at m/z 463.3541 [M+Na]⁺ (Calculated 463.3547 for [C₃₀H₄₈NaO₂]⁺) which confirmed the molecular formula of Compound-**6**.

Figure-3.2 Compound 6: 3 β -hydroxy-20(29)-en-lupan-30-al

The ¹H-NMR spectrum of Compound-**6** (CDCl₃) showed twenty four signals for protons and ¹³C-NMR spectrum of Compound **6** (CDCl₃) showed thirty signals for thirty carbons (Table 3.6). The spectral data of Compound **6** was compared with reported NMR spectral data (Table-3.6) [66]. From the physical properties and spectroscopic data and comparison with reported values [65-66] Compound **6** was identified as a **3 β -hydroxy-20(29)-en-lupan-30-al**. Compound-**6** found as a minor compound of this plant.

Table-3.6: The ^1H and ^{13}C NMR data of Compound **6** in comparison with reported data

Position	Our data (CDCl_3)			Reported data (CDCl_3) [66]		
	δ_{H} (mult., J (Hz)) ppm		δ_{C} ppm	δ_{H} (mult., J (Hz)) ppm		δ_{C} ppm
	H_{α}	H_{β}		H_{α}	H_{β}	
1	0.87	1.65	38.71	0.88	1.65	38.70
2	1.55		27.38	1.61	1.55	27.40
3	3.17 (m)		79.00	3.18		78.99
4			38.86			38.87
5	0.67		55.29	0.67		55.29
6	1.54	1.40	18.30	1.54	1.40	18.30
7	1.39		34.28	1.39		34.28
8			40.78			40.77
9	1.22		50.25	1.22		50.24
10			37.14			37.14
11	1.36	1.22	20.94	1.36	1.22	20.94
12	0.919	1.07	27.64	0.92	1.07	27.64
13	1.66		37.74	1.66		37.73
14			42.69			42.69
15	1.03	1.70	27.34	1.03	1.70	27.34
16	1.45	1.52	35.39	1.45	1.52	35.39
17			43.28			43.28
18	1.64		51.18	1.64		51.2
19		2.74	36.67		2.75	36.7
20			157.19			157.0
21	1.238	2.15	32.66	1.23	2.16	32.6
22	1.378	1.44	39.93	1.38	1.44	39.93
23	0.960		27.98	0.963		27.99
24		0.751	15.35		0.755	15.37
25	0.807		16.05	0.811		16.07
26		1.008	15.93		1.013	15.94
27	0.919		14.40	0.923		14.41
28	0.814		17.78		0.818	17.79
29	5.91	6.28	132.94	5.91	6.28	132.9
30		9.51	195.08		9.51	195.08

Compound **7**: **29-Nor-20-oxolupeol** was obtained as white needle shaped crystal. Melting point was recorded 194°C and specific rotation was $[\alpha]_D^{25} = -173.80$ (c 0.02, MeOH), Reported melting point and specific rotation were 196°C and $[\alpha]_D^{28} = -160$ (c 0.013, MeOH) [67] respectively. The difference between reported and recorded value of specific rotation is might be due presence of impurity and or experimental error. The molecular formula was determined as $C_{29}H_{48}O_2$ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 451.3623 $[M+Na]^+$ (Calculated 451.3547 for $[C_{29}H_{48}NaO_2]^+$) which confirmed the molecular formula of Compound **7**.




Figure-3.3 Compound 7: 29-Nor-20-oxolupeol

The 1H -NMR spectrum of Compound **7** ($CDCl_3$) showed twenty three signals for protons and ^{13}C -NMR spectrum showed twenty nine signals for twenty nine carbons. The 1H and ^{13}C NMR data of Compound **7** were compared with reference data are shown in Table-3.7. The 1H and ^{13}C NMR spectral data and mass of Compound **7** matched with reported data of **29-Nor-20-oxolupeol** [68]. The Compound **7** showed negative optical rotation which was also comparable with reported data [67]. Therefore, the Compound **7** was characterized as a **29-Nor-20-oxolupeol**. The single crystal X-ray also confirmed the structure of compound **7**. Compound **7** found as a minor compound of this plant.

Table-3.7: The ^1H and ^{13}C NMR data of Compound **7** in comparison with reported data

Position	Our data (CDCl_3)		Reported data (CDCl_3) [68]	
	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm
1		38.64		38.65
2		27.36		27.31
3	3.20 (dd, 11.37, 4.8)	78.93	3.21 (dd, 11.4, 4.8)	78.92
4		38.85		38.85
5	0.68 (brd, 12)	55.24	0.75 (brd, 10.5)	55.24
6		18.28		18.28
7		34.17		34.18
8		40.72		40.71
9		50.25		50.25
10		37.16		37.16
11		20.89		20.89
12		27.17		27.17
13		37.01		37.01 ^a
14		43.05		43.05
15		27.31		27.31
16		34.96		34.96
17		42.66		42.66
18	1.84 (t, 11.4)	49.69	1.84 (t, 10.5)	49.67
19	2.58 (ddd, 11.2, 11.2, 5.9)	52.62	2.60 (ddd, 11.4, 11.4, 6)	52.62
20		213.00		212.93
21	2.05 (m)	27.65	2.06 (m)	27.64
22		39.85		39.84
23	0.97 (s)	27.98	0.99 (s)	27.98
24	0.77 (s)	15.38	0.79 (s)	15.36
25	0.82 (s)	16.08	0.85 (s)	16.07
26	1.01 (s)	15.90	1.04 (s)	15.90
27	0.97 (s)	14.46	0.99 (s)	14.46
28	0.76 (s)	17.98	0.78 (s)	17.98
30	2.15 (s)	29.18	2.16 (s)	29.15

a=C-13 mistake in literature

Compound **8**: **3 β ,6 β -Dihydroxylup-20(29)-ene** was obtained as white crystal and melting point was recorded as 198 °C and optical rotation was $[\alpha]_D^{27} = +2.54$ (c 0.21, CHCl₃) but reported value was $[\alpha]_D^{20} = +3.2$ (c 0.19, CHCl₃) [69]. The molecular formula was determined as C₃₀H₅₀O₂ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 465.3702 [M+Na]⁺ (Calculated 465.3702 for [C₃₀H₅₀NaO₂]⁺) which confirmed the molecular formula of Compound **8**.




Figure-3.4 Compound-8: 3 β ,6 β -Dihydroxylup-20(29)-ene

¹H-NMR spectrum of Compound **8** (CDCl₃) showed twenty five signals for protons and the ¹³C-NMR spectrum showed thirty signals for thirty carbons. The ¹H and ¹³C NMR spectral data of Compound **8** were compared with reference data (Table-3.8). The ¹H and ¹³C NMR spectral data and mass of Compound **8** matched with reported data [69] of **3 β ,6 β -Dihydroxylup-20(29)-ene**. The Compound **8** showed positive optical rotation which was also comparable with reference data [69]. This comparison of spectroscopic data confirmed that the Compound **8** was a **3 β ,6 β -Dihydroxylup-20(29)-ene**. The single crystal X-ray confirmed the structure of compound **8**. Compound **8** found as a major compound of this plant.

Table- 3.8: The ^1H and ^{13}C NMR data of Compound **8** in comparison with reported data

Position	Our data (CDCl_3)		Reported data (CDCl_3) [69]	
	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm
1	0.91	40.69	0.91	40.7
	1.66		1.67	
2	1.60	27.52	1.59	29.7
3	3.13 (t, 7.4)	79.13	3.14 (t, 7.3)	79.1
4		39.60		39.6
5	0.68 (d, 1.72)	55.62	0.68 (br s)	55.6
6	4.52 (br s)	69.03	4.53 (br s)	69.0
7	1.66	42.11	1.67	42.1
8		39.90		39.9
9	1.29	51.09	1.30	51.9
10		36.72		36.7
11		21.05		21.1
12		25.30		25.3
13	1.75	37.17	1.76	37.2
14		43.05		43.0
15		27.57		27.5
16		35.52		35.5
17		43.05		43.1
18	1.38	48.38	1.38	48.4
19	2.39 (ddd, 11,11,5.5)	47.96	2.39 (m)	48.0
20		150.92		150.9
21		29.84		29.9
22		39.96		40.0
23	1.05 (s)	27.59	1.06 (s)	27.6
24	1.15 (s)	16.99	1.15 (s)	16.8
25	1.20 (s)	17.71	1.20 (s)	17.7
26	1.35 (s)	16.92	1.36 (s)	16.9
27	0.91 (s)	14.88	0.92 (s)	14.9
28	0.79 (s)	17.98	0.80 (s)	18.0
29	4.57 (br s)	109.92	4.59 (br s)	109.4
	4.69 (d, 2.04)		4.70 (br s)	
30	1.68 (s)	19.34	1.69 (s)	19.3

Compound **9**: **3,3',4'-Tri-*O*-methylellagic acid** was obtained as yellow powder, melting point was recorded as 296 °C (lit 287-289 °C) [70]. The molecular formula was determined as C₁₇H₁₂O₈ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 345.0611 [M+H]⁺ and calculated value for the formula is 345.0605 [C₁₇H₁₃O₈]⁺) that confirmed the molecular formula of compound **9**.

Figure-3.5 Compound **9**: 3,3',4'-tri-*O*-methylellagic acid

¹H-NMR spectrum of the Compound **9** (in DMSO-*d*₆) showed five signals for protons and ¹³C-NMR spectrum gave seventeen signals for seventeen carbons (Table 3.9). The ¹H and ¹³C NMR spectral data were compared with NMR spectral data reported of other compounds (Table-3.9) and the Compound **9** fitted very well with **3,3',4'-tri-*O*-methylellagic acid** [70] Therefore, it was concluded that the Compound **9** was **3,3',4'-tri-*O*-methylellagic acid** which is a common constituent of bark of the terrestrial medicinal plants but in the *A. rivularis* plant it was isolated as one of the minor constituents.

Table-3.9: The ^1H and ^{13}C NMR data of Compound **9** in comparison with reported data

Position	Our data (DMSO- d_6)		Reported data (DMSO- d_6) [70]	
	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm
1		111.5		111.2
2		141.3		140.9
3		140.5		140.3
4		152.9		152.5
5	7.54 (s)	111.9	7.54 (s)	111.6
6		112.2		111.9
7		158.6		158.3
1'		112.8		112.4
2'		141.8		141.5
3'		141.1		140.8
4'		154.1		153.8
5'	7.62 (s)	107.8	7.64 (s)	107.5
6'		113.7		113.4
7'		158.8		158.5
3-OMe	4.04 (s)	61.3	4.05 (s)	61.0
3'-OMe	4.06 (s)	61.6	4.06 (s)	61.3
4'-OMe	4.00 (s)	57.0	4.01 (s)	56.7

Compound **12**: **3,3'-Di-O-methylellagic acid** was obtained as yellow powder and melting point was more than 300 °C (lit >300 °C) [70]. The molecular formula was determined as C₁₆H₁₀O₈ from high resolution mass spectroscopy (HRMS-ESI-TOP) at *m/z* 331.0467 [M+H]⁺ (Calculated 331.0448 for [C₁₆H₁₁O₈]⁺) which confirmed the molecular formula of the isolated Compound **12**.

Figure-3.6 Compound **12**: 3,3'-di-O-methylellagic acid

¹H-NMR spectrum of Compound **12** (DMSO-*d*₆) showed two signals for protons and in ¹³C-NMR spectrum it gave eight signals for sixteen carbons. The ¹H and ¹³C NMR spectral data of the Compound **12** in comparison with reference data are shown in Table-3.10. The ¹H and ¹³C NMR signals and mass of the Compound **12** (in DMSO-*d*₆) was matched with reported data of **3,3'-di-O-methylellagic acid** in DMSO-*d*₆ [70]. The melting point of the Compound **12** was also comparable with reference data [70]. Therefore, the compound **12** was identified as **3,3'-di-O-methylellagic acid**. Compound **12** was found as a minor compound of this plant.

Table-3.10: The ^1H and ^{13}C NMR data of Compound **12** in comparison with reported data

Position	Our data (DMSO- d_6)		Reported data (DMSO- d_6) [70]	
	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm
1		111.7		111.5
2		141.2		141.1
3		140.3		140.1
4		152.2		152.2
5	7.51 (s)	111.5	7.52 (s)	111.3
6		112.1		112.1
7		158.2		158.4
1'		111.7		111.5
2'		141.2		141.1
3'		140.3		140.1
4'		152.2		152.2
5'	7.51 (s)	111.5	7.52 (s)	111.3
6'		112.1		112.1
7'		158.5		158.4
3-OMe	4.03 (s)	60.9	4.05 (s)	61.0
3'-OMe	4.03 (s)	60.9	4.05 (s)	61.0

Compound **13**: **4',5,7-Trihydroxyflavanone** was obtained as yellowish needle shaped crystal, melting point and specific rotation were found to be 253-255 °C and $[\alpha]_D^{25} = -17.6$ (c 0.16, EtOH), respectively. The values were close to the reported values of flavonoid compounds (lit. >300 °C and $[\alpha]_D^{25} = -20.7$ (c 1.0, EtOH) [71,72]. The molecular formula was determined as $C_{15}H_{12}O_5$ from high resolution mass spectrometry (HRMS-ESI-TOP) at m/z 295.0565 $[M+Na]^+$ (Calculated 295.0577 for $[C_{15}H_{12}NaO_5]^+$) which confirmed the molecular formula of Compound **13**.

Figure-3.7 Compound-13: (S)-Naringeni (4',5,7-Trihydroxyflavanone)

1H -NMR and ^{13}C -NMR spectra of the Compound **13** in Acetone- d_6 showed nine signals for protons and thirteen signals for fifteen carbons. The 1H NMR and ^{13}C NMR spectral data of Compound **13** in comparison with reference data are shown in Table-3.11. The 1H & ^{13}C NMR and mass spectra of the Compound **13** (in Acetone- d_6) was matched with reported data of **4',5,7-trihydroxyflavanone** (in Acetone- d_6) [73]. The melting point of Compound **13** and negative specific rotation were also comparable with reported data [71-72]. By all physical and spectroscopic data Compound **13** was confirmed as **4',5,7-trihydroxyflavanone** which isolated for the first time from the plant as a minor constituents.

Table-3.11 The ^1H and ^{13}C NMR data of Compound **13** in comparison with reported data

Position	Our data (Acetone- d_6)		Reported data (Acetone- d_6) [73]	
	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm
2	5.45 (dd,12.88,2.92)	79.05	5.42 (dd,13.1,2.76)	79.1
3a	2.72 (dd,17.1,3)	42.59	2.70 (dd,17.1,2.5)	42.7
3e	3.18 (dd,17.13,12.92)		3.20 (m)	
4		196.35		196.4
5	12.18 (s, OH-5)	164.40		164.2
6	5.94 (d,2.08)	95.92	5.93 (d,2.04)	96.0
7	9.84 (s, OH-7)	166.57		166.6
8	5.95 (d,2.08)	94.96	5.94 (s)	95.0
9		163.48		163.6
10		102.22		102.3
1'		129.85		129.9
2'	7.39 (d,8.48)	128.11	7.36 (d,8.28)	128.2
3'	6.89 (d,8.57)	115.29	6.87 (d,8.28)	115.3
4'	8.69 (s, OH-4')	157.87		157.9
5'	6.89 (d,8.57)	115.29	6.87 (d,8.28)	115.3
6'	7.39 (d,8.48)	128.11	7.36 (d,8.28)	128.2

Compound **14**: *p*-Cumaric acid was obtained as white crystal which showed melting point 207°C (**wiki**- 210-213°C). The melting point value is low compare to the reported value might be due to the presence of insignificant amount of impurity. The molecular formula was determined as C₉H₈O₃ from high resolution mass spectroscopy (HRMS-ESI-TOP) at *m/z* 187.0370 [M+Na]⁺ (Calculated 187.0307 for [C₉H₈NaO₃]⁺) which confirmed the molecular formula of Compound **14**.




Figure-3.8 Compound **14**: *p*-Cumaric acid ((*E*)-3-(4'-hydroxyphenyl)-2-propenoic acid)

¹H NMR and ¹³CNMR spectra of the Compound **14** (in MeOD) showed four signals for protons and seven signals for nine carbons. The ¹H and ¹³C NMR spectral data of compound **14** were with other known compounds (Table-3.12). Spectroscopic data of the Compound **14** and the reported data [74] confirmed that the Compound **14** was *p*-Cumaric acid is also reported first time from this plant.

Table-3.12: The ¹H and ¹³C NMR data of Compound **14** in comparison with reported data

Position	Our data(CD ₃ OD)		Reported data (CD ₃ OD) [74]	
	δ _H (mult., <i>J</i> (Hz)) ppm	δ _C ppm	δ _H (mult., <i>J</i> (Hz)) ppm	δ _C ppm
1		171,15		171.06
2	6.28 (d,15.89)	115.77	6.28 (d,16)	115.49
3	7.60 (d,15.92)	146.78	7.60 (d,16)	146.68
1'		127.39		127.17
2'	7.45	131.22	7.45	131.06
3'	6.80	116.95	6.80	116.76
4'		161.29		161.04
5'	6.80	116.95	6.80	116.76
6'	7.45	131.22	7.45	131.06

Compound **15**: **2,3-Dihydro-*p*-Cumaric acid** was obtained as white crystal, melting point was found to be 127°C (wiki 129-131°C). The molecular formula was determined as C₉H₁₀O₃ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 189.0524 [M+Na]⁺ (Calculated 189.0522 for [C₈H₈NaO₄]⁺) which confirmed the molecular formula of compound **15**.




Figure-3.9 Compound 15: 2,3-Dihydro-*p*-Cumaric acid; (3-(4'-Hydroxyphenyl)-propanoic acid)

¹H and ¹³C NMR spectra of the Compound **15** (in MeOD) showed four signals for protons and seven signals for nine carbons. The ¹H and ¹³C NMR spectral data of Compound **15** in comparison with reported [75] data are shown in Table-3.13. The spectroscopic data of Compound **15** and reported data confirmed that Compound **15** was **2,3-Dihydro-*p*-Cumaric acid** and also isolated from this plant as a minor compound.

Table-3.13: The ¹H and ¹³C NMR data of Compound **15** in comparison with reported data

Position	Our data (CD ₃ OD)		Reported data (CD ₃ OD) [75]	
	δ _H (mult., <i>J</i> (Hz)) ppm	δ _C ppm	δ _H (mult., <i>J</i> (z)) ppm	δ _C ppm
1		177.13		179.11
2	2.53 (t,7.84)	37.34	2.50 (t*)	38.62
3	2.81 (t, 7.76)	31.38	2.79 (t*)	31.69
1'		133.11		133.63
2'	7.03 (d,8.49)	130.35	7.03 (d*)	130.19
3'	6.69 (d,8.52)	116.32	6.70 (d*)	116.15
4'		156.85		156.10
5'	6.69 (d,8.52)	116.32	6.70 (d*)	116.15
6'	7.03 (d,8.49)	130.35	7.03 (d*)	130.19

d*,t*=pseudodoublet or triplet in AA'XX' spin system.

Compound **16**: **3,4-Dihydroxybenzoic acid** was obtained as white needle crystal out which showed melting point 202°C (Ref. 198-200°C) [76]. The molecular formula was determined as C₇H₆O₄ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 177.0151 [M+Na]⁺ (Calculated 177.0158 for [C₇H₆NaO₄]⁺) which confirmed the molecular formula of compound **16**.




Figure-3.10 Compound 16: Protocatechuic acid (3,4-Dihydroxybenzoic acid)

The NMR spectrum of compound **16** in DMSO-*d*₆ showed three signals for protons and seven signals for carbon. The NMR spectral data of compound **16** in comparison with reference data are shown in Table-3.14. The spectroscopic data, melting point and mass of Compound **16** in DMSO-*d*₆ is matched with reported data of **3,4-Dihydroxybenzoic acid** in DMSO-*d*₆ [76]. The comparison of all spectroscopic data with reported confirmed that the compound **16** was **3,4-Dihydroxybenzoic acid**. Compound-**16** found as a minor compound of this plant.

Table-3.14: The ¹H and ¹³C NMR data of Compound **16** in comparison with reported data

Position	Our data (DMSO- <i>d</i> ₆)		Reported data (DMSO- <i>d</i> ₆) [76]	
	δ _H (mult., <i>J</i> (Hz)) ppm	δ _C ppm	δ _H (mult., <i>J</i> (Hz)) ppm	δ _C ppm
1		121.6		121.6
2	7.33 (1H,d,J=2.0)	116.5	7.33 (1H, d, J=1.8)	116.5
3		144.9		144.8
4		150.0		150.0
5	6.78 (1H, d, J=8.2)	115.1	6.79 (1H, d, J=8.5)	115.1
6	7.28 (1H, dd, J=8.2,2.0)	121.9	7.28 (1H, dd, J=8.5,1.8)	121.9
1-COOH		167.3		167.2

Compound **17**: **Stigmast-5-en-3-*O*- β -glucoside** was obtained as white needle crystal out which showed melting point 276°C (Ref. 284°C). The molecular formula was determined as C₃₅H₆₀O₆ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 599.4343 [M+Na]⁺ (Calculated 599.4282 for [C₃₅H₆₀NaO₆]⁺) which confirmed the molecular formula of compound **17**.

Figure-3.11 Compound 17: Stigmast-5-en-3-*O*- β -glucoside

The NMR spectrum of compound **17** in pyridine-*d*₅ showed thirty two signals for protons and thirty five signals for thirty five carbons. The spectral data of compound **17** in comparison with reference data are shown in Table-3.15. The spectroscopic data, melting point and mass of compound **17** in pyridine-*d*₅ is matched with reported data of **Stigmast-5-en-3-*O*- β -glucoside** in pyridine-*d*₅ [77]. The comparison of all spectroscopic data confirmed that the compound **17** was **Stigmast-5-en-3-*O*- β -glucoside** and was found as a major compound in this plant. **Stigmast-5-en-3-*O*- β -glucoside** was commonly found in almost all plant.

Table-3.15: The ¹H and ¹³C NMR data of Compound **17** in comparison with reported data

Position	Our data (pyridine- <i>d</i> ₅)			Reported data (pyridine- <i>d</i> ₅) [77]		
	δ_H (mult., <i>J</i> (Hz)) ppm		δ_C ppm	δ_H (mult., <i>J</i> (Hz)) ppm		δ_C ppm
	H _{α}	H _{β}		H _{α}	H _{β}	
1	1.01 (m)	1.72 (m)	37.86	0.98 (m)	1.72 (m)	37.46
2	2.15 (m)	1.78 (m)	30.63	2.14 (m)	1.75 (m)	30.21
3	4.02 (m)		78.83	3.98 (m)		78.38

4	2.76 (br, dd, 2.5, 13.2)	2.5 (br.t, 11.7)	39.72	2.27 (ddd, 1.98, 4.69, 12.94)	2.49 (ddd, 1.98, 12.94, 12.94)	39.31
5			141.31			140.95
6		5.37 (t,2.4)	122.28		5.35 (t,2.5)	121.90
7	1.58 (m)	1.94 (m)	32.55	1.60 (ddd, 2.5, 7.0, 16.0)	1.95 (ddd, 16.0, 2.5, 7.0)	32.15
8		1.39 (m)	32.44		1.36 (m)	32.04
9		0.89 (m)	50.73		0.85 (m)	50.34
10			36.76			36.08
11	1.45 (m)	1.44 (m)	21.66	1.42 (m)	1.42 (m)	21.26
12	1.98 (m)	1.10 (m)	40.33	1.98 (dd, 4.3, 12.47)	1.10 (m)	39.95
13			42.86			42.47
14		0.95 (m)	57.21		0.95 (m)	56.83
15	1.03 (m)	1.56 (m)	24.88	1.05 (m)	1.57 (m)	24.48
16	1.26 (m)	1.86 (m)	28.90	1.25 (m)	1.85 (m)	28.50
17		1.12 (m)	56.64		1.10 (m)	56.25
18		0.67 (s)	12.35		0.66 (s)	11.95
19		0.95 (s)	19.79		0.94 (s)	19.39
20		1.41 (m)	37.30		1.40 (m)	36.36
21		1.00 (br.d)	19.38		0.98 (d, 6.5)	18.99
22	1.39 (m)	1.08 (m)	34.60	1.40 (m)	1.10 (m)	34.20
23	1.25 (m)	1.26 (m)	26.80	1.25 (m)	1.25 (m)	26.40
24		1.01 (m)	46.43		1.00 (m)	46.04
25		1.68 (m)	29.87		1.68 (m)	29.47
26		0.87 (br.s)	19.59		0.84 (d, 7.0)	19.20
27		0.89 (br.d)	20.34		0.86 (d, 7.0)	19.94
28	1.309 (m)	1.30 (m)	23.78	1.30 (m)	1.30 (m)	23.38
29		0.91 (br.d)	12.53		0.88 (t, 7.5)	12.13
1'		5.09 (d, 7.72)	102.96		5.04 (d, 7.69)	102.57
2'		4.10 (dd, 8.2, 8.8)	75.71		4.04 (dd, 7.69, 7.50)	75.27
3'		4.32 (m)	78.97		4.27 (t, 7.50)	78.54
4'		4.32 (m)	72.10		4.27 (t, 7.50)	71.67
5'		3.98 (m)	78.52		3.96 (m)	78.13
6'	4.60 (dd, 2.2, 11.76)	4.44 (dd, 5.2, 11.78)	63.23	4.55 (dd, 2.5, 11.77)	4.40 (dd, 5.2, 11.77)	62.62

Compound **18**: **Loliolide** was obtained as white crystal, melting point 151 °C (Ref. 149.5 °C). The molecular formula was determined as C₁₁H₁₆O₃ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 219.0984 [M+Na]⁺ [Calculated 219.0992 for C₁₁H₁₆NaO₃]⁺ which confirmed the molecular formula of compound **18**.




Figure-3.12 Compound 18: Loliolide (6-Hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydro-4H-benzofuran-2-one)

¹H and ¹³C NMR spectra of the compound **18** in CDCl₃ showed eight signals for protons and eleven signals for eleven carbons (Table-3.16). The spectral were compared with reference spectral data [78,79], melting point and mass of the Compound **18** (in CDCl₃) which matched with **Loliolide**. The comparison of all spectroscopic data confirmed that the compound **18** was **Loliolide(6-Hydroxy-4,4,7a-trimethyl-5,6,7,7a-tetrahydro-4H-benzofuran-2-one)**. Compound **18** found for the first time as a minor compound of this plant.

Table-3.16: The ¹H and ¹³C NMR data of Compound **18** in comparison with reported data

Position	Our data (CDCl ₃)		Reported data [78]	Reported data (CDCl ₃) [79]	
	δ_H (mult., <i>J</i> (Hz)) ppm	δ_C ppm	δ_H (mult., <i>J</i> (Hz)) ppm	δ_H (mult., <i>J</i> (Hz)) ppm	δ_C ppm
2		182.40			183.00
3	5.70 (1H, s)	113.09	5.71 (1H,s)	5.69 (1H, s)	112.43
4		35.90			35.99
5	1.54 (dd, 14.5, 2.3)	45.73	1.53 (dd, 14.7, 3.7)	1.4-2.56 (m,4a-H,	45.52
	1.98 (broad d, 14.24)		1.97 (ddd,14.5, 3.0, 2.3)	4b-H)	
6	4.34 (broad peak)	66.88	4.33 (quintet)	4.33 (1H, quint.)	66.38
7	1.79 (broad peak)	47.36	1.78 (dd, 13.5, 3.7)	1.4-2.56 (m, 6a-H,	47.14
	2.47 (broad d)		2.46 (ddd, 14.0, 3.2,2.3)	6b-H)	
8		171.88			172.11
7a		86.64			87.12
7a-CH ₃	1.79 (3H, s)	30.69	1.78 (s)	1.78 (3H, s)	30.61
4-CH ₃	1.47 (3H, s)	26.52	1.47 (s)	1.47 (3H, s)	26.40
4-CH ₃	1.28 (3H, s)	27.09	1.27 (s)	1.27 (3H, s)	26.91

Compound **19**: **Vanillic acid** was obtained as white crystal, melting point was recorded as 210 °C (Wiki 210-213 °C). The molecular formula was determined as C₈H₈O₄ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 191.0313 [M+Na]⁺ (Calculated 191.0315 for [C₈H₈NaO₄]⁺) which confirmed the molecular formula of Compound **19**.




Figure-3.13 Compound 19: Vanillic acid (3-methoxy 4-hydroxybenzoic acid)

¹H-NMR spectrum of compound **19** (in MeOD) showed three signals for protons and ¹³C-NMR spectrum of the compound showed eight signals for eight carbons. The ¹H and ¹³C NMR spectral data of the Compound **19** in comparison with reference data [80,81] are shown in Table-3.17. From melting point, ¹H, ¹³C NMR spectral data and mass of Compound **19** [80] and in comparison with all spectroscopic data confirmed that the compound **19** was **vanillic acid (3-methoxy 4-hydroxybenzoic acid)**. It was found as one of the as a major compounds of this plant.

Table-3.17: The ¹H and ¹³C NMR data of Compound **19** in comparison with reported data

Position	Our data (CD ₃ OD)		Reported (CD ₃ OD)	Reported data
	δ_H (mult., J (Hz)) ppm	δ_C ppm	data [81]	(CD ₃ OD) [80]
1		123.3	123.1	
2	7.56 (m)	113.9	113.9	7.56 (m)
3		148.7	148.6	
4		152.7	152.6	
5	6.83 (d, 8.72)	115.9	115.9	6.85 (d, 9.0)
6	7.56 (m)	125.4	125.3	7.56 (m)
COOH		170.2	170.0	
3-OCH ₃	3.89 (s)	56.5	56.4	3.92 (s)

Compound **20** was obtained as white crystal, melting point was recorded 125°C and specific rotation was $[\alpha]_{\text{D}}^{25} = +25.2690$ (c 0.29, MeOH). The molecular formula was determined as $\text{C}_{20}\text{H}_{22}\text{O}_3$ from high resolution mass spectrometry (HRMS-ESI-TOP) at m/z 297.1488 $[\text{M}+2\text{H}-\text{CH}_3]^+$ (Calculated 297.1485 for $[\text{C}_{19}\text{H}_{21}\text{O}_3]^+$) which supported the molecular formula of Compound **20**.

FTIR(NEAT) shows the absorption bands at ν_{max} 2958, 2922.75 (stretching of $-\text{CH}_3$), 2851.93 (stretching of $\text{O}-\text{CH}_3$), 1605 1554, 1516, 1486, 1463 1432 ($\text{C}=\text{C}$ stretching of aromatic ring), 1151 ($\text{C}-\text{O}$ stretching of furan), 972.60 (stretching of $\text{CH}=\text{CH}$ -trans), 898, 884, 850, 775, 751, 725, 678,653and 620 cm^{-1} . The UV spectral data of aromatic showed absorbance at λ_{max} : 207 (+0.4669), 235 (+0.18103) and 282(+0.08477) nm.




Figure-3.14 Compound-20: (2-(3',4'-Dimethoxy-phenyl)-3-methyl-5-propenyl-2,3-dihydro-benzofuran) (New)

The ^1H -NMR spectrum of the Compound **20** (in CDCl_3) showed eleven signals for fourteen protons and ^{13}C -NMR spectrum showed twenty signals for twenty carbons. DEPT-90 & DEPT-135 were performed to find out attachment of protons, i.e. primary, secondary, tertiary and quaternary carbons (Table 3.18). In the Compound **20**, four methyl, no methylene, ten methine carbons were found out and the rest were quaternary carbons. H-H COSY spectrum was done and linkages between protons were found out. From HSQC and HMBC all protons to carbons were assigned (Table 3.19). From ^1H NMR signal coupling constants were measured (Table 3.18) and proton carbon connectivity were found out from HMBC (Table 3.19 and Figure-3.15).

Table-3.18: The ^1H , ^{13}C , , DEPT-90 and DEPT-135 NMR data of compound-20

Position	Our data (CDCl_3)			
	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm	DEPT90 (CH)	DEPT135
2	5.08 (d, 9.12)	93.16	93.15	93.15
3	3.42 (m)	45.42	45.42	45.42
4	7.13 (brod. d, 9.44)	126.49	126.49	126.49
5		131.56		
6	7.13 (brod. d, 9.44)	120.94	120.89	120.89
7	6.78 (d, 7.96)	109.55	109.53	109.53
8		158.54		
9		133.24		
10	6.37 (d, 15.68)	130.96	130.90	130.90
11	6.10 (m)	123.32	123.32	123.32
12	1.86 (d, 6.0)	18.59	18.62	18.62
1'		132.57		
2'	6.96 (brod. d, 7.41)	109.44	109.30	109.30
3'		149.51		
4'		149.31		
5'	6.86 (d, 7.84)	111.25	111.11	111.11
6'	6.96 (brod. d, 7.41)	119.12	119.12	119.12
3'-O-CH ₃	3.89 (s)	56.16		56.12
4'-O-CH ₃	3.88 (s)	56.19		56.15
3-CH ₃	1.45 (d, 6.56)	17.88		17.82

^{13}C NMR DEPT 90 and 135 showed in Compound **20**, 2,3,4,6,7,10, 2',5',6' carbons were -CH- and 3'-O-CH₃, 4'-O-CH₃, 3-CH₃ were -CH₃ and C-11,C-12 were -HC=CH- 5,8,9,1',3' 4' were for quaternary carbons (Table-3.18). The H-10 has *trans* coupling with H-11 with J value 15.68 Hz indicated that -CH=CH- group in side chain and H-11 gave multiplet signal coupling with H-10 and H-12. The H-3 gave a multiplet coupling with H-2 & protons of 3-CH₃. H-2 gave a doublet coupling with H-3. The protons of 3-CH₃ and H-12 (methyl proton) coupled and gave doublet similarly H-3 and H-11 coupled with J values 6.56 Hz and 6.0 Hz. The protons of 3'-O-CH₃ and 4'-O-CH₃ gave singlet at δ_{H} values 3.89 and 3.88 ppm. The H-4 is *meta* coupling with H-6 and gives doublet with coupling constant 2-4 Hz. Here *para* coupling with H-7 to be zero. For H-6 is

ortho coupling with H-7 and *meta* coupling with H-4 and should give *dd* coupling constant 6-8 Hz. The H-4 and H-6 are gave chemical shift at the same region and gave broad doublet at δ 7.3 with coupling constant 9.44 Hz. The H-7 has *ortho* coupling with H-6 and *para* coupling with H-4 is zero and gave doublets with coupling constant 7.96 Hz. The H-2' is *meta* coupling with H-6' and *para* coupling with H-5' is zero. H-6' is *ortho* coupling with H-5' and *meta* coupling with H-2'. Both H-2' and H-6' are gave chemical shift at the same region and gave broad doublet at δ 9.6 with coupling constant 7.41 Hz. The H-5' has *ortho* coupling with H-6' and *para* coupling with H-2' is zero and gave doublets with coupling constant 7.84 Hz. 7.84 Hz (Table-3.18).




Figure-3.15 The HMBC correlation of compound-20

In HMBC correlations; H-2 (δ 5.08) coupled with C-(3-CH₃; δ 17.82), C-3 (δ 45.42), C-9 (δ 133.24), C-1' (δ 132.57), C-2' (δ 109.30) and C-6' (δ 119.12). These correlations supported that dimethoxyphenyl group at C-2 position of dihydrobenzofuran. Correlation of H-(3-CH₃; δ 1.45) with C-2 (δ 93.15), C-3 (δ 45.42), C-9 (δ 133.24), C-1' (δ 132.57) supported that C-3 position of dihydrobenzofuran contain -CH₃ group. Correlation of H-10 (δ 2.75) with C-4 (δ 126.49), C-5 (δ 131.56), C-6 (δ 120.89), C-12 (δ 18.62) supported that propenyl group at C-5 position of dihydrobenzofuran. The H-4 correlated with C-3 (δ 45.42), C-5 (δ 131.56), C-6 (δ 120.89), C-10 (δ 130.90) and the H-2' Correlated with C-2 (δ 93.15), C-6' (δ 119.12), C-3' (δ 149.51) these connectivity also supported the structure of Compound **20** as dihydrobenzofuran derivatives (Table-3.19).

Table-3.19: The HSQC and HMBC correlation data of compound-20

Our data (CDCl ₃)		
δ_H ppm	HSQC correlation	HMBC correlation
5.08 (H-2)	93.15 (C-2)	17.82 (3-CH ₃), 45.42 (C-3), 109.30 (C-2'), 119.12 (C-6'), 132.57 (C-1'), 133.24(C-9)
3.42 (H-3)	45.42 (C-3)	132.57(C-1'), 133.24(C-9)
7.13 (H-4)	126.49 (C-4)	45.42 (C-3), 131.56 (C-5), 120.89 (C-6), 158(C-8), 130.90(C-10)
7.13 (H-6)	120.89 (C-6)	126.49 (C-4), 131.56 (C-5), 158(C-8), 130.90(C-10)
6.78 (H-7)	109.53 (C-7)	131.56 (C-5), 158(C-8), 133.24(C-9),
6.37 (H-10)	130.90 (C-10)	126.49 (C-4), 131.56 (C-5), 120.89 (C-6), 18.62 (C-12)
6.10 (H-11)	123.32 (C-11)	131.56 (C-5), 130.90(C-10), 18.62 (C-12)
1.86 (H-12)	18.62 (C-12)	131.56 (C-5), 130.90(C-10), 123.32 (C-11)
6.96 (H-2')	109.30 (C-2')	93.15 (C-2), 119.12 (C-6'), 149.51(C-3')
6.86 (H-5')	111.11 (C-5')	132.57(C-1'), 149.51(C-3'), 149.31(C-4')
6.96 (H-6')	119.12 (C-6')	93.15 (C-2), 109.30 (C-2'), 149.31(C-4')
3.89 (H-(3'-O-CH ₃))	56.12 (3'-O-CH ₃)	149.51(C-3')
3.88 (H-(4'-O-CH ₃))	56.15 (4'-O-CH ₃)	149.31 (C-4')
1.45 (H-(3-CH ₃))	17.82 (3-CH ₃)	93.15 (C-2), 45.42 (C-3), 133.24(C-9), 132.57(C-1')

From H-H COSY H-2 was found to linked with H-3, H-3 with H-(3-CH₃), H-7 with H-7, H-10 with H-11, H-11 with H-12 and H-5' with H-6'. All the correlations supported that they are attached to adjacent carbon atom (Table-3.20). The NOESY correlation is not effective for this compound because all groups are in same plane. From all spectroscopic studies structure of the Compound **20** was elucidated as **[2-(3',4'-Dimethoxy-phenyl)-3-methyl-5-propenyl-2,3-dihydro-benzofuran]**. Literature search including SciFinder showed the Compound 20 is new compound and has not been reported earlier from neither from plant origin nor from synthetic sources.




Figure 3.16: The COSY correlation of compound-20

Table 3.20: The COSY correlation data for selected protons of compound-20

Our data (CDCl ₃)	
δ_H ppm	Protons correlated with δ_H ppm
5.08 (H-2)	3.42 (H-3)
3.42 (H-3)	1.45 (H-(3-CH ₃))
7.13 (H-6)	6.78 (H-7)
6.37 (H-10)	6.10 (H-11)
6.10 (H-11)	1.86 (H-12)
6.86 (H-5')	6.96 (H-6')

Compound **21** was obtained as yellow powder, melting point was 225-227°C and specific rotation was $[\alpha]_D^{25} = +192.87$ (c 0.36, MeOH). The molecular formula was determined as $C_{30}H_{22}O_{10}$ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 565.1080 $[M+Na]^+$ (Calculated 565.1105 for $[C_{30}H_{22}NaO_{10}]^+$) which supported the molecular formula of Compound **21**.

FT-IR (NEAT) showed the absorption bands at ν_{max} 3197 broad peak for O–H stretching and aromatic =C–H stretching, 1634, 1627 (C=O stretching of ketone), 1616, 1592, 1569, 1515, 1507, 1499, 1480 and 1457 (C=C stretching of aromatic ring), 1151 (C–O stretching of furan), 1077, 1011, (C–O stretching of phenol), 946, 876, 827, 808, 763, 739, 694 cm^{-1} . The UV spectral data of aromatic showed absorbance at λ_{max} : 213 (+0.7506), 229 (+0.56132) and 296 (+0.51057) nm.




Figure-3.17 Compound- 21: Dimer of 4,6-dihydroxy-2-(4'-hydroxy-benzyl)-benzofuran-3-one (New)

The 1H -NMR spectrum of the Compound **21** (in MeOD) showed six signals for protons and ^{13}C -NMR spectrum showed thirteen signals for fifteen carbons. DEPT-90 & DEPT-135 were performed to find out attachment of protons, i.e. primary, secondary, tertiary and quaternary carbons (Table 3.21). In the Compound **21**, no methyl, no methylene, eight methine carbons

were found out and the rest were quaternary carbons. H-H COSY spectrum was done and linkages between protons were found out. From HSQC and HMBC all protons to carbons were assigned (Table 3.22). From ^1H NMR signal coupling constants were measured (Table 3.21) and proton carbon connectivity were found out from HMBC (Table 3.22 and Figure 3.18).

^{13}C NMR DEPT 90 and 135 showed in Compound **21**, 2,5,7,10,2',3',5',6' carbons were -CH- and 4,6, 4' were quaternary carbon with -OH group and 8,9,1' were quaternary carbon and 3 was =CO group (Table-3.21). The H-2 & H-10 gave doublet coupling with each other with J value 11.8 Hz. The H-5 & H-7 gave doublet (J value 2 Hz) coupling with *meta* protons. The H-2' & H-3' and H-5'&H-6' gave doublet (J value 8.6 Hz) coupling with *ortho* protons.(Table-3.21).

Table 3.21: The ^1H , ^{13}C , DEPT-90 and DEPT-135 NMR data of compound-**21**

Position	Our data (MeOD)			
	δ_{H} ppm (mult., J (Hz)) ppm	δ_{C} ppm	DEPT-90 (CH)	DEPT-135
2	5.78 (d, 11.8)	85.09	85.10	85.10
3		198.09		
4		164.50		
5	5.79 (d, 2)	96.24	96.24	96.24
6		165.60		
7	5.88 (d, 2)	97.39	97.40	97.39
8		168.56		
9		103.47		
10	2.75 (d, 11.8)	51.41	51.42	51.41
1'		129.15		
2'	6.89 (d, 8.6)	130.42	130.42	130.42
3'	6.76 (d, 8.6)	116.45	116.65	116.64
4'		159.70		
5'	6.76 (d, 8.6)	116.45	116.65	116.64
6'	6.89 (d, 8.6)	130.42	130.42	130.42

In HMBC correlation: H-2 (δ 5.78) couple with C-10 (δ 51.41), C-3 (δ 198.09), C-1' (δ 129.15), C-9 (δ 103.47), C-2' and C-6' (δ 130.42). This correlation supported that hydroxyl benzyl group at C-2 position of benzofuran. Correlation of H-10 (δ 2.75) with C-10 (δ 51.41), C-2 (δ 85.09), C-1' (δ 129.15), C-3 (δ 198.09) supported that it was a dimer of benzofuran and also supported that hydroxyl benzyl group at C-2 position (Table-3.22).




Figure-3.18 The HMBC correlation of compound-21

Table 3.22: The HMQC and HMBC NMR data of compound-21

Our data (MeOD)		
δ_H ppm	HMQC correlation	HMBC correlation
5.78 (H-2)	85.10 (CH-2)	51.41(C-10), 198.09(C-3), 129.15(C-1'), 103.47(C-9), 130.42(C-2', C-6')
5.79 (H-5)	96.24 (CH-5)	97.39(C-7), 103.47 (C-9), 165.60(C-6), 168.56(C-8)
5.88 (H-7)	97.40 (CH-7)	96.24(C-5), 103.47(C-9)
2.75 (H-10)	51.42 (CH-10)	51.41(C-10), 85.09(C-2), 129.15(C-1'), 198.09(C-3)
6.89 (H-2')	130.42 (CH-2')	130.42(C-6'), 159.70(C-4')
6.76 (H-3')	116.45 (CH-3')	116.45(C-5'), 129.15(C-1'), 159.70(C-4')
6.76 (H-5')	116.45 (CH-5')	116.45(C-3'), 129.15(C-1'), 159.70(C-4')
6.89 (H-6')	130.42 (CH-6')	130.42(C-2'), 159.70(C-4')

From H-H COSY H-2 was found to be linked with H-10, H-2' with H-3', H-5' with H-6'. All the correlations supported that they are attached to adjacent carbon atoms (Table-3.23). The NOESY correlation is not effective for this compound because all groups are in the same plane. From all spectroscopic studies the structure of the Compound **21** was elucidated as **[4,6-dihydroxy-2-(4'-hydroxy-benzyl)-benzofuran-3-one]**. Literature search including SciFinder showed that Compound **21** is a new compound and has not been reported earlier from either natural or synthetic sources.




Figure-3.19 The COSY correlation of compound-**21**

Table 3.23: The COSY correlation data for selected protons of compound-**21**

Our data (MeOD)	
δ_H ppm	Protons correlated with δ_H ppm
5.78 (H-2)	2.75 (H-10)
6.89 (H-2)	6.76 (H-3')
6.76 (H-5')	6.89 (H-6')

Compound-**22** was obtained as yellow powder, melting point was recorded 170-172°C and specific rotation $[\alpha]_D^{25} = +19.58$ (c 0.37, MeOH). The molecular formula was determined as $C_{15}H_{12}O_7$ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 327.0478 $[M+Na]^+$ (Calculated 327.0475 for $[C_{15}H_{12}NaO_7]^+$).

FT-IR (NEAT) showed the absorption bands at ν_{max} 3422.38 (O–H stretching), 3132.99 and 2918.35 (aromatic =C–H stretching), 1635.43 (C=O stretching of ketone), 1623, 1616, 1608, 1570, 1521 and 1472 (C=C stretching of aromatic ring), 1250 (C–O stretching of phenol), 1159 (C–O stretching of furan), 1136 and 1116 (C–O stretching of alcohol), 1080, 1018, 949, 858, 810, 778, 703, 666 cm^{-1} . The **UV** spectral data of aromatic showed absorbance at λ_{max} : 206 (+0.36106), 231 (+0.1847) and 289 (+0.11909) nm.




Figure-3.20 Compound-**22**, 2-[(3',4'-Dihydroxy-phenyl)-hydroxy-methyl]-4,6-dihydroxy-benzofuran-3-one (New)

The 1H -NMR spectrum of the Compound **22** (in Acetone- d_6) showed eleven signals for seven protons and ^{13}C -NMR spectrum showed fifteen signals for fifteen carbons. DEPT-90 & DEPT-135 were performed to find out attachment of protons, i.e. primary, secondary, tertiary and quaternary carbons (Table 3.24). In the Compound **22**, no methyl & methylene, seven methine carbons were found out and the rest were quaternary carbons. H-H COSY spectrum was done and linkages between protons were found out. From HSQC and HMBC all protons to carbons

were assigned (Table 3.25). From ^1H NMR signal coupling constants were measured (Table 3.24) and proton carbon connectivity were found out from HMBC (Table 3.25 and Figure-3.21).

^{13}C NMR, DEPT 90 and 135 showed in Compound **22**, 2,5,7,10,2',5',6' carbons were -CH-carbon and 4,6, 3',4' were quaternary carbon with -OH group and 8,9,1' were quaternary carbon and 3 was =CO group (Table-3.24). The H-2 gave doublet (J value 11.49 Hz) with coupling with H-10. H-10 gave doublet of doublet (J value 11.48Hz and 3.8Hz) coupling with H-2&10-OH protons respectively. The H-5 & H-7 gave doublet (J value 2.08 Hz.) coupling with *meta* protons. The H-2' & H-6' were found in *meta* coupling each other with J value 1.96 Hz and gave doublet. The H-5'&H-6'gave doublet (J value 8.12 Hz) coupling with *ortho* protons and H-6' gave doublet of doublet (J value 8.12 &1.96 hz) coupling with *ortho* and *meta* protons (Table-3.24).

Table-3.24: The ^1H , ^{13}C , DEPT90 and DEPT135 NMR data of compound-**22**

Position	Our data (Acetone- d_6)			
	δ_{H} (Mult., J (Hz)) ppm	δ_{C} ppm	DEPT90 (CH)	DEPT135
2	5.02 (d, 11.49)	84.62	84.62	84.62
3		198.32		
4		165.10		
5	5.99 (d, 2.08)	97.16	97.16	97.16
6		164.25		
7	5.95 (d, 2.08)	96.13	96.13	96.13
8		167.99		
9		101.62		
10	4.62 (dd, 11.48,3.8)	73.26	73.26	73.26
1'		129.88		
2'	7.07 (d, 1.92)	115.97	115.97	115.97
3'		145.89		
4'		146.71		
5'	6.87 (d, 8.12)	115.86	115.87	115.87
6'	7.02 (dd, 8.12,1.96)	120.92	120.92	120.93

In HMBC correlations of H-2 (δ 5.02) coupled with C-10 (δ 73.26), C-3 (δ 198.32), C-1' (δ 129.88), C-2' (δ 115.97) and C-6' (δ 120.92). These correlations supported that hydroxyl benzyl group at C-2 position of benzofuran. Correlation of H-10 (δ 2.75) with C-2 (δ 84.62), C-3 (δ 198.32) carbon atom but this proton cannot show any correlation with C-1' (δ 129.88), C-2' (δ 115.97) and C-6' (δ 120.92) this indicate that twisting of hydroxyl benzyl group of benzofuran due to H-bonding or OH group. These correlations also supported the structure of Compound **22** as dihydroxybenzofuranone derivatives (Table-3.25).




Figure-3.21 The HMBC correlation of compound-**22**

Table-3.25: The ^1H , HMQC and HMBC NMR data of compound-**22**

Our data (Acetone- d_6)		
δ_{H} (ppm)	HMQC correlation	HMBC correlation
5.02 (H-2)	84.62 (C-2)	73.26(C-10), 129.88(C-1'), 115.97 (C-2'), 120.92 (C-6'), 198.32(C-3)
5.99 (H-5)	97.16 (C-5)	96.13 (C-7), 101.62(C-9), 167.99(C-8), 164.25(C-6), 165.10 (C-4)
5.95 (H-7)	96.13 (C-7)	97.16 (C-5), 101.62(C-9), 165.10 (C-4), 164.25(C-6), 167.99 (C-8)
4.62 H-10)	73.26 (C-10)	84.62(C-2), 198.32(C-3)
7.07 (H-2')	115.97 (C-2')	84.62 (C-2), 120.92(C-6'), 145.89(3'), 146.71(C-4')
6.87 (H-5')	115.87 (C-5')	129.88(C-1'), 145.89 (3'), 146.71(C-4'), 115(C-2')
7.02 (H-6')	120.92 (C-6')	115.87(C-5'), 115.97(C-2'), 146.71(C-4'), 84.62(C-2)

From H-H COSY H-2 was found to be linked with H-10', H-5' with H-6'. All the correlations supported that they are attached to adjacent carbon atoms (Table-3.26). The NOESY correlation is not effective for this compound because all groups are in the same plane. From all spectroscopic studies the structure of the Compound **22** was elucidated as [2-[(3',4'-Dihydroxy-phenyl)-hydroxy-methyl]-4,6-dihydroxy-benzofuran-3-one]. Literature search including SinFinder showed that Compound **22** is a new compound and has not been reported earlier from either plant origin or from synthetic sources.




Figure-3.22 The COSY correlation of compound-**22**

Table 3.26: The COSY correlation data for selected protons of compound-**22**

Our data (Acetone- d_6)	
δ_H (ppm)	Protons correlated with δ_H (ppm)
5.02 (H-2)	4.62 (H-10)
6.87 (H-5')	7.02 (H-6')

Compound-**23** was obtained as white needle crystal, melting point was recorded 135-138 °C and specific rotation was $[\alpha]_D^{25} = +8.12$ (c 0.22, MeOH). The molecular formula was determined as $C_{18}H_{20}O_4$ from high resolution mass spectroscopy (HRMS-ESI-TOP) at m/z 323.1261 $[M+Na]^+$ (Calculated 323.1254 for $[C_{18}H_{20}NaO_4]^+$).

FT-IR (NEAT) shows the absorption bands at ν_{max} 3293 (O–H stretching), 2963 and 2927 (C–H stretching), 1613, 1598, 1514, 1443 and 1375 (C=C stretching of aromatic ring), 1261, 1239 (C–O stretching of ether), 1212 (C–O stretching of phenol), 1168 (C–O stretching of furan), 1136, 1107 (C–O stretching of alcohol), 1107, 1075, 1055, 1019, 987, 947, 901, 835, 825, 805, 782, 755, 716 cm^{-1} . The UV spectral data of aromatic showed absorbance at λ_{max} : 206 (+0.57164), 227 (+0.67019) and 277 (+0.14745) nm.




Figure-3.23 Compound-**23** 2,5-Bis-[(4'-hydroxy-phenyl)(4''-hydroxy-phenyl)]-3,4-dimethyl-tetrahydro-furan-3-ol (New)

The 1H -NMR spectrum of the Compound **23** (in MeOD) showed nine signals for protons and ^{13}C -NMR spectrum showed fourteen signals for eighteen carbons. DEPT-90 & DEPT-135 were performed to find out attachment of protons, i.e. primary, secondary, tertiary and quaternary carbons (Table 3.18). In the Compound **23**, two methyl, no methylene, eleven methine carbons were found out and the rest were quaternary carbons. H-H COSY spectrum was done and linkages between protons were found out. From HSQC and HMBC all protons to carbons were assigned (Table 3.28). From 1H NMR signal coupling constants were measured (Table 3.27) and proton carbon connectivity were found out from HMBC (Table 3.28 and Figure 3.24).

The ^{13}C NMR, DEPT 90 and 135 showed in Compound **23**, 2,4,5,2',3',5',6',2'',3'',5'',6'' carbons were -CH- and C-3,C-1', C-4',C1'', C-6' were quaternary carbon with containing -OH group. The C-3 and C-4 were containing methyl (-CH₃) carbon (Table-3.27). The H-4 gave multiplet signal coupling with H-5 & 4-CH₃ protons. The H-5 proton gave doublet (J value 7.7 Hz) coupling with H-4 and the H-2 gave singlet. The 3-CH₃ gave singlet but 4-CH₃ gave doublet (J value 7.5 Hz) coupling with H-4. The protons H-3',H-3'',H-5',H-5'' were in almost same chemical environment that's why they gave doublet (J value 8.5 Hz) coupling with *ortho* protons. The H-2'&H-6' and H-2''&H-6'' gave doublet (J value 8.5 Hz,) coupling with *ortho* protons. The OH proton gave broad singlet at δ 4.63 ppm (Table-3.27).

Table-3.27: The ^1H , ^{13}C , DEPT90 and DEPT135 NMR data of compound-**23**

Position	Our data (MeOD)			
	δ_{H} (mult., J (Hz)) ppm	δ_{C} ppm	DEPT90 (CH)	DEPT135
2	4.78 (s)	90.41	90.41	90.41
3		82.55		
4	2.44 (m)	50.64	50.63	50.63
5	5.33 (d, 7.7)	82.49	82.49	82.49
1'		131.32		
2'	7.30 (d, 8.5)	128.85	128.85	128.85
3'	6.80 (d, 8.5)	115.97	115.97	115.97
4'		158.09		
5'	6.80 (d, 8.5)	115.97	115.97	115.97
6'	7.30 (d, 8.5)	128.85	128.85	128.85
1''		132.10		
2''	7.23 (d, 8.5)	128.80	128.80	128.80
3''	6.80 (d, 8.5)	115.92	115.92	115.92
4''		157.76		
5''	6.80 (d, 8.5)	115.92	115.92	115.92
6''	7.23 (d, 8.5)	128.80	128.80	128.80
3-CH ₃	0.78 (s)	21.14		21.14 (3-CH ₃)
4-CH ₃	0.58 (d, 7.5)	11.83		11.83 (4-CH ₃)
-OH	4.63 (br. S)			

In HMBC correlations; H-2 (δ 4.87) with C-3 (δ 82.55), C-1' (δ 131.32), C-2' (δ 128.85), C-6' (δ 128.85) and C-(3-CH₃) (δ 21.14). These correlations supported that one hydroxyl phenyl group at C-2 position of tetrahydrofuran. Correlation of H-5 (δ 5.33) with C-3 (δ 82.55), C-1'' (δ 132.10), C-2'' (δ 128.80), C-6'' (δ 128.80) and C-(4-CH₃) (δ 11.83) supported that another hydroxyl phenyl group at C-5 position of tetrahydrofuran. Correlation of H-4 (δ 2.44) with C-(3-CH₃) (δ 21.14), C-(4-CH₃) (δ 11.83), C-3 (δ 82.55), C-5 (δ 82.49) and C-1'' (δ 132.10) also supported that the hydroxyl phenyl group at C-5 position of tetrahydrofuran. This connectivity also supported the structure of compound 23 as tetrahydrofuran derivative (Table-3.28).




Figure-3.24 The HMBC correlation of compound-23

Table-3.28: The ^1H , HMQC and HMBC correlation of compound-23

Our data (MeOD)		
δ_{H} ppm	HMQC correlation	HMBC correlation
4.78 (H-2)	90.41 (C-2)	82.55 (C-3), 21.14 (3-CH ₃), 131.32(C-1'), 128.85(C-2'), 128.85 (C-6'),
2.44 (H-4)	50.63 (C-4)	11.83(4-CH ₃), 21.14(3-CH ₃), 82.55(C-3), 82.49(C-5), 132.10(C-1'')
5.33 (H-5)	82.49 (C-5)	82.55(C-3), 11.83(4-CH ₃), 132.10(C-1''), 128.80 (C-2''), 128.80(C-6'')
7.30 (H-2')	128.85 (C-2')	82.55(C-3), 128.85(C-6'), 158.09(C-4')
6.80 (H-3')	115.97 (C-3')	115.97(C-5'), 131.32(C-1'), 158.09(C-4')
6.80 (H-5')	115.97 (C-5')	115.97(C-3'), 131.32(C-1')158.09(C-4'),
7.30 (H-6')	128.85 (C-6')	82.55(C-3), 128.85(C-2'), 158.09(C-4')
7.23 (H-2'')	128.80 (C-2'')	128.80(C-6''), 157.76(C-4''), 82.49(C-5)
6.80 (H-3'')	115.92 (C-3'')	115.92(C-5''), 132.10(C-1''), 157.76(C-4'')
6.80 (H-5'')	115.92 (C-5'')	115.92(C-3''), 132.10(C-1''), 157.76(C-4'')
7.23 (H-6'')	128.80 (C-6'')	128.80(C-2''), 157.76 (C-4''), 82.49(C-5)
0.78 (3-CH ₃)	21.14 (3-CH ₃)	90.41(C-2), 50.63(C-4), 82.55(C-3)
0.58 (4-CH ₃)	11.83 (4-CH ₃)	50.63(C-4), 82.49(C-5), 82.55 (C-3)

From H-H COSY H-4 was found to be linked with H-5 and H-(4-CH₃), H-2' with H-3', H-5' with H-6', H-2'' with H-3'' and H-6'' with H-6''. All the correlations supported that they are attached to adjacent carbon atoms (Table-3.29).


**Figure-3.25** The COSY correlation data for selected protons of compound-23

Table 3.29: The COSY correlation data for selected protons of compound-**23**

Our data (MeOD)	
δ_H ppm	Protons correlated with δ_H (ppm)
2.44 (H-4)	5.33 (H-5), 0.58 (4-CH ₃)
7.30 (H-2')	6.80 (H-3')
6.80 (H-5')	7.30 (H-6')
7.23 (H-2'')	6.80 (H-3'')
6.80 (H-5'')	7.23 (H-6'')

The relative stereochemistry of compound **23** was determined on the basis of NOESY experiment. The correlation of H-2 with H-4 and H-5 indicate that they were lying in same plane. The 3-CH₃ proton correlates with H-2' and 4-CH₃ protons and 4-CH₃ proton correlates with H-2' and 3-CH₃ protons which indicate that two CH₃ group and two hydroxyphenyl group were lying in same plane (Table-3.30). From all spectroscopic studies structure of the Compound **23** was elucidated as **2,5-Bis-[(4'-hydroxy-phenyl)(4''-hydroxy-phenyl)-3,4-dimethyl-tetrahydro-furan-3-ol]**. Literature search including SciFinder showed the Compound **23** is a new compound and has not been reported earlier from neither from plant origin nor from synthetic sources.


**Figure-3.26:** The NOESY correlation of compound-**23**

Table 3.30: The NOESY correlation data for selected protons of compound-23

Our data (MeOD)	
δ_{H} ppm	Protons correlated with δ_{H} (ppm)
4.78 (H-2)	2.44(H-4), 5.33(H-5)
0.78 (3-CH ₃)	0.58(4-CH ₃), 7.30(H-2')
0.58 (4-CH ₃)	0.78(3-CH ₃), 7.23(H-2'')

PART-B

Herbal Formulations

3.3 Microbial Contamination

For the evaluation of microbial contamination, total bacterial aerobic, total coliform, total *E. coli*, *E. coli* 0157 and *Salmonella* spp. count were determined (Figure 3.27). All the preparations showed different levels of total aerobic bacterial count and exceeded the safety limit according to USP (United States Pharmacopoeia) (Tables 3.31 and 3.32) but six of them (ADHP-2, ADHP-4, ADHP-6, ADHP-10, ADHP-11) exceeded the safety limit as indicated by EP (European Pharmacopoeia) and WHO (World Health Organization) guidelines (Table 3.32) whereas two of them (ADHP-5 and ADHP-9) were in marginal level. Total coli form count is the indicator of faecal contamination and found in six of the samples where they exceeded the safety limit (Tables 3.31 and 3.32). Total *E. coli* count, a specific Gram negative bacterial species count included in the range of total coli form count, also exceeded the safety limit in fifty percent of the studied preparation. Specific species count such as *E. coli* 0157 and *Salmonella* spp. were found to be present in around 25% of the preparation (*E. coli* 0157 in ADHP-9, ADHP-11 and ADHP-13 and *Salmonella* spp. in ADHP-4) (Tables 3.31 and 3.32).

Table 3.31: Microbial assessment of different ADHPs

Sample Name	Total aerobic bacterial count/ml	Total coliform count/ml	Total <i>E.coli</i> count/ml	<i>E.coli</i> O157 count/ml	<i>Salmonella</i> spp. Count/ml
ADHP-1	2.0×10^4	2.0×10^2	Negative	Negative	Negative
ADHP-2	1.4×10^6	Negative	Negative	Negative	Negative
ADHP-3	4.0×10^4	2.7×10^3 , 1.7×10^3 (w,c)	Negative	Negative	Negative
ADHP-4	5.72×10^6	8.4×10^3 (P) 8.00×10^2 (W)	3.1×10^3 (W) 6.0×10^2 (P)	Negative	2.75×10^3
ADHP-5	2.9×10^5	Negative	Negative	Negative	Negative
ADHP-6	5.7×10^5	Negative	Negative	Negative	Negative
ADHP-7	7.08×10^4	2.08×10^4	2.34×10^4	Negative	Negative
ADHP-8	5.36×10^4	Negative	Negative	Negative	Negative
ADHP-9	2.5×10^5	2.89×10^3	9.5×10^2	4.4×10^2	Negative
ADHP-10	8.3×10^5	8.0×10^2	2.9×10^2	Negative	Negative
ADHP-11	1.38×10^6	3.93×10^4	1.34×10^4 (P)	2.1×10^3 (P)	Negative

			7.8×10^3 (W)		
ADHP-12	2.03×10^4	Negative	Negative	Negative	Negative
ADHP-13	1.87×10^6	5.0×10^3	5.0×10^2 (P) 1.6×10^3 (W)	1×10^2 (P)	Negative




Figure-3.27 Incubation of antidiabetic herbal preparations (ADHPs) in different agar media for microbial count. a) ADHP-9 incubated in Tryptic Soya Agar (TSA) plate for total aerobic count, b) ADHP-7 incubated in Chromocult agar plate for total coliform count, c) ADHP-7 and ADHP-11 incubated in Sorbitol MacConkey (SMAC) agar plate for total *E. coli* count, e) ADHP-6 incubated in Caprylate-thallos (CT) agar plate for *E. coli* 0157 count and f) ADHP-11 incubated in Bismuth sulfite agar (BSA) plate for *Salmonella* spp. count.

Almost seventy percent of the total preparation studied (nine preparations) failed to comply with the safety limit at least in one method of microbial contamination evaluation like total microbial counts or specific species count. In this study we counted microorganism in five different ways (total aerobic bacterial count, total coliform count, total *E. coli* count, specific *E. coli* 0157 count and *Salmonella* spp. count), where ADHP-4 and ADHP-11 exceeded safety limit in four different microbial counting methods. ADHP-9 is in second position in failure the safety limit as it exceeded the safety limit evaluated by three different counts. At least in two different microbial counts, the level of microbial contamination was higher than the safety limit in ADHP-7, ADHP-10 and ADHP-13 as mention in the EP, USP and WHO guidelines (Tables 3.31 and 3.32). From the data, it is found that two of these preparations (ADHP-1 and ADHP-12) only could be able to comply with the safety limit evaluated by all the different microbial counts. If we consider the presence of fungi in the preparation then none of these herbal preparations could comply with different standardizing body for the assurance of safety as all of the thirteen ADHPs have shown positive response in Potato dextrose agar (PDA)(figure 3.28).




Figure 3.28 Incubation of ADHP-8 and ADPH-11 in Potato Dextrose agar (PDA).

The presence of large numbers of pathogenic bacteria in the studied herbal preparations indicates several windows to consider as a source of contamination. It is worth to mention that pH of all the preparations was within the suitable range (pH 5-8.5) which may appreciate bacterial growth [82]. The contamination could start at the initial phase of raw materials collection as soil influences bacterial growth in several ways. This initial contamination could be carried along to harvesting, drying and storage. Moreover, during the preparation of finished preparation the source of contamination includes personnel, equipments and materials. Therefore, the process of raw material collections, processing of the raw materials and the process of manufacturing for finished preparation should ensure the highest possible level of hygiene to maintain lowest possible level of pathogenic organism in the preparation and thereby assure the quality and safety of herbal preparation.

The level of microbial contamination is mentioned in different standards for publication including EP, USP and WHO guideline to maintain the safety of herbal preparations (Table 3.32). Gram negative bacteria such as *Salmonella*, *Shigella* and *E. coli* should be absent in the preparation. Moreover, the limit for coliforms also mentioned, as it is the most reliable indicator of faecal contamination, which may indicate the possible presence of other harmful disease-causing organisms. The presence of fungi in herbal preparations under certain conditions, may lead to the secretion of toxic metabolites such as mycotoxins, which when ingested, inhaled or absorbed through the skin cause illness or human and animal death [83].

These mycotoxins possess substantial risk of carcinogenic, neurotoxic, immunotoxic and mutagenic effects[53-58]. It is reported that a substantial amount of medicinal plants are contaminated naturally by fungi from soil and environment and thereby may contain mycotoxins[52]. As most of the herbal preparation majorly contains medicinal plants, it is important to assure that the level of mycotoxins are below the safety limit as set by different bodies. For conclusive remark we further need to determine the level of mycotoxins in these herbal preparations.

Table 3.32: Microbial limits for finished herbal/botanical preparations (in colony-forming units/gram (cfu/g) or colony-forming units/ml (cfu/ml)), (Current as of July 2014)

Reference	EP category C	USP	WHO
Product	Product with Ingredients demonstrated to fail Category B w/Processing/ Pretreatment	Containing Botanical Ingredients	Herbal Materials for internal use
Total aerobic microbial count	10^5 (maximum acceptance limit: 5×10^5)	10^4	10^5
Total combined yeast and mold count	10^4 (maximum acceptance limit: 5×10^4)	10^3	10^3
Enterobacterial Count (Bile-tolerant Gram-negative bacteria)	10^4	NA	10^3 (other than E. coli)
Escherichia coli	Absence in 1 g	Absence in 10 g	10 in 1 g
Salmonella spp.	Absence in 25 g	Absence in 10 g	Absence in 1 g
Staphylococcus aureus	NA	NA	NA
Clostridia	NA	NA	Absence in 1 g
Shigella	NA	NA	Absence in 1 g

EP- European Pharmacopoeia Ed. 8.0, 5.1.8 (Microbiological quality of herbal medicinal products for oral use and extracts used in their preparation), 2013. **USP**- United States Pharmacopeial Convention, USP-NF 37-32, 2014. **WHO**- World Health Organization, WHO Guidelines for Assessing Quality of Herbal Medicines with Reference to Contaminants and Residues, 2007. **NA**- Not Assigned

3.4 Heavy Metal Content:

In this study, we determined heavy metal (Cu, Cd, Cr, Mn, Pb and Zn) contents in different ADHPs to identify whether any potential risk of accumulation of these heavy metals leading to toxicity (Table 4). All the thirteen ADHPs contain Copper (Cu), Chromium (Cr), Manganese (Mn), Lead (Pb) and Zinc (Zn) in some level with few exceptions (Cr in ADHP-9 and Zn in ADHP-7 and ADHP-12 was in below detection level) (Table 3.33).

Table 3.33: Heavy metal content of investigated ADHP samples

Sample ID	Zn (ppm)	Cu (ppm)	Mn (ppm)	Cr (ppm)	Cd (ppm)	Pb (ppm)
ADHP-1	5.38	5.38	6.5	9.25	BDL	8.50¶
ADHP-2	3.75	10.00	9.25	4.63	BDL	8.50¶
ADHP-3	2.00	10.50	6.63	4.38	BDL	7.00¶
ADHP-4	12.50	3.50	7.75	28.25	2.75 *§¶	41.38*
ADHP-5	2.88	4.88	1.63	8.25	BDL	6.63¶
ADHP-6	3.75	4.50	8.50	4.00	BDL	13.38*¶
ADHP-7	BDL	4.13	3.00	2.88	BDL	3.75
ADHP-8	2.75	3.75	0.88	6.00	BDL	11.50*¶
ADHP-9	2.88	8.88	6.88	BDL	BDL	3.88
ADHP-10	2	7.25	8.50	11.75	BDL	9.88¶
ADHP-11	2.38	4.50	8.00	2.13	BDL	5.75¶
ADHP-12	BDL	4.25	4.63	2.50	BDL	9.38¶
ADHP-13	10.50	3.13	6.00	24.63	1.38 *§¶	33.50*§¶

BDL (below detection level); * exceed WHO and US FDA permission limit; § exceed HAS Singapore permission limit; ¶ exceed Chines Pharmacopoeia permission limit

The amount of cadmium was below detection level in all the preparations except ADHP-4 and ADHP-13. There are several regulatory bodies that set specific allowable limit for heavy metal content in herbal and tradition preparations based on different guidelines and this permissible limit varies among these regulatory bodies (Table 3.34 and 3.36). It is found that lead content in almost all of the samples (except ADHP7 and ADHP9) exceeded the permissible limit if we consider the stringiest limit of Chines Pharmacopoeia (Table 3.33 and 3.34). Even if we consider a more relax permissible limit for lead (WHO and US FDA guidelines; Table 3.34), one third of the total ADHPs (ADHP4, ADHP6, ADHP8 and ADHP13) failed to comply with the

safety limit. Lead, a highly toxic environmental pollutant, can affect the function of various biomolecules by forming complex with them.

Table 3.34: Permissible limit of heavy metal in herbal drugs

Heavy/Toxic metal	WHO	US FDA	HSA Singapore	Chinese Pharmacopoeia
Cadmium	0.20 ppm	0.30 ppm	0.05 ppm	0.30 ppm
Lead	10.00 ppm	10.00 ppm	20.00 ppm	5.00 ppm
Arsenic	10.00 ppm	10.00 ppm	5.00 ppm	2.00 ppm
Mercury	1.00 ppm	1.0 ppm	0.50 ppm	0.20 ppm
Copper	20.00 ppm	20.00 ppm	150.00 ppm	20.00 ppm
Zinc	50.00 ppm	50.00 ppm	--	--

US FDA (United States Food and Drug Administration); HAS (Health Science Authority).

Moreover, excess lead exposure may responsible for poor muscle coordination, gastrointestinal symptoms, brain and kidneys damage, hearing and vision impairments and reproductive defects[84-86].Cadmium content was below detection level in all of the ADHP samples other than ADHP4 and ADHP13. Unfortunately these two (ADHP4 and ADHP13) samples were also failed to comply with safety based on cadmium content (table 3.33 and 3.34).Cadmium toxicity could induces tissue injury [87-89], epigenetic changes in DNA expression [90-92], hypertension [93], diabetes [94], apoptosis [95] and insulin resistance [96, 97].Moreover, excess cadmium may inhibits or up regulates transport pathways [98-100] and heme synthesis [101]. According to JECFA (The Joint FAO/WHO Expert Committee on Food Additives) heavy metal limits for herbal dietary supplements, none of these formulations contains heavy metals in such a level, which could exceed the daily allowable intake (Table 3.35 and 3.36). Considering all of these guidelines, it turned out that only two ADHP samples (ADHP7 and ADHP9) contains heavy metals in safe level. Metals are natural components of soils and some of them (Cu, Mn and Zn) are necessary for micronutrients of plant growth while others (Cd, Cr and Pb) are not but could be accumulated in plants at toxic level [102-104].

Table 3.35: Heavy metal content of investigated ADHP samples and the daily safe intake of different heavy metals

Sample ID	Cumulative Daily adult dose of preparation* (g)	Daily Adult intake of heavy metal (in µg) as calculated from the dose indicated on the label of the finished product.					
		Zn	Cu	Mn	Cr	Cd	Pb
ADHP-1	1.50	8.06	8.06	9.75	13.88	--	12.75
ADHP-2	1.00	3.75	10.00	9.25	4.63	--	8.50
ADHP-3	3.00	6.00	31.50	19.88	13.13	--	21.00
ADHP-4	2.50	31.25	8.75	19.38	70.63	6.88	103.44
ADHP- 5	2.50	7.19	12.19	4.06	20.63	--	16.56
ADHP-6	3.75	14.06	16.88	31.88	15.00	--	50.16
ADHP-7	4.00	--	16.50	12.00	11.00	--	15.00
ADHP-8	3.50	9.63	13.13	3.06	21.00	--	40.25
ADHP-9	30.00	86.25	266.25	206.25	--	--	116.25
ADHP-10	2.50	5.00	18.13	21.25	29.38	--	24.69
ADHP-11	2.50	5.94	11.25	20.00	5.31	--	14.38
ADHP-12	4.00	--	17.00	18.50	10.00	--	37.50
ADHP-13	2.50	26.25	7.81	15.00	61.56	3.44	83.75

* This dose is calculated as indicated on the label of the finished product; BDL (below detection level)

As the major components of these herbal preparations are plants, the presences of heavy metals in ADHPs are very relevant. Some of the identified metals (Zn, Cu, Mn and Cr) have important biological role in the body.

Table 3.36: JECFA heavy metal limits for herbal dietary supplements

Heavy Metals	Stated Limit (PTWI- weekly)	Calculated Daily Limit (Adult, 70 kg)
Arsenic	15 µg inorganic arsenic/kg bw	150 µg
Cadmium	7 µg cadmium/kg bw	70 µg
Lead	25 µg lead/kg bw	250 µg
Mercury	1.6 µg methylmercury/kg bw	16 µg

JECFA (The Joint FAO/WHO Expert Committee on Food Additives); PTWI (Provisional tolerable weekly intake)

REFERENCES

1. Yue-Zhong Shu, (1998), *Journal of Natural product*, 61,1053-1071
2. Van Hensbrock, M.B., Onyiorath, E., Jaffer, S., Schneider, G., Palmer, A., Frenkel, J., Enwere , G., Forck, S., Nusmeijer, A., Bennett, S., Greenwood, B. and Kwiatkowski, D., (1996), *New Eng. J. Med.*, **335**, 69-75.
3. Currens, M.J., Gulakowski, R.j., Mariner, J.M., Moran R.A., Buckheit Jr., Gustafson, K.R., McMahon, J.B., and Boyd, M.r., (1996), *J.Pharmacol. Exp. Ther.*, **279**, 645-651.
4. Smitinad, T., (2001), Thai plants name (botanical name-varnacular names) revised edition, Royal Forest Department, Bangkok, Thailand.
5. Aubreville, A., Flore du Camboge, du laos et du Vietnam, Museum National D Histoire Naturelle, Laboratoire de phanerogamine, 16, Rue Buffon, Paris, 1969.
6. [http://en.wikipedia.org/w/index.php?title=Anogeissus & oldid=487094573](http://en.wikipedia.org/w/index.php?title=Anogeissus&oldid=487094573).
7. Scott, A.J., Arevision of *Anogeissus (Combretaceae)*. Kew bulletin 1979, **33**, 555-566.
8. [http://web3.dnp.go.th/botany/detail.aspx?words = %B5 %D0 %0 %A4 %D5 %C2 %B9 %E9 %D3 & typeword= group](http://web3.dnp.go.th/botany/detail.aspx?words=%B5%D0%0%A4%D5%C2%B9%E9%D3&typeword=group).
9. Jain, S.K., Tarafder, C.R., Medicinal plant-lore of the sandals, *Econ. Bot.*, 1976, **24**, 241-278.
10. Gobindrarajon, R., Vijayakumar,M., Rao, C.V., Shirwaikar, A., Rawat, A. K. S., Mehrotra, S., Pushpangadan, P., Anti oxidant potential of *Anogeissus latifolia*, *Biol Pharm. Bul.* 2004, **27(8)**, 1266-1269.
11. Ramachandran, V. S., Nair, N.C., Ethnobotanical observations on *irularis* of tamil nadu (India), *J. Econ. Tax. Bot.*, 1981, **2**, 183-190.
12. Vasileva, B., Plantes medicinales de Guinee, Republic de Guinee, Conakry, 1969.

13. Baoua, M., Fayyn, J., Bassiere J., Preliminary phytochemical testing of some medicinal plants of Niger, *Plant Med.* 1976, **10**, 251-266.
14. Adigun, J. O., Amuptain, J. O., Kelly, D. R., Isolation and investigation of antimicrobial effect of 3,4,3'-tri-O-methylflavellagic acid and its glycoside from *Anogeissus leocarpus*, *Bull. Chem. Soc. Ethiop.* 2000, 14(2), 169-174.
15. Fadulu, S. O., The antibacterial properties of the buffer extracts of chewing sticks used in Nigeria, *Planta media*, 1975, **27**, 122-126.
16. El-Hamidia, A., Drugs plants of the Sudan republic in native medicine, *Planta media*, 1970, **18**, 278-280.
17. Almagboul, A. Z., Bashir, A. k., Karim, A., Salih, M., Farouk, A., Khaled, S. A., Antimicrobial activity of certain Sudanese plants used in folkloric medicine, screening foe antifungal activity (VI), *Fitoterapia*, 1988, **59**, 393-396.
18. Singh, V.K., Ali, Z. A., Folk medicines in primary health care: common plants used for the treatmentof fevers in India. *Fitoterapia*, 1994, **65(1)**, 68-74.
19. Ramando, A. M., Pezzuto, J. M., Farnsworth, N. R., Santisuk, T., Reutrakul, V., Kawanishi, k., New liglans from *Anogeissus acuminata* with HIV-1 reverse transcriptase inhibitory activity, *J. Nat. Prod.*, 1994, **57 (7)**, 896-904.
20. Singh, A., Singh, A. V., Nath, L. K., Ghosh, T. K., *Anogeissus latifolia* : aresent update on its chemistry and pharmacological application, *Pharmacologyonline*, 2010, 446-449.
21. Gobindrarajon, R., Vijayakumar,M., Rao, C.V., Shirwaikar, A., Rawat, A. K. S., Mehrotra, S., Pushpangadan, P., Antiulcer and antimicrobial activity of *Anogeissus latifolia*, *Journal of Ethnopharmacology*, 2006, **106**, 57-61.
22. Sahoo, K., Misra, T., Dhal, N. K., Antimicrobial activity of *Anogeissus latifolia* (Robex, ex. DC) Wall. Ex. Guill. And Perr. *Environ. Conserv.* 2011, **17(2)**, 371-374.

23. Parvati, K. M. M., Ramesh, C. K., Krishna, V., Paramesh, M., Kuppast, I. J., Antihyperglycemic activity of *Anogeissus latifolia* in streptozotocine induced diabetic rats, *J. Chem. Sci.*, 2009, **7(3)**, 1974-1982.
24. Parvati, K. M. M., Ramesh, C. K., Krishna, V., Paramesh, M., Kuppast, I. J., Antihyperglycemic activity of *Anogeissus latifolia* bark and leaf extracts, *Asian J. Exp. Sci.* 2009, **23(3)**, 491-495.
25. Konate, K., Kiendrebeogo, M., Ouattara, M, B., Souza, A., Lamien-meida, A., Non gasida, Y., Baro, N., Millogo-Rasolodimby, J., Nacoulma, O. G., Antibacterial potential of aqueous acetone extracts from five medicinal plant used traditionally to treat infactious diseases in Burkina faco, *Curr. Res. J. Biol. Sci.*, 2011, 3(5), 435-442.
26. Mann, A., Banso, A., Clifford, L. C., An anti fungal property of crude plant extracts from *Anogeissus leiocarpus* and *Terminalia avicennioides*, *Tenzania Journal of Health Research*, 2008, **10 (1)**, 34-38.
27. Isimi, C., Obidike, I., Aboh, M., Emeje, M., Anti-plasmodial activity of the mixed stem bark extracts of *Anogeissus leiocarpus* and *Prosopis africana* and in vitro evaluation of its tablet dosage form, *J. of. Herbs, Spices & Medicinal Plants*, 2011, **17 (4)**, 419-435.
28. Hemalini, K., Gopalakrishnan, S., Phytochemical and antidermatophytic activity of methanolic extracts of *Anogeissus acuminata*, *Pharmacologyonline*, 2010, 507-511.
29. Ramando, A. M., Pezzuto, J. M., Farnsworth, N. R., Santisuk, T., Reutrakul, V., Kawanishi, k., Revision of the NMR assignments of pterostilbene and of Dihydro dehydro-dehydrodiconiferyl alcohol: cytotoxic constituents from *Anogeissus acuminata*, *Nat. Prod. Lett.*, 1994, **4**, 267-272.
30. Bhadoria, B. K., Lata, S., Tandan, S. k., A nonsteroidal anti-inflammatory compound from tree: *Anogeissus pendula*, *Indian Pat Appl.*, 2011, 20.
31. Srivastava, S., Govindarajon, R., Rawat, A. K. S., Phytochemical and antioxidant studies of two anogeissus species, India, Section B: Biological Science, 2011, **80(1)**, 72-80.

32. Marwah, R. G., Fatope, M. O., Al Mahrooqi, R., Varma, G. B., Al Abadi, H., Al-Burtamani, S., Antioxident capacity of some edible and wound healing plants in Oman, *Food Chemistry*, 2006, **101(2)**, 465-470.
33. Raw, L. R., Raju, R. R., Chemistry of Terminalia species-XI. Isolation of 3,4,3'-tri-O-methyl-flavellagic acid from *Termanila paniculata*, *Roth. Tetrahedron*, 1967, **23**, 879-884.
34. Deshpande, V. H., Patil, A. D., Rao, A. V. R., Venkataraman, K., 3,3'-di-O-methylellagic *Anogeissus acuminata* bark, *Indian J. Chem*, 1976, **14B**: 641-643.
35. Nduji, A. A., Okwute, S. K., Co-occurrence of 3,3'- tri-O-methylflave llagic acid and 3,3'-di-O-methylellagic *Anogeissus schimperii*, *Phytochemistry*, 1988, **27(5)**, 1548-1550.
36. Chaabi, M., Benayache, F., N Gom, S., Triterenes and polyphenols from *Anogeissus leiocarpus*, *Biochemical Systematics and Ecology*, 2008, **36**, 59-62.
37. Mohammad, S. R., Mohammad, Z. R., Mohammad, A. R., Steriod and triterpenoid from *Anogeissus latifolia*, *J. Pharm. Sci.*, 2007, **6 (1)**, 47-50.
38. Lin, T-C., Tanaka, T., Nonaka, G., Nishioka, I., Young, T-J., Tanin and Related compounds, *Chem. Pharm. Bull.*, 1991, **39(5)**, 1144-1147.
39. Chaturvedi, S. K., Chabra, B. S., Chemical constituents of *Anogeissus latifolia* , *Asian Journal of Chemistry*, 2005, 17(4), 2850.
40. Lata, S., Bhadoria, B. K., A noval chromone-substituted trimeric dihydroflavanol from *Anogeissus pendula* , *Chem. Nat. Compd.* 2010, **46(5)**, 726-729.
41. Attioua, B., Lagnika, L., Yeo, D., Antheaume, C., Kaiser, M., Weniger, B., Lobstein, A., Senceheau, C. V., In vitro anti-plasmodial and antileishmanial activity of flavonoids from *Anogeissus leiocarpus* , 2010, **11(2)**, 1-6.
42. Arunadevi, R., Lata, S., Bhadoria, B. K., Ramteke, V. D., Kumar, S. K., Sankar, P., Kumar, D., Tandan, S. K., Neuroprotective effect of 5,7 3',4',5'-pentahydroxy

- dihydroflavanol-3-O-(2"-O-galloyl)- β -D-glypiranoside, a polyphenolic compound in focal cerebral ischemia in rat, *Eur. J. Pharmacol.* 2010, **626**, 205-212.
43. Bent, S., Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. *J Gen Intern Med*, 2008, **23**(6), 854-859.
 44. WHO, Traditional Medicine Fact Sheet 134 [WWW Document]. World Health Organization, 2008.
 45. Sofowora, A., Research on medicinal plants and traditional medicine in Africa. *J Altern Complement Med*, 1996, **2**(3), 365-372.
 46. WHO, General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine, WHO/EDM/TRM/2000.1. WHO, 2000.
 47. Adeleye, I.A., G. Okogi, and E.O. Ojo, Microbial contamination of herbal preparations in Lagos, Nigeria. *J Health Popul Nutr*, 2005, **23**(3), 296-297.
 48. WHO, Research guidelines for evaluating the safety and efficacy of herbal medicines. 1993.
 49. Ernst, E., Toxic heavy metals and undeclared drugs in Asian herbal medicines. *Trends Pharmacol Sci*, 2002, **23**(3), 136-139.
 50. Wild, S., et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care*, 2004, **27**(5), 1047-1053.
 51. McCune, L.M. and T. Johns, Antioxidant activity in medicinal plants associated with the symptoms of diabetes mellitus used by the indigenous peoples of the North American boreal forest. *J Ethnopharmacol*, 2002, **82**(2-3), 197-205.
 52. Ashiq, S., M. Hussain, and B. Ahmad, Natural occurrence of mycotoxins in medicinal plants: a review. *Fungal Genet Biol*, 2014, **66**, 1-10.
 53. Petzinger, E. and K. Ziegler, Ochratoxin A from a toxicological perspective. *J. Vet. Pharmacol Ther.*, 2000, **23**(2), 91-8.

54. Nations, F.F.a.A.O.o.U., Manual on the Application of the HACCP System in Mycotoxin Prevention and Control, FAO Food and Nutrition Paper, Rome, 2001, **73**.
55. Bhatnagar, D., K.C. Ehrlich, and T.E. Cleveland, Molecular genetic analysis and regulation of aflatoxin biosynthesis. *Appl. Microbiol Biotechnol*, 2003, **61**(2), 83-93.
56. Aziz, N.A., et al., Contamination of some common medicinal plant samples and spices by fungi and their mycotoxins. *Botanical Bulletin of Academia Sinica*, 1998, **39**(4), 279-285.
57. Roy, A.K. and S. Kumar, Occurrence of ochratoxin A in herbal drugs of Indian origin - a report. *Mycotoxin Res*, 1993, **9**(2), 94-8.
58. Wu, H.C., et al., Aflatoxin B1 exposure, hepatitis B virus infection, and hepatocellular carcinoma in Taiwan. *Cancer Epidemiol Biomarkers Prev*, 2009, **18**(3), 846-53.
59. Munro, A.L.S., Chapter III Measurement and Control of pH Values, in *Methods in Microbiology*, J.R. Norris and D.W. Ribbons, , Academic Press, Editors. 1970, 39-89.
60. Maturin, L. and J.T. Peeler, *Chapter 3; Aerobic Plate Count*, B.A. Manual, FDA, USA. Editor. 2001
61. Feng, P., et al., Chapter 4: Enumeration of Escherichia coli and the Coliform Bacteria, B.A. Manual , Food and Drug Administration, USA, Editor. 2002
62. WHO, *Determination of microorganisms*, in *Quality control methods for herbal materials*, W.W.H. Organization), WHO Press: Switzerland, Editor. 2011,75-84.
63. Lee, S.M., et al., Cytotoxic triterpenoids from the fruits of Zizyphus jujube, *Planta medica*, 2003, **69**(11), 1051-1054.
64. Cichewicz, R.H. and S.A. Kouzi, Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection, *Medicinal Research Reviews*, 2004, **24**(1), 90-114.

65. Khan, M.F., et al., Design and synthesis of lupeol analogues and their glucose uptake stimulatory effect in L6 skeletal muscle cells, *Bioorganic & medicinal chemistry letters*, 2014, **24**(12), 2674-2679.
66. Burns, D., et al., Assignment of ¹H and ¹³C spectra and investigation of hindered side-chain rotation in lupeol derivatives, *Magnetic Resonance in Chemistry*, 2000, **38**(7), 488-493.
67. Ali, M.S., et al., Characterization and bioscreening of a new triterpenoid and a flavanone isolated from *Salvia nubicola*, *Chemistry & biodiversity*, 2005, **2**(7), 910-916.
68. Kotowicz, C., Cesar A.N. Catalan, Triterpenes and other constituents of *Nassauvia axillaris*, *Biochemical synthesis and ecology*, 2005, **33**, 737-742.
69. Núñez, M.J., et al., Lupane triterpenoids from *Maytenus* species, *Journal of natural products*, 2005, **68**(7), 1018-1021.
70. Ye, G., et al., Ellagic acid derivatives from the stem bark of *Dipentodon sinicus*, *Chemistry of Natural Compounds*, 2007, **43**(2), 125-127.
71. Chen, G.-y., et al., A new flavonol from the stem-bark of *Premna fulva*, *Arkivoc*, 2010, **2**, 179-185.
72. Olsen, H.T., et al., Isolation of the MAO-inhibitor naringenin from *Mentha aquatic* L, *Ethnopharmacology*, 2008, **117**(3), 500-502.
73. Yamauchi, K., T. Mitsunaga, and I. Batubara, Isolation, Identification and Tyrosinase Inhibitory Activities of the Extractives from *Allamanda cathartica*. *Natural Resources*, 2011, **Vol.02, No.03**, 6.
74. Bergman, M., et al., The antioxidant activity of aqueous spinach extract: chemical identification of active fractions. *Phytochemistry*, 2001, **58**(1), 143-152.
75. Owen, R., et al., Isolation, structure elucidation and antioxidant potential of the major phenolic and flavonoid compounds in brined olive drupes, *Food and Chemical Toxicology*, 2003, **41**(5), 703-717.
76. Zhang, H.L., et al., Sesquiterpene glycosides from cotton oil cake, *Phytochemistry*, 1998, **48**(4), 665-668.

77. Faizi, S., et al., Complete ^1H and ^{13}C NMR assignments of stigma-5-en-3-O- β -glucoside and its acetyl derivative, *Magnetic Resonance in Chemistry*, 2001, **39**(7), 399-405.
78. Kimura, J. and N. Maki, New Loliolide Derivatives from the Brown Alga *Undaria pinnatifida*. *Journal of Natural Products*, 2002, **65**(1), 57-58.
79. Günter Willuhn, R.-G.W., Loliolide (Calendin) from *Calendula officinalis*, *Planta medica*, 1987, **53**(3), 304.
80. Sakushima, A., M. Coşkun, and T. Maoka, Hydroxybenzoic acids from *Boreava orientalis*, *Phytochemistry*, 1995, **40**(1), 257-261.
81. Sang, S., et al., Antioxidative phenolic compounds isolated from almond skins (*Prunus amygdalus* Batsch), *Journal of Agricultural and Food Chemistry*, 2002, **50**(8), 2459-2463.
82. Lamikanra, A., Essential Microbiology for Students and Practitioners of Pharmacy, *Medicine and Microbiology*, 2nd Edition ed, Amkra Books, 1999
83. Pitt, J.I., What are mycotoxins? *Australian Mycotoxin Newsletter*, 1996, **7**(4), 1.
84. Johnson, F.M., The genetic effects of environmental lead, *Mutat Res*, 1998, **410**(2), 123-40.
85. Kalia, K. and S.J. Flora, Strategies for safe and effective therapeutic measures for chronic arsenic and lead poisoning, *J. Occup. Health*, 2005, **47**(1), 1-21.
86. Pearce, J.M., Burton's line in lead poisoning, *Eur Neurol*, 2007, **57**(2), 118-9.
87. Matovic, V., et al., Cadmium toxicity revisited: focus on oxidative stress induction and interactions with zinc and magnesium, *Arh. Hig. Rada. Toksikol*, 2011, **62**(1), 65-76.
88. Patra, R.C., A.K. Rautray, and D. Swarup, Oxidative stress in lead and cadmium toxicity and its amelioration, *Vet. Med. Int.*, 2011, **2011**, 457327.
89. Cuypers, A., et al., Cadmium stress: an oxidative challenge, *Biometals*, 2010, **23**(5), 927-40.
90. Martinez-Zamudio, R. and H.C. Ha, Environmental epigenetics in metal exposure, *Epigenetics*, 2011. **6**(7), 820-7.
91. Wang, B., et al., Cadmium and its epigenetic effects, *Curr. Med. Chem*, 2012, **19**(16), 2611-20.

92. Luparello, C., R. Sirchia, and A. Longo, Cadmium as a transcriptional modulator in human cells, *Critical Reviews in Toxicology*, 2011, **41**(1), 73-80.
93. Gallagher, C.M. and J.R. Meliker, Blood and urine cadmium, blood pressure, and hypertension: a systematic review and meta-analysis, *Environ Health Perspect*, 2010, **118**(12), 1676-84.
94. Edwards, J.R. and W.C. Prozialeck, Cadmium, diabetes and chronic kidney disease, *Toxicol Appl. Pharmacol*, 2009, **238**(3), 289-93.
95. Cannino, G., et al., Cadmium and mitochondria, *Mitochondrion*, 2009, **9**(6), 377-84.
96. Satarug, S. and M.R. Moore, Emerging roles of cadmium and heme oxygenase in type-2 diabetes and cancer susceptibility, *Tohoku J. Exp. Med*, 2012, **228**(4), 267-88.
97. Chen, Y.W., et al., Heavy metals, islet function and diabetes development, *Islets*, 2009, **1**(3), 169-76.
98. Thévenod, F., Catch me if you can! Novel aspects of cadmium transport in mammalian cells, *BioMetals*, 2010, **23**(5), 857-875.
99. Wan, L. and H. Zhang, Cadmium toxicity, *Plant Signaling & Behavior*, 2014, **7**(3), 345-348.
100. Van Kerkhove, E., V. Pennemans, and Q. Swennen, Cadmium and transport of ions and substances across cell membranes and epithelia, *Biometals*, 2010, **23**(5), 823-55.
101. Schauder, A., A. Avital, and Z. Malik, Regulation and gene expression of heme synthesis under heavy metal exposure--review, *J. Environ Pathol Toxicol Oncol*, 2010, **29**(2), 137-58.
102. Lasat, M.M., Phytoextraction of toxic metals: a review of biological mechanisms. *J. Environ Qual.*, 2002, **31**(1), 109-20.
103. Gaur, A. and A. Adholeya, Prospects of arbuscular mycorrhizal fungi in phytoremediation of heavy metal contaminated soils. *Current Science*, 2004, **86**(4), 7.
104. Cho-Ruk, K., et al., Perennial Plants in the Phytoremediation of Lead-contaminated Soils, *Biotechnology(Faisalabad)*, 2006, **5**(1), 1-4.

List of publication out of the M.Phil work

1. Rausan Zamir, **Anowar Hosen**, M. Obayed Ullah, Nilufar Nahar., Microbial and Heavy Metal Contamination of Antidiabetic Herbal Preparations Formulated in Bangladesh., Evidence-Based Complementary and Alternative Medicine, Volume 2015, p. **9**